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A great number of pharmaceutical drugs target nucleic acids. However, 
drug-DNA interactions can be region non-specific and lead to undesired side 
effects. Understanding the mechanisms that regulate drug-DNA binding can help 
in the design of potent and selective therapeutic agents with fewer deleterious 
side effects. The present investigation explores the metal-mediated DNA binding 
of a group of 2-(2-hydroxyphenyl)benzoxazole (HPB) ligands and the 
aggregation dependant G-quadruplex selectivity of a series of perylene 
tetracarboxylic acid diimides (PTCDI) compounds.   
HPB ligands are simplified analogs of the bis-benzoxazole natural product 
UK-1. This compound is able to inhibit cell growth of various tumor cell lines, bind 
divalent cations, and interact with DNA in a metal dependant fashion. The HPB 
moiety present in UK-1 was identified as relevant for its metal ion binding and 
 viii 
biological properties. For this work, novel HPB ligands were synthesized with 
different substitutions at the C4 or C7 position. Their ability to bind metal ions and 
DNA was evaluated and their cytotoxicity was assessed in multiple cancer cell 
lines. The ligands bound to Cu2+ with the highest affinity among metals studied. 
Consequently, Cu2+ promoted the most dramatic increase in DNA binding and 
affected the ligand’s cellular cytotoxicity.   
The second project focused on targeting four-stranded structures called 
G-quadruplexes, which can form in G-rich nucleic acid sequences. Compounds 
that stabilize these structures may inhibit nucleic acid-processing enzymes such 
as telomerase and potentially act as anti-cancer agents. PIPER is a PTCDI that 
is particularly selective for G-quadruplex DNA versus duplex DNA under 
conditions in which it forms aggregates. This work investigated ligand 
aggregation in a series of PIPER analogs with different structural features under 
high and low salt buffers, changes in pH, metal binding and temperature 
changes. A negatively charged analog was determined to form metal-mediated 
aggregates while novel thermophilic mediated aggregation was discovered for an 
analog with methoxyethoxymethyl groups. The ability of these ligands to bind 
different DNA structures was evaluated under aggregating and non-aggregating 
conditions. This study supports the idea that ligand aggregation increases their 
quadruplex selectivity and decreases double-stranded DNA binding. 
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PART I:  SYNTHESIS AND BIOLOGICAL EVALUATION OF 
BENZOXAZOLE ANALOGS OF UK-1 
CHAPTER 1. INTRODUCTION 
1.1. DNA as a good biological target 
  
DNA is the basis of heredity in all higher organisms, and its regulation 
determines the expression of gene products that promote homeostasis within the 
cell. Any variation of normal DNA regulation, whether by mutation or physical 
damage, can lead to changes in cellular balance potentially resulting in cell 
death. Therefore, the study of DNA is important for understanding physiological 
applications and to elucidate functions of human health.  
The structure of DNA was elucidated by Watson and Crick in 1953 (1). 
Since then, scientists have strived to understand the factors and structural 
features that encompass this unique biomolecule. DNA strands are composed of 
repeating nucleotide units, which consist of a 2’-deoxyribose sugar, a phosphate, 
and a heterocyclic base (2, 3). There are two types of bases, purines and 
pyrimidines. The first contains a fused five and six membered ring that are 
comprised of adenine and guanine, while the latter possess a six-membered 
heterocycle, and include the bases thymine and cytosine. The 2’-deoxyribose 
sugar is connected to the N9 of the purine bases and the N1 of the pyrimidine 
bases. The DNA chain is made through phosphodiester bonds between the 3’ 
and 5’ carbons of adjacent sugar rings (Figure 1.1A).  Due to the asymmetry in 
the sugar phosphate backbone, DNA strands have direction, and their ends are 
referred to as 3’ or 5’ according to the position of hydroxyl groups in the first and 
last sugar rings. 
Erwin Chargaff investigated the base composition of different sources of 
DNA and his studies revealed that the fraction of purines was always proportional 
 2 
to the amount of pyrimidines. (4). Watson and Crick incorporated Chargaff’s 
observations in their DNA model establishing that adenine could base pair with 
thymine through two hydrogen bonds and guanine could  base pair with cytosine 
through three hydrogen bonds (1). Two opposing complementary DNA strands 
can then interact through a hydrogen bonding network formed by their 
nucleobases. The base pairing between two DNA strands is known as the 
Watson-Crick base pairing and can give rise to a helical DNA structure such as 




























































































































Figure 1.1. DNA nucleotides and base-pairing. (A) Nucleotides consist of a 2’-deoxyribose sugar, 
a phosphate, and a heterocyclic base. DNA strands are formed through phosphodiester linkages 
in the 3’ and 5’ of adjacent sugars. (B) Double stranded DNA is formed from the base-pairing of 
Adenine with Thymine and Guanine with Cytosine 
 
 
There are many structural traits in DNA that make this biopolymer 
distinctive. Its stacked nucleobases form a hydrophobic interior, while its 
negatively charged sugar-phosphate backbone is hydrophilic. The majority of 
genomic double stranded DNA is found as a right-handed helical structure 
 3 
termed “B-DNA”, which has 10.5 base pairs per helical turn, an average of 24 Å 
in diameter and 3.3 Å in length per base-pair (5, 6). Under certain conditions 
DNA can adopt other helical conformations that vary in width, and size of the 
grooves such as “A” or “Z” DNA (7). These and other, non-canonical DNA 
structures will be elaborated upon in chapter 7.  
The phosphate backbones of two DNA strands in the B conformation form 
different sized grooves as they twist around each other: a major groove, 22 Å 
wide, and a minor groove, 12 Å wide (8).  As seen in Figure 1.2, the minor 
groove contains the pyrimidine O2 and the purine N3 of the base pair, while the 
major groove is located on the opposite side.  Many of the structural features of 
DNA play crucial biological roles. For instance, groove recognition is essential for 





























Figure 1.2. Major and minor grooves in DNA.  The glycosidic bonds in a base pair are not located 
in opposite positions in the helix. This defines two sides of different size, a larger defined as major 
groove, and a smaller side, or minor groove.  
 
 
DNA is the carrier of genetic information and has critical cellular functions 
such as cell division. Therefore, it is not surprising that many drugs that are 
currently in clinical use or in advanced clinical trials are directed at nucleic acids 
(10). As illustrated in the simple schematic in Figure 1.3, small molecules that 
 4 
bind to nucleic acids can alter gene expression or induce apoptotic cell death by 
interfering with the cell’s replication, transcription, or translation machinery. 
Therefore, targeting DNA to inhibit or alter the expression of a particular gene or 
to selectively influence infected or diseased cell populations presents very 
attractive possibilities for drug design. Therapeutic applications of DNA-































Figure 1.3. DNA binding molecules may interfere with DNA processing enzymes. When small 
molecules bind to nucleic acids they can alter the processes carried out by DNA processing such 
as unwinding, replication and transcription, eventually causing cell death 
 
DNA binding molecules are particularly important as anticancer agents 
because of the differential growth rate of healthy tissues and cancerous cells.  
Cancer cells divide and replicate uncontrollably and thus can be predominantly 
targeted for cell death. Early data suggesting that small molecules could act as 
 5 
chemotherapeutic agents was indirectly discovered from chemical warfare used 
in World Wars I and II (11). It was noted that survivors of mustard gas exposure 
had lower white blood cell counts. Researchers eventually recognized that cell 
division was affected in these cells and realized that other fast-dividing cells such 
as cancer could be potentially targeted (12). Consequently, in the 1940s, 
nitrogen mustard was used successfully to treat several patients with advanced 
lymphomas (13). It is now known that mustard gas, or 1,1-thiobis(2-
chloroethane), acts by forming cross-links to DNA (14-16). These discoveries led 
to a rapidly expanding field that investigates DNA-binding drugs to treat diseases 
such as cancer. 
However, as evidenced with the toxic mustard gas, DNA-binding drugs 
can have negative side effects that include increased mutagenic and 
carcinogenic properties (14-17). Many have poor tissue specificity and may non-
specifically target other fast-diving cells such as bone marrow or germ cells (18).  
In order to design potent and selective DNA-interactive anticancer agents, it is 
necessary to identify important structural elements involved in DNA binding and 
understand the factors that regulate their interactions with DNA.  Some of these 
factors will be elaborated on in the following sections of this chapter. However, a 
brief summary of classical DNA interactive molecules and their binding modes to 
DNA will be discussed next. 
 
1.2. Small molecules that bind to DNA 
 
Small molecules can bind to DNA either covalently or non-covalently 
through electrostatic, hydrogen bonding, or hydrophobic interactions. In contrast 
to non-covalent agents, most covalent interactions are irreversible. Robust, 
irreversible interactions are useful in treatment of tumors or foreign bodies such 
as viruses and bacteria (19). These drugs ultimately generate cell death in 
targeted cells by inducing DNA lesions. Therefore covalent drugs can be toxic 
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and have long-lasting effects which make them less desirable from a clinical 
standpoint. (10). The challenge in drug design is to develop agents that can 
effectively bind to their targets and have fewer deleterious side effects by 
selectively targeting the cancerous over regular cells (20).  
                                       
1.2.1. Covalent Interactions  
 
Compounds that form covalent bonds with nucleic acids can interfere with 
the normal function of DNA by irreversibly modifying nucleotides, either by 
causing base-pairing mismatches during DNA replication, or by cross-linking the 
strands of the DNA helix. Some examples of such covalent drugs are Cisplatin, 
Mitomycin C, and Alkeran, shown in Figure 1.4. Cisplatin, or cis-diamine-
dichloro-platinum, is the most widely used anticancer drug. Studies have shown 
that cisplatin can platinate the N-7 of guanine bases, causing intra-strand 
crosslinks, potentially interfering with the mobility of DNA polymerases. 
Mitomycin-C is an anti-tumor antibiotic which can form cross-links between 
guanine bases on adjacent strands of DNA.  This inhibits the formation of single 
stranded DNA and affects the cells’ replication and transcription machinery. 
Alkeran is an alkylating agent that can react with nucleophilic sites on the DNA. It 
attacks the N7 position of guanine bases causing a conformational change in the 
base. Although covalent DNA binding drugs represent vast opportunities for drug 
design, this chapter will focus on non-covalent DNA binders, as they represent 


























Figure 1.4. Examples of covalent DNA-binding drugs. (A) Cisplatin. (B) Mitomycin-C. (C) Alkeran. 
 
1.2.2. Non-covalent Interactions 
 
Non-covalent DNA binding interactions include external electrostatic 
binding, groove binding, and intercalation. The schematic in Figure 1.5 illustrates 




Figure 1.5. Non-covalent Small molecule-DNA interactions. (A) External electrostatic. (B) Groove 
binding. (C) Intercalation 
 
 
The first type of reversible association occurs through non-specific 
electrostatic interactions. DNA is a highly charged polyion with two negative 
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charges per base pair.  Positively charged counter-ions surround the DNA and 
affect its stability, structure and interactions. Cationic ligands can interact with the 
negatively charged phosphates in the DNA backbone (21). These associations 
can be favored entropically by the release of counterions upon binding and are 
generally not sequence or location specific. An example of a group of drugs that 
binds through this mode are the cationic polyamines such as spermine and 
spermidine, shown in Figure 1.6 Polyamine drugs are currently being studied to 
induce apoptosis in cancer cells as these have a higher requirement of natural 














Figure 1.6. Examples of external electrostatic DNA binders. (A) Spermine. (B) Spermidine 
 
 
Groove-binding molecules interact with the major or minor groove of DNA. 
They are generally composed or simple aromatic rings that are connected by 
bonds with torsional freedom (2, 23, 24). There are many groove binding 
molecules that are currently in clinical or preclinical trials; for a review see 
reference (24). Figure 1.7 shows some of the classical groove binders, DAPI 
(4’,6’-diamidino-2-phylindole), Hoechst 33238, and distamycin. Groove binders 
can displace cations and water molecules from the grooves and can extend over 
many base-pairs, which can allow for high sequence specific recognition (23). 
They tend to bind preferentially to AT rich sequences since they can form 
hydrogen bonds with the C2 carbonyl oxygen of thymine bases and the N3 
nitrogen of adenine bases (2). In contrast, the amino group of guanine hydrogen 
bonds with the carbonyl oxygen of cytosine, sterically blocking other molecules 







































Figure 1.7. Examples of Groove Binders. (A) DAPI. (B) Hoechst 33258. (C) Distamycin 
 
 
Intercalation occurs when molecules fit themselves in between base pairs 
of DNA (25). Intercalators are mostly polycyclic, aromatic, and planar 
compounds, such as ethidium, proflavine, daunomycin, or the naphthalene 
bisimides (Figure 1.8). Unlike the first two types of non-covalent binding modes, 
intercalation requires a degree of unwinding of the DNA helix to open up a space 
between the base pairs to fit the intercalating ring system (26). This mode of 
binding is generally slower than groove binding and is stabilized by hydrophobic 
contacts between the drugs and the DNA bases. Most intercalators display either 
no binding preference or a slight GC base pair preference (25). This is probably 
due to the larger dipole moment of the GC relative to AT base pairs (2). Many 
intercalating drugs are presently used to treat a variety of cancers and others are 





























1.3. Factors that affect DNA binding 
 
There are many factors that affect small molecule-DNA interactions. As 
discussed in the previous section, a drug’s structure can influence its mode of 
binding, for instance by facilitating hydrogen bonding with the grooves or π-π 
stacking interactions with the DNA bases. Modifying structural elements of a drug 
can alter its mode of action and selectivity. Hence, structure-activity relationship 
studies are useful to determine key structural elements in a drug’s mechanism of 
action. A molecule’s chirality and spatial characteristics can also determine 
whether it will fit and interact with its desired target. The physicochemical 
properties of a drug are central for its interactions. For instance, solubility and 
partition coefficient are critical for its transport between lipophilic and hydrophilic 
compartments in the cell. Other conditions such as ionic strength, temperature or 
pH affect drug-DNA interactions as well. 
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Because DNA is a charged polyion, metal cations also play a vital role in 
the mechanism of action of DNA-targeting pharmaceuticals. They can change a 
ligand’s geometry and physico-chemical properties, help direct a drug to specific 
targets, change their oxidation state, or affect their bioavailability (27-29). 
Furthermore, metal ions can affect the structures and interactions of nucleic 
acids and proteins, and can regulate cellular processes such as DNA-packaging, 
repair, recombination, replication, transcription and translation (30, 31).  The 
metal ions involved are generally the ubiquitous divalent cations Mg2+ or Ca2+, 
but transition metals can substitute them in some cases.  
Due to the intrinsic relationship between metal ions and nucleic acid 
structure and function, innovative metal-containing compounds may serve as 
useful probes in the fight of diseases and cancer. The metal-related interactions 
of a family of novel ligands will be the focus of the body of work in this study. 
Examples of these and other metallo-DNA binders are given in the following 
section. 
 
1.4. Metallo-DNA binders 
 
Pharmaceutical agents having metal ions as components are becoming 
increasingly prevalent in treating a wide variety of diseases and metabolic 
disorders (27, 28, 32-36). Cancerous cells experience unchecked growth, 
requiring tumor cells to have an elevated level of nutrients, membrane 
permeability and blood flow with a consequent accumulation of transition metals 
(32, 37-40). The result can be a greater uptake of metallo-pharmaceuticals within 
the cancerous cells (38-41) . Metal complexes also have higher tendency for 
hydrolysis, redox and photoreactions that may be exploited as a mechanism of 
action (42). In addition, having a positive metal ion facilitates the interaction of 
drugs to the negatively charged nucleic acids, which makes many metal 
complexes promising therapeutic agents (30, 31, 43, 44).  
 12 
There are many metallodrugs that are currently in clinical trials, including 
cisplatin, carboplatin, auranofin, sodium nitroprusside, and cardiolyte (36). 
Cisplatin (section 1.2.1) is perhaps the most commonly used chemotherapeutic 
agent, and is administered to treat various types of cancer, particularly testicular 
cancer (45). In spite of the wide usage of cisplatin, this drug presents high 
general toxicity that result in undesired side effects, and many tumor cell types 
are resistance to this drug (46). Studies of cisplatin have stimulated research of 
other transition-metal based compounds. Metallodrugs have emerged that show 
promising antibacterial or antineoplastic activity, including complexes with 
palladium, ruthenium, gold, rhodium, copper, and lanthanum (43, 47). A few 
representative examples will be discussed in the next section.  
 
1.4.1. Aureolic acid group of antitumor antibiotics 
 
The aureolic acid antitumor antibiotics, such as chromomycin or 
mithramycin (Figure 1.9), were originally isolated from Streptomyces species and 
consist of tricyclic polyketides attached to oligosaccharide chains of variable 
length such as (48). Mithramycin has been studied since the 1950s and is 
currently used as a chemotherapeutic agent for the treatment of several types of 
cancer (49, 50).  
Chromomycin and mithramycin are known to interact with the DNA minor 
groove of GC rich sequences in the presence of divalent cations (51). The metal-
mediated DNA binding in the presence of Mg2+ is well documented, but other 
metal complexes have also been recently investigated (51-57). Besides 
magnesium ions, mithramycin has also been shown to bind to Cu2+, Fe3+, and 
Tb3+ ions (58). A recent study showed that mithramycin formed stable complexes 
with Fe3+ ions with higher cytotoxicity in several cancer cell lines and higher 



















































Quinolones and fluoroquinolones were first investigated as bactericidal 
drugs. The first generation of compounds were originally synthesized in the 
1960’s and included compounds such as nalidixic acid (Figure 1.10A), which was 
used for urinary tract infections (59). However, because of its poor efficacy and 
side-effects, it was dropped from clinical use several years later. By 1980’s a 
series of improved quinolones such as Ciprofloxacin (Figure 1.10B) were 
developed with a fluorine addition at the C-6 position; these compounds showed 
enhancement of potency against Gram negative and positive bacteria (60, 61). 
To date, Ciprofloxacin is the most active and broad range oral antibacterial in 
clinical use. Third generation quinolones include compounds such as 
Levofloxacin with increased efficacy against resistant strains of bacteria (Figure 
1.10C) (62). 
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Studies have shown that some of the main targets of these compounds 
are DNA gyrase and topoisomerase IV-DNA complexes which are essential in all 
bacteria (63). Quinolones interact at or near site of DNA scission of these 
enzymes; they perturb the local DNA structure and increase levels of enzyme-
DNA cleavage complexes eventually leading to cell death. 
Later studies showed that some quinolones did not display antibacterial 
activity but were cytotoxic against several cancer cell lines (64). The cytotoxicity 
has been correlated with Topoisomerase II inhibition, which is the eukaryotic 
counterpart of DNA Gyrase. These properties are being exploited and new 






















Figure 1.10. Members of the quinolone family of drugs. (A) Nalidixic acid (B) Ciprofloxacin (C) 
Levofloxacin 
 
A key determinant in the mechanism of action of these drugs is their ability 
to bind to single-stranded DNA. These interactions are closely related to their 
interactions with metal ions. As with the aureolic acids, Mg2+-quinolone 
complexes have been extensively studied and coordination with this metal has 
proven to be fundamental with the DNA-enzyme complexes (67). Recent studies 
have also investigated complexes of quinolones with other transition metals such 
as Co2+, Cu2+, Ni2+, and Zn2+; in vitro tests indicate that the complexes display 
stronger activity than that of uncomplexed drugs (68). Some compounds 
described in the following section of exhibit similar binding characteristics to this 
family of compounds and will be discussed further in later chapters.  
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1.4.3. Benzoxazole, Benzothiazole, and Benzimidazole Ligands 
  
Benzoxazole, benzothiazole and benzimidazole compounds have been 
studied for decades for their wide array of biological properties (69-71). They 
possess a degree of structural similarity with purine nucleic bases such as 
guanine or adenine that can facilitate their interactions with biopolymers such as 
DNA. Not surprisingly, as in other groups of DNA-interactive molecules, these 
moieties are often encountered in compounds that present a variety of 
therapeutic activities, including antimutagen, antiallergic, analgesic, anti-
inflammatory, antipyretic, antioxidant, antiaggregant, antiparasitic, antibacterial, 
antiviral, or antitumor properties (69-84). In many cases these compounds can 
coordinate metal ions through the nitrogen or oxygen atoms of the ring system 
(85-95). UK-1 is an example of a bis-benzoxazole ligand that can form metal 
complexes and presents very interesting biological properties.  The first part of 
this dissertation encompasses the synthesis and biological evaluation of 
simplified benzoxazole analogs of UK-1. Further discussion of this natural 
product and some of its analogs are given in the following sections. 
 
1.5. The Bis-benzoxazole natural product UK-1  
1.5.1. Discovery 
 
UK-1 was originally isolated from Streptomyces sp. 517-02 by Akei and 
coworkers while screening for new antibiotics (96). Although UK-1 did not 
present any growth inhibitory activity against Gram-negative and Gram-positive 
bacteria, yeasts or fungi up to 100 µg/ml, it did show cytotoxicity against the 
cancer cell lines B16, HeLa and P388 (IC50 = 3.0, 3.2, and 0.3 µM respectively). 
The same research group also carried out the structural elucidation of this novel 
metabolite (97),  uncovering a unique bis-benzoxazole in which the 2-position of 
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one benzoxazole  was  joined to the 4-position of the second ring as shown in 
Figure 1.11A.  
As part of the structural characterization of UK-1 two new derivatives were 
prepared, the mono-methyl ether MUK-1 produced by methylation with methyl 
iodide and anhydrous potassium carbonate, and the corresponding carboxylic 
acid, DMUK-1, generated by alkaline hydrolysis (97). Later biological studies of 
DMUK-1 and MUK-1 revealed that these non-cytotoxic compounds possessed 
antibacterial and antifungal activity against certain strains (98, 99). Sato et al. 
also isolated a related bis-benzoxazole product from Streptomyces sp AJ9561 
(100). This compound, AJI9561, like UK-1, presented cytotoxicity against Jurkat 
and P388 cells (0.88 µM and 1.63 µM respectively). The structures of MUK-1, 

































1.5.2. Biological properties 
 
The Kerwin research group became interested in the unusual biological 
properties of these bis-benzoxazoles compounds as potential anticancer agents. 
Previous studies by DeLuca and Kerwin achieved the total synthesis of UK-1 and 
DMUK-1, confirming the assigned structures (101). Further biological studies 
were conducted to obtain insight into the possible mechanism of action of  UK-1 
(102).  
One of the aspects explored was the possibility that the interactions of UK-
1 could involve metal ions. The rationale was initiated by the structural 
comparison to known synthetic metal complexes that contain the 2-(2’-
hydroxyphenyl) benzoxazole moiety present in UK-1 (85, 93, 95). Furthermore, 
the related 2-(2’-hydroxyphenyl)oxazoline moiety is present in several microbial 
siderophore natural products that can bind iron or copper, such as Nocobactin 
NA, Asteroidic acid, Mycobactin M, Brasilibactin A, Parabactin or Exochelin 
772SM (103-107). Experiments by Reynolds et al. showed that in fact UK-1 did 
exhibit spectral changes upon addition of several divalent cations (102). It was 
determined that this compound could form stable complexes with Mg2+ and Zn2+ 
with an overall stoichiometry of 1:1. Weaker binding to other ions like Fe3+ and 
Ca2+ was observed, while no variations in the spectra occurred in the presence of 
monovalent cations like K+. Addition of excess NaOH caused similar changes as 
those examined upon metal ion binding, suggesting that the phenolate species is 
involved in metal coordination.  
Unlike the unbound ligand, the 1:1 complexes of UK-1 with divalent and 
trivalent metal ions are cationic, which could lead to favorable interactions with 
DNA. This led Kumar et al. to investigate the affinity of UK-1 for calf thymus DNA 
in the presence and absence of Mg2+ ions. A ten-fold tighter association was 
observed when magnesium was present, as well as an increase in the melting 
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temperature of the DNA (102). This study also showed that UK-1 could inhibit the 
activity of human Topoisomerase II in decatenation assays, indicating that it can 
interfere with DNA-processing enzymes. The metal-mediated DNA binding of 
UK-1 was corroborated by mass spectrometry studies, where complexes of UK-1 
with oligonucleotide sequences were only observed in the presence of divalent 
cations like Zn2+, Co2+, and Ni2+ (108). To further understand the structural basis 
of the biological properties of UK-1 structure-activity relationship studies were 
previously carried out as described below. 
 
1.5.3. Structure activity relationships of UK-1 analogs 
 
A number of analogs of UK-1 were synthesized by Kumar and co-workers 
in which the carbomethoxy-substituted benzoxazole ring was either modified or 
deleted, as shown in Figure 1.12 (109). To evaluate their anticancer activity, 
cytotoxicity studies were performed in various cancer cells lines, including the 
breast cancer (MCF-7), leukemia (HL-60), colon carcinoma (HT-29), and prostate 
cancer (PC-3) cells. Table 1.1 shows the IC50 values obtained which represent 
the concentration of the compound required for 50% growth inhibition compared 
to untreated cells.  
Modification to a benzimidazole ring as in 1 abolished the cytotoxicity in 3 
of the 4 cell lines studied. The benzyl adduct 2 was isolated as a side product 
during the synthesis of UK-1. This compound presented a diminished degree of 
activity compared to UK-1 except in HT-29 cells. Most of the other analogs 
studied did not exhibit anticancer activity against the cancer cell lines, except for 
the 2-(2-hydroxy-phenyl)-benzooxazole-4-carboxylic acid methyl ester 8, which 


















































Figure 1.12. Structures of UK-1 analogs 1-8. Analogs synthesized by Kumar et al (109). 
 
 
Table 1.1. Anticancer activity of UK-1 and analogs 1-8. Table adapted from reference (109). 
Cytotoxicity against MCF-7, HL-60, HT-29, and PC-3 cells was determined after 72 h incubation 
with compound at 37 oC using the AlamarBlue Assay. 
IC50  (µM)  
Compound MCF-7 HL-60 HT-29 PC-3 
UK-1 1.6 0.32 65 0.4 
1 >100 70 >100 >100 
2 13 27 5.2 4.5 
3 >100 >100 >100 >100 
4 >100 >100 >100 >100 
5 >100 >100 >100 >100 
6 >100 >100 >100 >100 
7 >100 >100 >100 >100 
8 1.5 5.7 9.1 0.88 
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The antibacterial activity of these series against was also examined in two 
strains of S.aureus. The benzimidazole acid 3 and the benzoxazole acid 4 
presented very modest activity against the two bacterial strains. Like UK-1, the 
rest of the compounds did not show any antibacterial activity up to a 
concentration of 50 µg/ml.  
It was also established that within this series of compounds there was a 
correlation between metal binding affinity and cytotoxicity. The spectra of 
methanolic solutions of these compounds were monitored in the presence of 
varying concentrations of Mg2+, Zn2+, Ca2+, or Fe3+ ions. Analogs that have a 
benzyl or methyl protected phenyl group (compounds 3-6) did not form 
complexes with any of the metal ions studied and were not active against cancer 
cells. The inactive 4-unsubstituted 2-(2’-hydroxyphenyl)-benzoxazole 7 could 
form complexes with some of the metals, but not magnesium. Likewise, the 
benzimidazole analog 1 showed lower affinity for Mg2+ compared to UK-1. 
Conversely, the cancer cell cytotoxic analog 8 presented similar Mg2+ and other 
metal ions binding with respect to the natural product. These results indicate that 
substituting the 4-(benzoxazo-2-yl) moiety in UK-1 for a 4-carbomethoxy 
substituent, as in 8, retain Mg2+ ion binding ability and cytotoxicity, while the 4-
(benzimidazo-2-yl) substituent (as in 1) does not. Removing the 4-
carboxymethoxy group altogether, as in 7 greatly reduces metal ion affinity and 
abolishes activity. The data taken together indicated that compound 8 represents 
a minimum pharmacophore of the selective anticancer activity and metal ion 
chelation of UK-1.  
As noted earlier, UK-1 has been shown to form metal ion complexes that 
can bind to DNA and can inhibit DNA processing enzymes (102, 108). While it is 
unlikely that metal ion binding per se is the origin of the selective cytotoxicity of 
UK-1 or compound 8, this study pointed out that metal ion affinity, in particular 
Mg2+, might be key to retain activity.  An appropriately substituted 2-(2’-
hydroxyphenyl) benzoxazole moiety, such as the simplified analog 8, is crucial to 
preserve the biological properties of UK-1. However, the structural basis for 
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metal ion recognition and anticancer activity for this structure requires further 
investigation.  
Compound 8 represents an important lead to design more potent 
anticancer drugs, and has been used as a starting point encompassed in the 
following work. An experimental plan was developed with the following aims: 1) 
To design and synthesize novel benzoxazole analogs of compound 8, 2) to 
examine key structural elements for metal binding, and 3) to investigate the 
effects of metal binding on DNA affinity and  biological activity. 
The synthesis and design of DNA interacting compounds is a potentially 
important strategy in the treatment of cancer cells. Determining the binding 
conditions of novel metal chelated ligands and their DNA targets provide a 
powerful mechanism to inhibit unchecked cell growth. Furthermore, the study of 
these small molecules may offer insight into how metal ion complexes can be 
harnessed in the design of selective cytotoxins.  
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CHAPTER 2. DESIGN AND SYNTHESIS OF NOVEL SIMPLIFIED 
BENZOXAZOLE ANALOGS OF UK-1 AND METAL 
COMPLEXES 
 
2.1. Rationale for the Design of New Analogs  
2.1.1. Disposition of N and O in the benzoxazole moiety 
 
As discussed in section 1.5.3, structure-activity-relationship comparisons 
by Kumar and co-workers determined that the simplified compound 8 was the 
minimum pharmacophore structure that retained the selective cytotoxicity of the 
natural product UK-1 (109). It was also noted that affinity for metal ions was 
correlated with their activity. In order to further investigate the relationship 
between biological activity and metal coordination it is important to examine the 
structural elements that are important for metal binding. Compound 8 consists of 
a 2-(2’-hydroxyphenyl)-benzoxazole with a methyl ester at position 4 of the 










































Figure 2.1. Disposition of the Nitrogen and Oxygen atoms in the benzoxazole moiety of 
compounds 8 and 9. (A). The methyl ester is positioned in the same side as the N in the 
benzoxazole ring in compound 9. (B) The methyl ester is positioned in the opposite side of the 
ring as the N heteroatom. 
 
Studies on benzoxazole itself have revealed that this compound is able to 
form metal complexes with Co2+, Cu2+, Ni2+ and Zn2+ through coordination with 
 23 
the nitrogen heteroatom of the cycle (86, 88). Improved coordination is found in 
the compound 2-(2’-hydroxyphenyl)-benzoxazole (compound 7) which has been 
reported to chelate with Co2+, Cd2+, Cu2+, Ni2+ and Zn2+, stabilized through 
interactions with both the phenolate O and its benzoxazole ring N (87, 93, 95, 
110). However, this compound is unable to bind Mg2+ ions and did not present 
any cytotoxicity in the cancer cell lines studied by Kumar et al. (109). Introduction 
of 4-carbomethoxy substituent to the benzoxazole core, as in 8, appeared to 
impart Mg2+ ion binding ability as well as activity against cancer cell lines to the 2-
(2’-hydroxyphenyl)-benzoxazole core.  
To expand on this idea, the isomeric benzoxazole analog (9), 2-(2’-
hydroxy-phenyl)-benzooxazole-7-carboxylic acid methyl ester, was synthesized 
as described in the following section. Compound 9 differs with 8 solely in the 
disposition of the benzoxazole N and O atoms within the cycle; unlike compound 
8, the methyl ester is located on the opposite face of the ring to the N heteroatom 
(see Figure 2.1). If the methyl ester is not involved in metal coordination, no 
differences between metal affinities would be expected between the two 
compounds. Discrepancies between within their binding modes and biological 
activities would aid in the understanding of the structural significance of a 
substitution at the 4 position of benzoxazole ligands. 
2.1.2. Effect of modification of the methyl ester position 
 
To design more potent analogs with improved physicochemical properties 
it is imperative to modify structural elements that will not lessen their biological 
activity. Modifications of the 4-carbomethoxy position of compound 8 could serve 
as a starting point for new structure activity relationships. Because it is likely that 
metal coordination occurs between the N in the benzoxazole ring, the phenolate 
O and is further stabilized through interactions with an O in the methyl ester, it is 
important to design analogs that retain these characteristics. 
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Further evidence for this idea came from the studies of Wang and 
coworkers (111). The authors synthesized three new UK-1 analogs and studied 
their inhibition of the enzyme Topoisomerase II. They observed that deletion of 
the methyl ester or the 2’-hydroxyl group in UK-1 (Compounds Wang-1 and 
Wang-2 in Figure 2.2) did not affect enzymatic inhibition significantly.  On the 
other hand, the removal of both functional groups abolished the compound’s 
activity (Compound Wang-3). Their research suggested that the analogs required 
a structural motif comprised of an isosceles triangular arrangement between the 
oxygen atom of carbonyl group, the heterocyclic nitrogen atoms, and/or the 
phenolic hydroxyl for enzyme inhibition (Figure 2.2). They also noted that the 
simplified compound 8 possesses a similar arrangement of basic sites; they 





























Figure 2.2. Structural motif in UK-1 analogs important for activity. UK-1 analogs prepared by 
Wang et al. suggest that an isosceles triangular arrangement between the nitrogen atom in the 
benzoxazole core and at least two other heteroatoms, as in compound 8, UK-1, and Wang 
compounds 1 and 2, is necessary to retain activity. The calculated distances between the 
highlighted groups are 2.9–3.0 Å  on two sides and 4.5–4.7 Å on the remaining side (111). 
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Keeping these considerations in mind, a new series of compounds that 
explore effects of different 4-substituents of compound 8 while retaining the 
benzoxazole core and the 2-(2’-hydroxyphenyl) substituent were prepared. In 
particular, the effect of homologation of the 4-methyl ester and its replacement 
with an amide were addressed. Given the evidence that metal ion complexation 
is important for cytotoxicity in previous UK-1 derivatives, additional potential 
metal ion coordination sites were introduced in some analogs. As previously 
observed, UK-1 and compound 8 have low aqueous solubility, so polar groups at 
this position were also included (102, 109). 
 
 
2.2. Synthesis of Novel Benzoxazole ligands 
 
The synthesis of these analogs was accomplished through adaptation of 
the previously reported procedures for UK-1 and compound 8 (101, 109). The 
synthesis of methyl 2-(2’-hydroxyphenyl)-benzoxazole-7-carboxylate (9) was 
carried out as a one-pot procedure depicted in Scheme 2.1.  The condensation of 
2-benzyloxybenzoic acid chloride with 3-amino-2-hydroxybenzoic acid yielded 
the intermediate 3-(2-benzyloxy-benzoylamino)-2-hydroxy-benzoic acid which 
was cyclized and de-protected with p-TsOH. Methylation using TMS-CHN2 
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Scheme 2.1. Synthesis of compound 9 
 
Modification at the C4 position of compound 8 were carried out using a 
key intermediate, the benzyl-protected carboxylic acid 4 (Figure 1.12) through 
esterification (compounds 10,15) or coupling with a primary amine (compounds 
11-14). Analog 10 possesses an ethoxy group instead of the methoxy group, and 
was synthesized as described in Scheme 2.2; esterification of compound 4 in 
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10  
Scheme 2.2. Synthesis of Compound 10. Coupling of EtOH to compound 4 was achieved 
through a simple esterification with thionyl chloride. 
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The methylamide 11 was prepared with a 49% yield from the methyl ester 
5 through coupling with a methylaluminumchloride-methylamide reagent 
(Scheme 2.3). Other analogs with extended esters and amides were also 
synthesized via CDI coupling of compound 4 with butylamine, aminohexanol, 2-
(2-aminoethoxy)ethanol, or tetraethylene glycol to give compounds 12-15 




















     49%
 
Scheme 2.3. Synthesis of compound 11. The benzyl protected ester 5 was reacted with a 












12: R=NH-(CH2)3-CH3   45%
13: R=NH-(CH2)6-OH    45%
14: R=NH-(CH2)-O-(CH2)2OH   86%






i) CDI/DCM, rt 1h
ii) Alcohol/amine (iia-d)
         Reflux, 2d
          45-86%
 
Scheme 2.4. Synthesis of compounds 12-15. Compound 4 was coupled using CDI to various 
esters and amines yielding analogs 12-15. 
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The resulting esters and amides were subjected to hydrogenolysis to 
remove the benzyl phenol protecting group to afford the 2-(2’-hydroxyphenyl) 









16: R=O-CH2-CH3  96%
17: R=NH-CH3  85%
18: R=NH-(CH2)3-CH3 91%
19: R=NH-(CH2)6-OH   90%
20: R=NH-(CH2)-O-(CH2)2OH  63% 
















CHAPTER 3. AFFINITY OF ANALOGS FOR METAL IONS 
 
The majority of DNA binding agents do not require metal ions to exert their 
biological activity, but some, such as members of the aureolic acid group of 
antitumor antibiotics and quinolone derivatives (see section 1.4) require metal 
coordination for proper function and structure. Similarly, the bis-benzoxazole 
natural product UK-1 is able to form complexes with divalent and trivalent cations 
and can bind to DNA in the presence of metal ions (102, 112). The new simplified 
benzoxazoles discussed in the previous chapter contain a 2-(2’-
hydroxyphenyl)benzoxazole (HPB) moiety present in UK-1 which has been 
associated with its ability to bind to transition metals  and with its biological 
properties (102, 109). It is therefore important to investigate if substitutions to the 
C4 or C7 position in the HPB core affect metal coordination of these ligands. 
 
3.1. Methyl ester at the C4 or C7 position of the HPB ring affects 
metal binding ability 
 
As discussed in section 2.1.1, compounds 8 and 9 differ in the disposition 
of the nitrogen and oxygen atoms with respect to their carbomethoxy substituent; 
the methyl ester is located on position C4 in compound 8 whereas it is located on 
position C7 in compound 9. NMR studies were carried out to compare the metal 
ion binding affinity of compound 8 and 9. Solutions of 8 in 1:1 CD3OD/CDCl3 (100 
mM) were prepared and all 1H and 13C NMR resonances were assigned by a 
combination of COSY, HMBC, and HMQC NMR spectra (see Appendix A). 
Compound 8 was then titrated with Mg(NO3)2·(H2O)6 in CD3OD (2.5 M) and the 
NMR spectra was recorded after each addition (1H NMR spectra is shown in 
Figure 3.1). The initial addition of Mg2+ (0.25 eq.) caused a marked broadening of 
all the 1H NMR resonances and shifts in specific peaks. Notably, certain 
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resonances, such as that due to the benzoxazole C7 hydrogen (ca. 7.5 ppm), 
shifted downfield while other resonances, such as those due to the 4-
carbomethoxy group (ca. 3.7 ppm) shifted upfield (a complete list of 1H and 13C 
NMR shifts is shown in Appendix B). Further additions of Mg2+ resulted in upfield 
shifts of all resonances, but in particular those due to the 4-carbomethoxy group 
and the ortho-hydroxyphenyl moiety (ca. 6.7 and 6.8 ppm), indicating that these 
residues are most affected upon metal coordination.  
These solution studies support the role of the 4-carbomethoxy group in 
metal binding by 8 and also implicate the benzoxazole moiety and the ortho-
hydroxyphenyl substituent in metal ion coordination. The complex relationship 
between 1H NMR resonance shifts and Mg2+ concentration may be due to the 
formation of different metal ion complexes of different stoichiometries during the 
titration experiment.  
 
C5C6’-H C7-H C4’C6-H C3’-H C5’-H CH3  
Figure 3.1. 
1
HNMR Spectrum of Compound 8 in the presence of Mg
2+. Line broadening of all 
peak resonances occurred after the first addition of 0.25 eq. Mg2+, and continued until 1 eq. Peak 
resonances corresponding to hydrogens in the structure of compound 8 are indicated beneath the 




Further evidence for the role of the benzoxazole moiety in metal ion 
coordination can be achieved by comparing the results obtained from metal 
binding with compound 9. As discussed in the previous chapter, this analog is the 
reverse isomer of 8 in which the position of the benzoxazole N and O atoms are 
interchanged with respect to the carbomethoxy substituent. The 1H NMR spectral 
changes observed upon addition of Mg2+ to the isomeric benzoxazole analog 9 
(Figure 3.2, Appendix B ) are quite distinct from those observed for 8. The 1H 
NMR resonances for this analog are uniformly shifted upfield in the presence of 
increasing concentrations of Mg2+, with no evidence of the line broadening 
emblematic of metal binding until an excess of Mg2+ is added. The apparent 
difference in the metal ion complexation between the 8 and 9 must be due to the 
difference in the disposition of the benzoxazole N and O atoms, further 
supporting a role for Mg2+ coordination between the phenol oxygen and the 
nitrogen atom in the benzoxazole moiety aided by the carbonyl oxygen of the 
methyl ester group. 
C6’-H C6-H C4-H C4’C5-H C3’-H C5’-H CH3  
Figure 3.2. 
1
HNMR Spectrum of Compound 9 in the presence of Mg
2+
.Peak resonances are 
uniformly shifted upfield upon addition of increasing concentrations of Mg2+, but are not 
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significantly broadened. Peak resonances corresponding to hydrogens in the structure of 
compound 9 are indicated beneath the spectrum; for structure, see Figure 2.1. 
 
Unfortunately, attempts to shed light on potential differences in structure 
between the complexes formed with 8 and 9 Mg2+ or Ni2+ by NMR titrations are 
precluded by the paramagnetic properties of the latter. NMR titrations of 8 with 
various Cu2+ salts also resulted in severe line broadening, presumably due to 
formation of paramagnetic Cu+ species. To circumvent this issue, the spectral 
changes of these analogs in the presence of varying concentrations of metal ions 
were monitored by UV-Vis (Figure 3.3). These measurements were carried out in 
methanolic solutions due to the low solubility of compounds 8 and 9 in aqueous 
buffers. 
As with NMR experiments, the spectral changes of compounds 8 and 9 
were distinct. Addition of Mg2+ to a 10 µM solution of 8 in methanol resulted in a 
marked hyperchromycity in the 350-450 nm region, even at low Mg2+/ligand ratios 
(Figure 3.3A). In contrast, compound 9 displayed no significant shifts even at 1 
mM concentration of Mg2+ (Figure 3.3B). Both compounds displayed spectral 
shifts upon addition of Cu2+ metal ion salts, but compound 9 required much 
higher concentrations to reach saturation (Figure 3.3C and D respectively). The 
data indicates that an appropriate substituent at the C4 position, represented by 
compound 8, aids in tighter copper coordination and grants the ability to bind 
magnesium cations. The triangular arrangement between the phenolic hydroxyl 
group, the benzoxazole nitrogen atom, and the ester in this ligand could have a 
favorable geometry for metal coordination. Analogs with different modifications at 
the C4 position, such as those covered in the following section, can help 

































































































Absorbance spectra of 10 µM compounds 8 (A and C) and  9 (B and D) in methanol in the 
presence of increasing concentrations of Mg2+ (A) and (B) or Cu2+ (C) and (D) respectively. Metal 
concentrations ranged from 0-90 µM in the case of compound 8, and were varied from 0-1 mM in 
the case of compound 9. Arrows denote the changes in absorbance with increasing metal ion 
concentrations. 
 
3.2. Ester and amide substitutions at the C4-position of the HPB 
ring affect metal binding abilities 
 
Because metal binding has been correlated with cytotoxicity in other 
benzoxazole compounds, the affinity of new benzoxazole analogs of 8, 
compounds 16-21 (which contain a substitution at the C4 position, Figure 3.4) for 
various metal ions was studied. All of these analogs posses a carbonyl group, 
whether an amide or an ester, that can potentially aid in metal coordination. 
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Solutions of these compounds in methanol change from colorless to yellow upon 
addition of divalent cation such as Mg2+, Zn2+, Ni2+, and Cu2+, indicating 
complexation between the analogs an the metal ions. Although compounds 19-
21 displayed increased water solubility relative to UK-1 and compound 8, metal 
coordination was assayed in methanol due to the low aqueous solubility of some 
of the ligands. Compound 21 with a tetraethyleneglycol side chain was the most 
soluble in the series, and the only one which remained in solution in aqueous 









































Figure 3.4. Structures of benzoxazoles 16-21 modified at the C4 position.  
 
 
The most pronounced change occurs in the presence of copper ions. The 
metal complex formation with these divalent ions was monitored by UV/Vis spectral 
changes upon addition of increasing concentrations of the metal ion nitrate salts in 
methanol. A marked hyperchromicity in the 350-450 nm region was observed upon 
addition of the metal ion, concomitant with a hypochromicity in the 315-350 region. A 
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clear isosbestic point was present at approximately 350 nm, with slight variation of 
the wavelength of maximum absorbance depending on the analog studied. The 
observation of an isosbestic point indicates that the two species, bound and 
unbound ligand have the same molar absorptivity at this particular wavelength. A 
representative data set for compound 17 for binding to the four divalent cations is 
shown in Figure 3.5. The methyl phenyl ether 6 (Figure 1.12) was used as a 
negative control, and no significant spectral changes were observed upon addition of 

































































Figure 3.5. UV-Vis spectral changes of compound 17 upon addition of divalent cations. 
Absorbance spectra of 10 µM compound 17 in methanol was recorded in the presence of 
increasing concentrations of Mg2+, 0-500 µM (A); Zn2+, 0-500 µM (B); Ni2+,  0-500 µM (C); or Cu2+, 





To compare the binding affinity of the new modified benzoxazole ligands 
with that of the bis-benzoxazole UK-1, metal ion binding was also examined 
using the natural compound. As seen in Figure 3.6, UK-1 readily forms 
complexes with the four metal cations and, as with the other benzoxazole 
ligands, the spectral changes were most prominent with Cu2+. There is an 
evident hyperchromicity in the 375-500 and 260-290 nm regions, with an 
associated hypochromicity in the 355-375 nm wavelengths.  Several isosbestic 





































































Figure 3.6. UV-Vis spectral changes of UK-1 upon addition of divalent cations. Absorbance 
spectra of 10 µM UK-1 in methanol was recorded in the presence of increasing concentrations of 
Mg2+, 0-500 µM (A); Zn2+, 0-500 µM (B); Ni2+, 0-500 µM (C); or Cu2+, 0-90 µM (D). Arrows denote 
the changes in absorbance with increasing metal ion concentrations. 
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3.3. Apparent association constants to divalent cations  
 
The change in absorbance of the peak in the 350-500 nm region was 
plotted against metal ion concentration to obtain binding isotherms, from which 
the association contestants of all the analogs were determined and are 
summarized in Table 3.1. Data fitting was accomplished using nonlinear 
regression of the quadratic equation [2] (section 6.2), with assumption of 
formation of a 1:1 complex (1:1 complexes resulted in higher correlation factors 
than using alternate stoichiometries). A representative data set for the binding 
isotherms of compound 17 with the four divalent cations is shown in Figure 3.7.  
 








 in MeOH (M
-1
). 




Compound Mg2+ Zn2+ Ni2+ Cu2+ 
UK-1 5±1 *105 1.0±0.5 *106 5±2 *104 
a8±3 *106 
6 cNo binding bn.d. bn.d. cNo binding 
7 cNo binding bn.d. bn.d. 4±1 *105 
8 7±3 *105 4±2 *106 6±2 *104 a3±2 *107 
9 No binding bn.d. bn.d. 3.8±0.4 *104 
16 1.5±0.4 *105 2.5±0.5 *105 2.6±0.5 *104 a3±2 *106 
17 6±2 *104 4.5±0.5 *104 4±1 *105 a6±2 *106 
18 1.1±0.2  *104 3±1 *104 5.6±0.6 *105 a6±4 *107 
19 2.4±0.4 *104 5.5±0.8 *104 1.1±0.2 *106 a2±1 *107 
20 2.8±0.7 *105 8±2 *105 8±4 *106 a7±6 *107 
21 8±3 *105 1.3±0.4 *104 2.0±0.7 *104 a7±6 *107 
a Values represent lower limit for the association constant 
b Not determined 
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Figure 3.7. Binding isotherms of Compound 17 with metal cations. The normalized increase in 
absorbance (∆A/∆Amax) was monitored with respect to the free metal ion concentration at 387 nm 
for Mg2+ (A), 391 nm for Zn2+ (B), and 400 nM for Ni2+ and Cu2+ (C and D respectively). The 
connecting curves were generated by nonlinear fitting of experimental points as described in the 
experimental section. 
 
As seen in Table 3.1, the C4-substituted HPB analogs 16-21 bind copper 
with relatively high affinity as 1:1 complexes; after addition of 1 equivalent Cu2+ 
ions there are no further changes in the absorbance spectra. In contrast, the C7-
substitued benzoxazole analog 9 is a relatively poor ligand for Cu2+ compared to 
the rest of the analogs, and is the only HPB that does not bind Mg2+. In addition, 
the methyl phenyl ether 6 did not form complexes with any of the salts studied. In 
general, the Cu2+ binding ability of the C4-substituted benzoxazoles, UK-1, 8 and 
16-21, is relatively insensitive to changes in the 4-substituent. In contrast, the 
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binding affinity towards the other metals is dependant on the nature of the groups 
at this position. The analogs with amide substituents do not bind Mg2+ as well as 
those with ester groups. As a result, the amides particularly, are more selective 
ligands for Cu2+ versus Mg2+.  On the other hand, the amides bind Ni2+ with 
stronger affinity than the esters, with longer side chains such as in compound 19 
and 20 binding better than those with smaller groups, like 17 and 18. The ability 
to bind Zn2+ decreased in the order of compound 8>16>21, indicating that the 
length of the side chains could also play a role in Zn2+ coordination.  
The critical role played by the benzoxazole C4-substituent in metal ion 
recognition is also demonstrated by comparison of these substituted 
benzoxazoles with 2-(2’-hydroxyphenyl)benzoxazole (compound 7, Figure 1.12). 
Under these conditions this compound does not bind Mg2+, and although it does 
complex Cu2+, its apparent association constant for is significantly lower than any 
of the C4-substituted benzoxazoles.  
Because all of the C4-substituted HPB appear to have very tight binding to 
copper ions (close to or higher than 1*107 M-1), attempts were made to determine 
the association constants of these analogs with greater accuracy at lower ligand 
concentrations. As seen in Figure 3.8 and Table 3.2, tight copper binding is still 
observed at 1 µM ligand (compare with the results obtained for 17 and UK-1 in 
Figure 3.5 and Figure 3.6).  Figure 3.9 shows an example of the fraction metal 
bound as a factor of ligand concentration using compound 8 at 10, 5, 2.5 and 1 
µM. All of the graphs overlap and yield association constants in the same range 
(107 M-1).  Unfortunately, the signal to noise ratio precluded lower compound 
concentrations to be examined. Therefore, the copper binding constants shown 
in Table 3.1 and 3.2 can only be regarded as lower binding limits.  
The strong binding to copper ions is very interesting because previous 
studies suggested that Mg2+ was the primary cation involved in coordination with 
UK-1 and 8 (109). However, Cu2+ could be a significant player in the interaction 
of both UK-1 and the C4 substituted HPB ligands The binding preference of the 
natural product for Cu2+ relative to other cations studied previously is also 
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exciting in light of the many copper chelates possessing anticancer activity (27, 
28, 32, 34, 36, 41, 113). Furthermore, as discussed in the introductory chapter, 
UK-1 was originally thought to be similar to bacterial siderophores. However, its 
affinity for iron was relatively low (102). This study has shown that UK-1 prefers 
to chelate copper ions with higher affinity than any other metals studied so far, 
which raises the possibility of its involvement in the biological role for the natural 
product. Transition metal coordination can greatly affect the properties of DNA-
binding molecules and therefore the DNA-binding properties of UK-1 and the 
HPB series should be studied in the presence of Cu2+ and the more abundant 









































Figure 3.8. UV-Vis spectral changes of compound of 1 µM Compound 17 and UK-1 upon 
addition of Cu
2+
. Absorbance spectra of 1 µM compound 17 (A) or UK-1 (B) in methanol were 
recorded in the presence of increasing concentrations of Cu2+, ranging from 0-9 µM. Arrows 
denote the changes in absorbance with increasing metal ion concentrations. 
 
 
Table 3.2. Lower limit of the association constants for Cu2+ binding in MeOH (M-1) at 1 µM ligand  
 
Compound Cu2+ 
UK-1 5±5 *107 
8 4±2 *107 
16 3±1 *107 





























Figure 3.9. Fraction Cu
2+
 bound to Compound 8 at various ligand concentrations. The 
absorbance at 410 nm was monitored by increasing the ratios of metal/ligand using 10 µM (filled 
diamonds), 5 µM (empty squares), 2.5 µM (filled triangles), or 1 µM (empty circles) compound 8. 
 
3.4. Synthesis of a UK-1-Cu2+ chelate 
 
To further study the copper chelation of UK-1, its copper complex was 
prepared by refluxing the ligand with cupric acetate as shown in Scheme 3.1. 
Elemental analysis and mass spectroscopy confirmed the formation of a 1:1 
complex which was isolated as green needle-like crystals. It is anticipated the 
copper atom is coordinated between the two nitrogen atoms of the benzoxazole 
rings, and the oxygen from the phenol group of UK-1. There may also be an 
additional coordination site with the carbonyl oxygen of the methyl ester. Similar 
coordination sites could occur between the benzoxazole nitrogen, the phenol 
oxygen and the carbonyl oxygen in the C4-substituted HPB analogs, and could 
explain the lower metal affinities observed for the C7 or unsubstituted analogs. 
Attempts to generate a 2:1 ligand:metal neutral complex were 
unsuccessful, even at excess concentration of UK-1. Further evidence of the 
stoichiometry of the UK-1 copper complex arises by comparison to the chelates 
of compound 7, hydroxyphenyl 2-(2’-hydroxyphenyl)benzoxazole. It has been 
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reported that metal complexes from this compound with different stoichiometries 
differ in their fluorescence quantum yields; transition metal 1:1 metal chelates, 
unlike the neutral molecular complexes do not display fluorescence (95). 





















Scheme 3.1. Synthesis of UK-1 Cu Complex. 
 
 
The IR spectra of the UK-1-copper chelate was compared to the unbound 
ligand. As seen in Figure 3.10, the IR resonances change significantly upon 
metal chelation. In particular, the phenol group around 3000 cm-1 becomes very 
pronounced. The peak corresponding to the ester, at approximately 1712 cm-1 
also shifts to 1750 cm-1. The IR bands assigned to the v(C=N) 1592 and 1548, 
are shifted to 1562 and 1529 upon coordination to the copper ions. Most of the 
peaks between the 600-1600 area were also broaden upon metal chelation and 
an intense peak above 3000 cm-1 appeared. These results support a possible 
coordination of copper with the nitrogen atoms of the benzoxazole rings, the 
phenol oxygen and possibly the carbonyl oxygen. 
The UV spectrum of the copper complex was also recorded in MeOH, and 
is shown in Figure 3.11. The complex displays peaks at 418, 348, 333, 317, 275, 
267, and 236 nm, similar to those observed from the Cu2+ titration experiments 
with the natural compound (see Figure 3.6D). This could indicate that similar 
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Figure 3.11. UV-Vis Spectrum of the UK-1-Cu
2+ 
Complex in MeOH. The spectra were recorded at 
5, 10, 20, 30 and 50 µM complex concentrations. 
 
 
The isolation of the UK-1 copper complex will allow for direct comparison 
of the biological properties of the chelate and those of the uncomplexed ligand. 
Future X-Ray crystallography studies could aid in the structural elucidation of the 
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complex. It is possible that Cu2+ coordination could facilitate DNA interactions by 
charge attraction to the negatively charged phosphates in nucleic acids. The 
metal could also assist in cellular entry or alter reactivity and thus lower 
cytotoxicity values could be obtained when the ligand is complexed. Some of 
these properties will be investigated in the following chapter. 
 
3.5. General trends observed for metal affinity  
 
The metal ion binding ability of a series of novel benzoxazole ligands was 
determined spectrophotometrically in methanol. The spectral differences 
observed between the C4 and C7 substituted compounds 8 and 9, have made 
evident that the disposition of the N and O with respect to the carbomethoxy 
substituent plays an important role in metal ion coordination. The geometry in 
compound 8 with a C4-ester facilitates Mg2+ and Cu2+ ion binding ability whereas 
metal affinity is greatly diminished in the C7-substituted benzoxazole. This 
suggests that metal coordination occurs between the nitrogen atom in the 
benzoxazole ring, the oxygen phenol group and is assisted by coordination with 
the carbonyl oxygen at the C4 position. 
This study has also shown that it is possible to modify the C4 position with 
esters and amides of varying length and retain metal binding capability. While the 
Cu2+ ion binding of the C4-substituted HPB analogs is relatively unaffected by the 
nature of the groups at this position, metal ion binding affinities for the other 
metals vary with the nature of this substituent. The effect that these structural 
modifications have on DNA binding and cytotoxicity in cancer cell lines will be 
addressed in the following chapter. It should also be noted that UK-1 and all of 
the 2-(2’-hydroxyphenyl) benzoxazoles bind copper with greater affinity than the 
rest of the metal ions studied. This is relevant because it was previously thought 
that Mg2+ was the cation of preference for UK-1 and compound 8 (102). In 
addition, many copper chelates have the ability to inhibit cancer cell growth, 
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which raises the possibility that these compounds could also be useful as 
therapeutic drugs (114-118). A 1:1 UK1-copper complex was also synthesized 
and isolated. The biological properties of this chelate will also be investigated in 
the next section. 
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CHAPTER 4.  METAL MEDIATED DNA BINDING AND 
CYTOTOXICITY 
4.1. Analog affinity for DNA in the presence and absence of 
metals 
 
Metal ions can facilitate the interaction of drugs with negatively charged 
nucleic acids, and thus many metal complexes are promising DNA-targeting 
therapeutic agents. Because all of the new 2-(2’-hydroxyphenyl)-benzoxazoles 
(HPBs) form complexes with divalent cations it is important to investigate if metal 
binding affects their affinity for DNA. It is also essential to examine if the 
substitutions at the C4 and C7 position affect the biological properties of the HPB 
ligands. The chapter will discuss the metal-mediated DNA binding and 
cytotoxicity of the new benzoxazole compounds. Structure-activity relationships 
derived from this study may aid in the design of future metallo-drugs.  
As mentioned in the introductory chapter, one of the unique properties of 
the natural compound UK-1 is its ability to bind to DNA in the presence of metal 
cations (102, 108). UK-1 was originally studied as a possible siderophore for the 
producing Streptomyces organism because the 2-(2’-hydroxyphenyl) moiety in 
UK-1 is actually present in a class of microbial siderophores that bind Fe3+ (106, 
119). However, its affinity to bind Fe3+ was not found to be particularly strong 
(102). Nevertheless, there are examples of Cu2+ binding siderophores, and as 
discussed in the previous chapter, both UK-1 and the 2-(2’-
hydroxyphenyl)benzoxazoles bind to copper with high affinities. It is possible that 
copper or another transition metal plays a role in the mechanism of action of UK-
1. Therefore, the cytotoxicity and biological properties of a UK-1-Cu2+ complex 
will also be examined.  
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4.1.1. Results obtained from SPR  
 
Spectroscopy methods commonly used to monitor the interactions of small 
molecules with DNA could not be used to investigate the metal-mediated 
benzoxazole-duplex DNA interactions due to the complex spectral properties of 
the metal complexes. In addition, UV/Vis spectral changes of UK-1 and HPB 
ligands upon DNA binding were subtle compared to those due to metal ion 
complexation. Fluorescence spectroscopy was precluded because the metals of 
interest such as Cu2+ and Ni2+ completely quenched the intrinsic fluorescence of 
UK-1 and the HPB analogs upon metal ion binding. Metal ions of interest also 
quenched the fluorescence of dyes like ethidium bromide, preventing the use of 
displacement assays to study the metal-mediated DNA binding of these ligands 
(120).  
Surface-plasmon resonance (SPR) monitors the change in refractive index 
of flow cells on a sensor chip surface upon complex formation and is a very 
useful and sensitive technique to study small molecule-DNA interactions (121-
123). SPR can provide equilibrium and kinetic constants of complex formation by 
comparing response units (RU) between control and DNA-immobilized flow cells. 
This method is particularly useful to investigate the interactions of the 
benzoxazole ligands covered in this work because metal ions do not interfere 
with the measurement of resonance units observed upon compound binding to 
DNA on the surface of the chip. Furthermore, SPR metal-mediated DNA binding 
studies have been reported for the aureolic antibiotics Mithramycin and 
Chromomycin as well as for a series of quinolone derivatives (52, 124, 125).  
The interactions of UK-1 and selected HPB ligands were investigated 
using a biotin labeled short GC-DNA hairpin with limited number of binding sites 
which was immobilized on a streptavidin-coated sensor chip. Binding studies 
were carried out in 30 mM Tris-HCl, 50 mM NaCl, pH 7.3 with or without addition 
of 20 mM MgCl2. Compounds were tested between 650 nM to 20 µM and 
included 20 µM CuCl2 for the Cu
2+-DNA mediated binding studies.  Chromomycin 
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was used as positive control for Mg2+-mediated binding. Samples were 
supplemented with 0.5% or 5% DMSO due to the limited aqueous solubility of 
some of the analogs. Although sensograms were corrected by double reference 
subtraction for differences between flow cells caused by the high refractive index 
from DMSO, there were large spikes at the beginning and end of each sample 
injection, as seen in Figure 4.1.  This precluded analysis of kinetic kon and koff 
constants. Nevertheless, equilibrium binding data could be obtained from plateau 
steady-state regions in the sensograms.  
It is important to note that under the experimental conditions employed 
none of the analogs studied exhibited changes in RU signal in buffer alone or 
buffer containing 20 mM MgCl2. Figure 4.1A shows a representative series of 
sensograms obtained in 20 mM MgCl2 buffer after injection of UK-1 samples 
ranging between 650 nM and 20 µM; no changes in RU signal were observed 
indicating that no discernable complex between the ligands and the DNA hairpin 
were formed. In contrast, supplementing the samples with 20 µM CuCl2 (1000-
fold lower concentration than Mg2+) resulted in a marked increase in signal 
dependent on ligand concentration (Figure 4.1B). Steady state equilibrium was 
achieved even at low compound concentrations, with fast association and 
dissociation rates. Chromomycin-A was used as a positive control for 
magnesium-mediated binding and positive RU signals were obtained using this 
compound. In contrast to UK-1 and the HPB analogs, Chromomycin exhibited 
slow association and dissociation rates in the presence of 20 mM MgCl2 (Figure 
4.2), in accordance to the described behavior in the literature; it also required 
injections of  50 mM NaOH, 1 M NaCl to regenerate the surface (124). 
  Higher concentrations than 20 µM were not tested for the HPB ligands due 
to potential precipitation and clogging of the fluidics system. Because a maximum 
binding response was not achieved at this concentration, RUmax values were 
estimated in the data fitting parameters as described in section 6.3. The 
observed RU values were plotted as a function of ligand concentration (Figure 
4.3) and were fitted to a 1:1 binding model to obtain apparent binding constants 
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in the presence of Mg2+ or Cu2+; 2:1 models resulted in lower correlation factor 
than those obtained assuming 1:1 DNA ligand stoichiometry. The results are 
















































Figure 4.1. Sensograms of the UK-1-DNA interactions in the presence of 20 mM MgCl2 or 20 µM 
CuCl2. UK-1 samples (30 µl) were injected at a flow rate of  10 µl/min at 0.650 µM, 1.25 µM, 2.5 
µM, 5 µM, 10 µM, and 20 µM in the presence of 20 mM MgCl2 (A) or 20 µM CuCl2 (B) 
 
Although the DNA binding isotherms had not reached saturation under the 
experimental conditions employed and therefore the calculated binding constants 
carry significant error, it is still possible to examine the major differences in 
affinities observed between analogs. The fact that neither UK-1 nor the rest of 
the HPB ligands exhibited magnesium dependant DNA binding suggests that this 
metal does not promote significant binding to nucleic acids or that binding is not 


























Figure 4.2. Sensograms of Chromomycin -DNA interactions in the presence of 20 mM MgCl2. 
Chromomycin samples (30 µl) were injected at a flow rate or 10 µl/min at 0.650 µM, 1.25 µM, 2.5 


















Ligand Concentration (M)  
Figure 4.3. SPR response of benzoxazole ligands in the presence of 20 µM CuCl2. Differential 
RU units obtained between GC-Hairpin immobilized and reference flow cells with increasing 
ligand concentration were fitted to a 1:1 binding model as described in section 6.3. Only analogs 
that displayed differences between flow cells are shown. 
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Comparison between copper mediated DNA binding (Table 4.1) indicates 
that the substitutions at the C4 or C7 position of the 2-(2’-hydroxyphenyl 
benzoxazoles) greatly influence the interactions with the DNA-hairpin substrate. 
All of the C4 substituted ligands tested, compounds 8, 17, 20 and 21, exhibited 
copper mediated binding to the DNA hairpin with affinities ranging from 2 *103 to 
5 *105 M-1. As expected, the methyl ether 6, used as a negative control, was the 
only analog not capable of binding Cu2+ ions, did not present any binding to the 
DNA substrate in the presence of 20 µM CuCl2. Similarly, the unsubstituted HPB 
analog compound 7, and the C7 substituted analog 9, which displayed copper 
affinities several orders of magnitude lower than the C4 analogs (section 3.3), did 
not present any observable copper-mediated DNA binding.  The affinity 
calculated for Chromomycin here, 2.7±0.9 *105 M-1, was within the range 
reported in the literature (54).  
 
Table 4.1. Apparent binding constants of HPB ligands for GC-Hairpin DNA in the presence of 20 
mM MgCl2 or 20 µM CuCl2 
 
20 µM CuCl2 20 mM MgCl2 
Compound 
KA (1/M) RUmax KA (1/M) RUmax 
UK-1 3.7 ± 0.8 *104 73 ± 11 n.b.a n.b.a 
UK-1 Cu-
Complex 7 ± 1 *10
4 43 ± 5 n.b.a n.b.a 
Compound 6 n.b.a n.b.a n.b.a n.b.a 
Compound 7 n.b.a n.b.a n.b.a n.b.a 
Compound 8 5 ± 2*105 8 ± 1 n.b.a n.b.a 
Compound 9 n.b.a n.b.a n.b.a n.b.a 
Compound 17 1.3 ± 0.5 *104 75 ± 25 n.b.a n.b.a 
Compound 20 2.5 ± 1.0 *104 30 ± 9 n.b.a n.b.a 
Compound 21 2 ± 1*103 32 ± 21 n.b.a n.b.a 
Chromomycin n.d.b n.d.b 2.7±0.9 *105 245 ±28 
a No binding was observed 
b Not determined 
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4.1.2. Results obtained from mass spectroscopy  
 
The metal-mediated DNA binding behavior of the modified 2-(2’-
hydroxyphenyl) benzoxazoles was also investigated by Electrospray Ionization 
Mass Spectrometry (ESI-MS) in a collaborative work with the Jennifer Brodbelt 
research group. Studies were carried out by Carolyn Mazzitelli in ammonium 
acetate buffer containing 10 µM Mg2+, Ca2+, Ni2+, Cu2+, or Zn2+ and 10 µM 
benzoxazole ligand to screen for metal complex formation. No complexes were 
observed with Mg2+ or Ca2+ ions, even with a 10-fold increase in metal 
concentration. However, experiments carried out in 100% methanol did present 
abundant Mg2+ complexes, in agreement with the observed UV-Vis experiments 
(see Chapter 3). The lack of detectable magnesium complexes in aqueous 
buffers by ESI-MS may be due to the differences in metal ion solvation in 
different solvents, and highlights the importance of solvent for metal ion binding 
of the benzoxazole ligands, and may explain the lack of Mg2+-mediated binding 
seen in SPR experiments. Binding to Mg2+ was previously thought to be 
important for the mechanism of action of UK-1 and the HPB analogs, but the 
absence of Mg2+ complexes in aqueous buffers suggests binding to this cation 
does not have as much biological significance as does coordination to other 
transition metals. 
 In aqueous buffers, all of the C4-substituted HPB ligands formed 1:1 
complexes with the divalent transition metals Ni2+, Cu2+, and to a lesser extent 
Zn2+.  Ligands with shorter side chains, such as compound 8 and 16-18, 
displayed water adducts in their 1:1 complexes and were also able to form 2:1 
ligand/metal ion complexes. Longer side chains like those in  19-21 mainly 
formed 1:1 complexes without solvent adducts, possibly because of coordination 
of the metal ion with atoms within the ligand’s side chain. As expected, the 
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methyl ether 6, which lacks a phenyl moiety, did not form complexes with any of 
the metal ions studied.  
Ligand binding to duplex DNA in the presence and absence of metal ions 
was also evaluated at equimolar concentrations of ligand, metal and DNA (10 
µM) in ammonium acetate buffer using oligonucleotides of varying G/C and A/T 
base pair composition. No apparent sequence selectivity was evident. Long 
chained benzoxazoles 19-21 formed low abundance complexes with duplex DNA 
in the absence of metal ions, while the short chain compounds 8, and 16-18 did 
not, suggesting that longer side chains at the C4 position can promote non-metal 
mediated DNA binding.  
DNA-ligand interactions were also examined in the presence of the metals 
that formed complexes with the 2’-(2-hydroxybenzoxazoles) by ESI-MS, Ni2+, 
Cu2+, and Zn2+ (see supplementary table in Appendix C). The most significant 
increase in DNA binding occurred in the presence of Cu2+ ions for all of the 
analogs studied except compound 6, which did not display any interactions with 
the oligonucleotides studied. Although long chain analogs 19-21 exhibited slight 
binding in the absence of metal ions, DNA complexes increased upon Cu2+ 
addition, particularly for compounds 19 and 21. Overall, the benzoxazoles that 
demonstrated highest enhancement in DNA binding upon addition of metal ions 
were compounds 16 and 17 for the shorter side chain compounds and compound 
21 for those with longer side chains.  
 
4.2. Cytotoxicity of 2-(2-hydroxyphenyl)benzoxazole analogs 
4.2.1. Cytotoxicity of HPB analogs with a carbomethoxy group at the C4 or 
C7 position 
 
The effect of having a HPB with a carbomethoxy substituent either at the 
C4 or C7 position was addressed by evaluating the cytotoxicity of compound 8 
(C4) and its isomeric 2-(2’-hydroxyphenyl) benzoxazole 9 (C7) in the prostate 
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cancer cell line PC-3, and the colon cancer cell line HT-29 (Table 4.2). As 
previously reported, the C4 methoxy substituted HPB analog 8 displayed toxicity 
to both PC-3 and HT-29 cancer cells (IC50 = 0.4 and 9.1 µM, respectively) (109).  
In contrast, compound 9 displayed only weak cytotoxicity against PC-3 prostate 
cancer cells (IC50 = 47 µM), over 50-fold less than that of the isomeric 
benzoxazole 8, and over 100-fold weaker than the natural product UK-1 (109). 
The C7 substituted analog was also only weakly active against HT-29 cells (IC50 
= 36 µM), as compared to the isomeric benzoxazole 8 (IC50 = 9.1 µM). Thus, the 
cancer cell cytotoxicity of these benzoxazole analogs of UK-1 is strongly 
sensitive to their structural features, and mirrors their relative ability to form DNA-
drug-metal complexes. 
 
Table 4.2. Cytotoxicity of PC-3 or HT-29 cells after 72h incubation with UK-1, compound 8 or 
compound 9. Cellular proliferation was assayed using the AlamarBlue assay. IC50 values 
represent 50% growth inhibition relative to cell treated with vehicle alone 
 
Compound IC50 for  
PC-3 (µM) 
IC50 for  
HT-29 (µM) 
Compound 8 0.91 9.1 
Compound 9 47 36 
 
4.2.2. Cytotoxicity of HPB analogs with different C7 substituents 
 
The effects of having different substituents at the C7 position was also 
assayed by measuring the cytotoxicity of the new 2-(2’-hydroxyphenyl) 
benzoxazole analogs 16-21 using the AlamarBlue assay in the breast cancer cell 
line MCF-7 and the lung cancer cell line A549. For comparison, UK-1, and the 
benzoxazole carboxylic acid phenyl ether 6, an isomer of 8, were also tested. As 
expected based on previous reports, the anticancer activity of compound 8 was 
somewhat less than that of UK-1, whereas the phenyl ether 6 was not cytotoxic 
at the highest concentration tested (50 µM). Therefore, loosing the phenol moiety 
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completely abolishes activity, which points out the importance of having a 
phenolate group not only for metal coordination but also for cytotoxicity. 
 
Table 4.3. Cytotoxicity of MCF-7 or A549 cells treated with HPB analogs during 72h. Cellular 
proliferation was assayed using the AlamarBlue assay. IC50 values represent 50% growth 
inhibition relative to cell treated with vehicle alone 




UK-1 1.4 ± 0.9 2.0 ± 0.5 
Compound 6 >50 >50 
Compound 8 4±2 12±3 
Compound 9 7±1 35±4 
Compound 16 15 ± 5 40 ± 10 
Compound 17 10 ± 8 11 ± 1 
Compound 18 30 ± 10 14 ± 4 
Compound 19 31 ± 7 39 ±17 
Compound 20 > 50 41 ±17 
Compound 21 13 ± 2 11 ± 1 
MMC 0.20 ± 0.07 0.4 ± 0.1 
 
Structure activity relationships can be drawn by comparing the activity of 
the HPBs with different groups at the C4 position. Changing the methoxy group 
to a methyl amide retains the anticancer properties, as observed for compound 
17 (IC50 = 10 and 11 µM). However, as the side chain length of the amide group 
increases it appears that the cytotoxicity decreases as observed for the 
butylamide analog 18 (IC50 = 30 and 14 µM),  and more so for compounds 19 
(IC50 = 31 and 39 µM) and 20 (IC50 = 41 and > 50 µM). The ethyl ester 16 is less 
active than 8 in the A549 cells (IC50 = 40 µM), but has similar cytotoxicity in the 
MCF-7 cell line (IC50 = 15 µM). The tetraethyleneglycol ester 21 has a similar 
cytotoxic profile to 8, retaining activity against both cell lines. This compound has 
the advantage of having increased solubility in aqueous solutions, and therefore 
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is of particular interest as a drug candidate.  Overall, compounds 17 and 21 are 
the most promising HPB analogs investigated in this study in terms of metal-
mediated DNA binding and cytotoxicity.  
4.2.3. Cytotoxicity of UK-1 and it copper complex 
 
To test for the effect of copper chelation on the cytotoxicity of the natural 
product UK-1, cell viability of A549 and MCF-7 cell lines treated with either 
vehicle alone, UK-1, UK-1-Cu2+ complex, UK-1 + 10 µM CuCl2,  or vehicle + 10 
µM CuCl2, was measured at two time points, 24 and 72 h. Cellular growth of UK-
1 treated cells was compared to those treated with vehicle alone, whereas the 
cytotoxicity of the copper complex and UK-1 samples in the presence of 10 µM 
Cu2+ were compared to copper only treated cells. The IC50 values obtained are 
summarized in Table 4.4.  Treatment of both cell lines with 10 µM CuCl2 for 72 h 
did not affect cellular viability. On the other hand, there was marked difference 
between the cell death observed for both cell lines (> 3 fold) when treated with 
UK-1, the copper complex, or UK-1 with 10 µM CuCl2 at the 24 h time point, 
indicating a synergistic effect between UK-1 and copper treatments. At 72 h, the 
IC50 values for UK-1 treatment alone resulted in less marked differences 
compared to cells treated in the presence of copper. This results that copper 
binding may aid in the anticancer activity of UK-1, perhaps by facilitating access 
to its target.  
 
Table 4.4. Cytotoxicity of Cells treated for 24 or 72 h in the presence of UK-1 and copper 
analogs. IC50 values are expressed in µM concentration. 
MCF-7Cells  A549 Cells 
Compound 
24h 72h 24h 72h 
UK-1 31 ± 5 1.7 ± 0.2 17 ± 2 1 ± 0.1 
[UK-1]Cu2+ Complex 6.8 ± 1.2 1.2 ± 0.2 7.5 ± 1.5 0.4 ± 0.06 
UK-1 + 10 µM CuCl2 4.6 ± 0.6 1.2 ± 0.2 4.5 ± 0.7 0.20  ± 0.04  
Mitomycin-C 5 ± 2 0.29 ± 0.08 5 ± 2 0.24 ± 0.03 
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4.3. Apoptosis induced by UK-1 and its copper complex 
 
 Apoptosis is the process of programmed cell death (PCD). PCD is a 
normal physiological process used by the body to combat unchecked cell growth 
(126). Improper apoptosis has been connected to many diseases and forms of 
cancer (127, 128). Because various organic copper complexes have been used 
to induce apoptosis in human cancers, it is important to evaluate if coordination 
of UK-1 to copper affects cellular apoptosis (118, 129, 130). To do so, caspase-8 
levels in A549 cells were measured by Chad McKee using western blot analysis.  
Caspase-8 is an integral protein in driving the death-receptor mediated 
apoptotic pathway (131). Therefore, its expression and activation is commonly 
used as an indicator of apoptosis (132, 133). Cells were evaluated after 24 h 
treatment with UK-1 in the presence and absence of copper.  Figure 4.4 shows 
the protein levels observed at 55 kDa, corresponding to caspase-8 levels, after 
treatment with vehicle, 10 µM CuCl2, 5 µM UK-1, 5 µM UK-1 + 10 µM CuCl2, or 5 
µM UK-1-Cu2+-complex. As expected, the control lane displayed no discernable 
amounts of the protein whereas treatment with 10 µM CuCl2 resulted in only a 
modest increase in caspase-8 expression. Similar protein levels were detected 
after incubation with 5 µM UK-1 alone. In contrast, combined treatments of 5 µM 
UK-1 with 10 µM CuCl2 resulted in a marked increase in caspase-8 levels, 
indicating that the apoptotic pathway is significantly increased when both UK-1 
and copper are added to the cells. Higher caspase-8 levels were observed for 
the copper complex compared to treatment with either UK-1 or copper alone, but 
the effect was somewhat lower than that observed for the combined treatment.   
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Control 10 µM CuCl2 5 µM UK-1
5 µM UK-1 +
10 µM CuCl2







Figure 4.4. Caspase-8 levels in the presence of UK-1 and the UK-1-Cu
2+
 complex. (A) Caspase-
8 expression was measured via western blot analysis after 24 h treatment with vehicle, 10 µM 
CuCl2, 5 µM UK-1, 5 µM UK-1 + 10 µM CuCl2, or 5 µM UK-1-Cu
2+-complex  (B) β-actin loading 
control. 
 
4.4. Conclusions   
 
The results obtained from SPR and mass spectrometry experiments have 
shown that UK-1 and the C4 substituted HPB ligands form complexes with DNA 
in the presence of transition metals such as copper, but not the more abundant 
Mg2+ ions under the conditions studied; possible magnesium-ligand interactions 
were too weak in aqueous buffers to be observed even at 20 mM Mg2 
concentration. In contrast, significant binding was observed to a DNA substrate 
at 20 µM Cu2+, which is within the range reported of serum copper blood levels 
and thus has physiological relevance (134, 135). This study has also shown that 
substitutions at the C4 or C7 position can affect metal-mediated DNA binding and 
cytotoxicity of the 2-(2’-hydroxyphenyl) benzoxazole compounds. Although 
compound 7, an HPB analog without substituents, and compound 9, with a 
carbomethoxy group at position C7, had the ability to bind to Cu2+ ions, they did 
not exhibit copper mediated DNA binding. This is likely due to their lower affinity 
for Cu+ 2 ions in comparison to the C4 substituted compounds. Compound 9 also 
exhibited less cytotoxicity than its isomeric C4-substituted analog compound 8, in 
the entire cell lines studied. Compound 6 was the only analog that did not display 
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any metal binding, and consequently, no metal-mediated DNA binding or 
cytotoxicity.  
In contrast, C4 substituted HPB analogs displayed Cu2+-mediated DNA 
binding by SPR and ESI-MS studies.  Slight non-specific binding was observed in 
the absence of metal ions for the analogs with longer side chains, 19-21, in ESI-
MS but these interactions were not strong enough to be observed in SPR 
experiments.  The lack of sequence selectivity in DNA binding suggests that the 
HPB analogs could interact via an intercalation mechanism. The longer side 
chains at the C4 position were also correlated to lower cytotoxicity for amide 
substituents. In particular, changing the methyl ester to a small amide group such 
as 17 retains anticancer activity, but as the length of the chain increases so do 
the IC50 values, as seen for amides 19 and 20.  Conversely, the longer ester 21 
was active against the cancer cell lines with the advantage of being more soluble 
in aqueous buffers. In general, there is a correlation between the HPBs that 
demonstrated highest enhancement in DNA binding upon addition of metal ions 
by ESI-MS and those that exhibited low IC50 values (i. e. compounds 17 and 21). 
This could indicate that the ability of these ligands to interact with DNA by 
coordination of transition metals may be related to their mechanism of action. 
The ability of UK-1 and its copper chelate to induce cytotoxicity in cancer 
cells was also surveyed. It appears that coordination of UK-1 with copper ions 
enhances the activity of the natural compound, particularly during shorter 
incubation periods. Additionally, caspase-8 levels were monitored after treatment 
with UK-1 in the presence and absence of Cu2+, and the UK-1-Cu2+ chelate. 
Higher caspase-8 levels were observed in the presence of both the copper 
complex and with treatment of UK-1 in the presence of Cu2+, indicating higher 
apoptotic levels under these conditions. This is important in light of the large 
number of copper complexes have been recently screened for anti cancer activity 
(114-117). Studies have shown that copper can accumulate in tumors due to the 
selective permeability of cancer cell membranes to copper compounds (37, 39-
41, 114). Furthermore, many anticancer DNA-binding drugs such as Mitomycin-
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C, Doxorubicin, and Mithramycin have been tested in the presence of metal ions 
such as Fe3+, Pt2+, and Cu2+ to amplify their potential in tumor cells (52, 136, 
137). Similarly, the enhancement of activity of UK-1 upon copper chelation could 
be a promising strategy for anticancer therapy.    
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
 
5.1. Summary   
 
DNA-binding molecules are widely used as therapeutic agents because 
they can interfere with DNA processing enzymes or cause DNA damage that 
may lead to cellular death.  Because DNA binding drugs target primarily fast-
dividing cells, they are commonly used for anti-cancer treatment. However, poor 
tissue specificity and non-specific binding can result in negative side effects. 
Understanding the mechanisms that influence the interactions of small molecules 
with nucleic acids can assist in drug design for more effective agents that 
preferentially enter the cell populations of interest. 
Amongst the many factors that affect drug-DNA interactions, metal cations 
play a very important role in the mechanism of action of ligands; coordination to a 
metal can change a drug’s physical and chemical properties, geometry, 
reactivity, and bioavailability. Furthermore, tumor cells require an elevated level 
of nutrients, membrane permeability and blood flow, which allows for 
accumulation of various transition metals. The result is a potentially greater 
uptake of metallopharmaceuticals and drugs that bind to DNA in a metal 
mediated fashion. Compounds with these characteristics can be potent 
antineoplastic agents. Examples of drugs that bind to DNA in the presence of 
divalent cations include compounds from aureolic group of antitumor antibiotics, 
such as Mithramycin and Chromomycin, as well as members of the quinolone 
family. Studies have shown that the nucleotide specific binding of these agents is 
dependent on the presence of divalent ions, and that metal complexes appear to 
have higher cell cytotoxicity than the drugs alone. 
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In order to design new potent metallopharmaceuticals that can target 
specific biomolecules such as DNA, it is important to find a suitable ligand that 
can form complexes with the metal of interest. Many oxazole and benzoxazole 
structures present a wide variety of biological activities and in many cases can 
also form metal complexes. UK-1 is an example of a bis-benzoxazole compound 
that presents very interesting biological properties. It is a natural product that was 
originally isolated from Streptomyces, can bind various metal ions, bind to DNA 
in a metal mediated fashion, and possesses growth inhibitory activity against a 
variety of human cancer cell lines. The simplified analog of UK-1, 2-(2’-hydroxy-
phenyl)-benzooxazole-4-carboxylic acid methyl ester, compound 8, was 
previously identified as having similar metal chelating and biological properties as 
the natural compound. 
This work investigated the effects of modifications to the 2-(2’-hydroxy-
phenyl)-benzoxazole (HPB) core on metal binding, metal-mediated DNA binding 
and cytotoxicity. Novel HPB analogs were synthesized with modifications at the 
C4 or C7 position. The isomeric analog of 8, compound 9 contains a methyl ester 
at position 7 instead of position 4. This analog showed diminished metal binding 
properties, did not display metal-mediated DNA binding, and exhibited lower 
cytotoxicity than compound 8. This highlighted the importance of the 
arrangement between the nitrogen and oxygen atoms in benzoxazole core with 
respect to the carboxymethyl substituent for metal coordination and biological 
properties.  
Modifications at the C4 position to extended amides and esters resulted in 
compounds that retained metal binding capability. The affinity for Mg2+, Zn2+ and 
Ni2+ was affected according to the type of side chain. In contrast, Cu2+ binding 
was largely unaffected with respect to the substituent; in general all the new 
analogs displayed strong binding to Cu2+ ions, with binding affinities several 
orders of magnitude stronger than analogs with no substituents in the HPB core, 
or groups at the C7 position.  While the C4 analogs showed Mg2+ binding in 
methanolic solutions, no magnesium binding was observed in aqueous buffers. 
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Consequently, no magnesium-mediated DNA binding was apparent for these 
analogs.  In contrast, abundant complexes with DNA were observed in the 
presence of Cu2+ ions. Compounds that exhibited the most pronounced 
enhancement in DNA binding in the presence of metal ions, the methyl amide 17, 
and the tetraethyleneglycol ester 21, were also the compounds with lowest 
cytotoxicity values in two cancer cell lines. The latter is of particular interest 
because of its increased water-solubility.  
Due to the preferential binding of all of the HPB analogs to Cu2+, the 
copper binding properties of UK-1 were also investigated. The bis-benzoxazole 
showed preference for this metal and presented increased DNA binding in the 
presence of Cu2+ ions. A UK-1 copper complex was synthesized to compare its 
biological properties with the natural compound. Copper complexation increases 
overall cytotoxicity in the cancer cells A549 and MCF-7. In addition, the reduction 
in cell viability is correlative with increases in caspase-8, and indicator of 
apoptosis. This study has shown that transition metal coordination could be 
involved in the mechanism of action of UK-1 and that copper complexes of UK-1 
and the HPB ligands could be promising anticancer agents.  
 
5.2. Future Directions  
 
This study suggests that UK-1 and the HPB ligands can bind to divalent 
metals through coordination with nitrogen atoms of the benzoxazole ring, the 
phenol oxygen, and the carbonyl oxygen at the C4 position. Further insights into 
the exact metal coordination geometry of the natural product can arise from X-
Ray crystallography studies of the synthesized UK-1 copper complex.  
This study also showed that substitutions at the C4 position can retain 
some of the key biological properties of the natural compound UK-1. In particular, 
compounds 17 and 21 have shown promising metal-mediated DNA binding and 
cytotoxicity in cancer cells. These compounds should be studied with respect to 
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non-cancerous cell lines as well as with DNA-processing enzymes such as 
Topoisomerase II in the presence and absence of transition metals to investigate 
if this could be relevant to their mechanism of action. The tetraethyleneglycol 
side chain of compound 21 allows for greater water solubility, making it suitable 
for cellular assays. 
  This study can also serve as a starting point for the design of more 
potent ligands. The compounds with hydrophilic groups at the C4 position can be 
further modified to increase cytotoxicity and retain water solubility. New analogs 
with modifications in the hydroxyphenyl ring are also currently being investigated 
(Figure 5.1). It is now known that changing the C2’ hydroxyl group on the 
phenolate ring to a methyl ether abolishes activity (i. e. as observed for 
compound 6). However, changing the OH group to other polar groups such as 
amides could actually increase copper binding affinity and potentially increase 
metal-mediated DNA binding and cytotoxicity. Design of novel HPB analogs 
includes ligands with NH2 or F at the C2’ position. The effect of the OH group at 
positions C2’, C3’ or C4’ is also presently being studied. In addition, having more 
than one  hydroxyl group could potentially increase activity or serve as an anchor 























R = OH, NH2, F  
Figure 5.1. Future HPB analogs with substitutions at the C2’, C3’ or C4’ position 
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CHAPTER 6.  EXPERIMENTALS FOR PART I 
 
6.1. General Information 
All reagents were purchased from commercial suppliers and used without 
further purification unless noted. Cell viability assays were carried out in sterile 
black polystyrene 96-well plates from Nalgene Nunc International (Rochester, 
NY, part no. 137101). The MCF-7 and A549 cell lines were kind gifts from Profs. 
Shawn Bratton and Bob Krug (The University of Texas at Austin) respectively. 
The media for the MCF-7 cell line was the improved MEM (Richter’s Modification, 
part no. 10-026-CV) and F-12 K (Kaighn's Modification, part no. 10-025-CV) for 
the A549 cell line (from MediaTech Inc., Manassas, VA); both contain L-
glutamine and were supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Cytotoxicity experiments with PC-3 and HT-29 cell lines 
were carried out by MDS Pharma Services (King of Prussia, PA). 
Unless otherwise noted, 1H and 13C NMR spectra were determined in 
CDCl3 on a Varian INOVA 500, or a Varian UNITY 300s spectrometer operating 
at 300 and 500 MHz respectively. Two dimensional NMR experiments were run 
on a 500 MHz instrument; selected spectra are shown in Appendix A. All mass 
spectra were obtained by chemical ionization using methane as the ionizing gas. 
Chromatography refers to flash chromatography on silica gel, and Rf values were 
determined using silica gel-GF TLC plates using the solvent system indicated. 
Melting points were determined using a Büchi B-540 melting point apparatus 
(New Castle, DE), and IR spectra were recorded in a Nicolet IR100 instrument 
from Thermo Electron (Waltham, MA). Elemental Analysis was performed by 
Quantitative Technologies, Incorporated of Whitehouse, NJ. Compounds 4, 5, 
and 8 were synthesized as described previously (101, 109). 
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6.2. Metal Binding Assays  
Stock solutions of UK-1 and analogs as well as Mg(NO3)2, Zn(NO3)2, 
Ni(NO3)3, and Cu(NO3)2, were prepared fresh on the day of the 
spectrophotometric titrations. The fraction of complex formed was measured by 
using solutions of increasing mole fraction of metal ion, keeping the 
concentration of ligand constant, at 10, 5, 2.5 or 1 µM, using as a reference the 
absorbance of a solution containing the same concentration of metal ion without 
the ligand. The change in absorbance was monitored from 600 to 200 nm for 
each sample, as a function of the concentration of metal ion.  The maximum 
absorbance change for the ligand-metal complex was recorded at each metal-ion 
concentration. 
Spectrophotometric data was analyzed by equations [1] and [2]. The 
apparent binding constants were calculated by non-linear regression of the 
experimental points using the program Kaleidagraph based on the equilibrium: 
 
Kd = [C0 – (∆A/∆Amax)C0][Cm-(∆A/∆Amax)C0]/[ (∆A/∆Amax)C0]  [1] 
C0(∆A/∆Amax)
2 –(C0 + Cm +Kd) (∆A/∆Amax) + Cm=0    [2] 
 
Where: 
Kd is the dissociation constant, C0 is the initial concentration of the UK-1 analog, 
Cm is the concentration of the metal ion, ∆A is the increase in absorption at the 
wavelength of maximum absorbance for the ligand-metal ion complex (~400 nm) 
upon addition of each metal ion concentration, and ∆Amax is the same parameter 
when the ligand is totally bound to the metal ion, determined in excess metal ion 
until no further spectral changes were observed. The apparent binding constants 
(Ka) were calculated as the inverse value of Kds. 
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6.3. Surface Plasmon Resonance  
 Binding measurements were performed with BIAcore 1000 or BIAcore 
3000 instruments using pre-coated streptavidin SA5 chips (part no. BR-1000-32, 
from BIAcore, Piscataway, NJ). With this technique, the change in resonance 
angle is monitored and is reported as resonance units (RU). The increase in RU 
is proportional to the amount of compound bound to an immobilized target, in this 
case a biotinylated oligonucleotide (138). 
To prepare the SA5 sensor chip, it was docked, primed and the buffer, 
HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% v/v polysorbate 
20, pH 7.4), was set at a flow rate of 20 µl/min. The surface was pre-conditioned 
with multiple 1-min injections of 50 mM NaOH, 1 M NaCl until there was a 
difference of less than 10 RUs of the baseline before and after the injections; this 
procedure was repeated for all 4 flow-cells. Biotin-labeled GGCC DNA hairpin, 
Bio-5’-CGGCCTCCTCCCCAGGCCG-3’, (Integrated DNA Technologies, 
Coralville, IA) at 25 nM concentration was injected  at a flow rate of 5 µl/min 
using the INJECT command and immobilized on the flow cell’s 2 and 3 surface 
by noncovalent capture. Buffer was injected until a stable baseline increase of 
457 and 461 RU units respectively were observed. Flow cell 1 was left blank as a 
control reference cell, while flow cell 3 was only used to compare relative 
responses between flow cells over time. 
Data was obtained from sensograms utilizing 30 mM Tris-HCl, 50 mM 
NaCl, and 0.0005% P20, pH 7.3 with or without addition of 20 mM MgCl2, as a 
running buffer. UK-1 and analogs samples, along with Chromomycin-A as a 
positive control (part no. 150686, from MP biomedicals, Solon, OH), were 
prepared in the running buffer and supplemented with 20 µM CuCl2 where 
indicated. DMSO was added to each sample to give a total of 0.5% or 5% final 
concentration as specified in the text. The sample concentrations ranged from 
650 nM to 20 µM. All sensograms included a double reference subtraction 
(subtraction of the signal from each injection in the underivatized reference flow 
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cell 1, in addition to the subtraction of an injection containing only the buffer with 
the appropriate amount of cations and DMSO).  The first subtraction corrects for 
any change in refractive index due to unbound ligand that flows through solution 
as well as non-specific interactions with the blank flow cell surfaces, while the 
second adjusts for any small differences between the reference and DNA flow 
cells (139). 
 Samples were injected using an auto-sampler at a flow rate of 10 µl/min 
using the KINJECT command for a total of 180 s (30 µl) with a delayed wash 
after 120 s. Surfaces were regenerated by sequential injections of injections of 
50 mM  EDTA (20 µl), 50 mM NaOH, 1 M NaCl (10 µl), and running buffer (20 
µl). During each ligand injection, a steady-state plateau can be reached when 
there is no change in signal with time; this is the RUeq at a particular drug 
concentration and represents that the rate of binding of the small molecule 
equals the rate of dissociation of the complex (121).  To obtain equilibrium 
binding constants, the steady state RUeq signals obtained from each injection 
were plotted against ligand concentration considering a single binding site for 
each nucleic acid sample, and fitted with the program Kaleidagraph by nonlinear 
least-squares to equation 3 (121): 
 
Req = RUmax(Keq[Ligandfree])/(1+Keq[Ligandfree])    [3] 
 
Where:  
Req is the observed steady state response in refractive index units at each ligand 
concentration, and Lfree is the unbound concentration of the ligand. When 
saturation of the immobilized nucleic acid is approached, the RUeq approaches 
the maximum value, RUmax. This parameter is included as a fit parameter in 
equation 3.  
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6.4. Electrospray ionization mass spectrometry 
 
ESI-MS studies were carried out by Carolyn Mazzitelli using the 
benzoxazole ligands and oligonucleotides from IDT Technologies (Coralville, IA). 
Duplex DNA was annealed by preparing equimolar (1 mM) concentrations of the 
non-self complementary oligonucleotides d(GCGGGATGGGGCG) and 
d(CGCCCCATCCCCGC); d(GCGGGAATTGGGCG) and d(CGCCCAATT 
CCCGC);  d(GCGGAAATTTGGCG) and d(CGCCTTTAAACCGC). Analytical 
solutions containing a ligand and metal salt, a ligand and DNA duplex, or a 
ligand, metal salt, and DNA duplex were prepared at equimolar (10 µM) 
concentrations in 50 mM ammonium acetate solutions with 50% methanol. The 
samples were directly infused at 3 µL/min into a Thermo Electron (San Jose, CA) 
LCQ mass spectrometer. For the DNA binding experiments, the instrument was 
operated in the negative ion mode with an electrospray voltage of 3.5 kV and a 
heated capillary temperature of 90 to 110 °C with sheath and auxiliary gas flows 
of 40 and 10 arbitrary units, respectively. Ligand/metal ion solutions were 
examined in the positive ion mode using an electrospray voltage of 4.5 kV and 
the same heated capillary and gas flow rates used for the solutions containing 
DNA. 
6.5. Cytotoxicity Assays  
Cell viability was determined using the AlamarBlue reagent (part no. 
BUF012B, from AbD Serotec, Kidlington, Oxford, UK). This reagent can be used 
to easily detect changes in cell proliferation based on the ability of viable cells to 
cause AlamarBlue to change from its oxidized (non-fluorescent) to a reduced 
(fluorescent) form (140). Cell culture cytotoxicity assays were carried out as 
described by Kumar et al (109). Aliquots of 100 µl cell suspension (1-3*103 cells) 
were placed in microtiter plates in an atmosphere of 5% CO2 at 37 
oC. After 24 h, 
100 µL of culture media and 2 µl of the compound in DMSO were added to each 
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well in duplicate, and the plates incubated an additional 24 or 72 h at 37 oC. 
There was no effect on the growth of cells compared to that of cells in culture 
media alone at this DMSO concentration. Compounds, along with Mitomycin-C 
(part no. 100498, from MP Biomedicals, Solon, OH) as a positive control were 
evaluated at final concentrations ranging from 0.001 to 50 µM. 
 After the 24 or 72 h incubation, the culture media was removed from each 
well, and 200 µL of fresh media and 20 µL of AlamarBlue reagent were added, 
followed by additional 6 h incubation. Cell viability was detected by fluorescence 
intensity using a Beckman Coulter DTX880 plate reader (Fullerton, CA)  with 
excitation at 530 nm and emission at 590 nm.  
The fluorescence data obtained from the cytotoxicity studies was used to 
calculate the percent growth according to the following equation: 
 
% Growth = 100*(MeanFtest – Mean Ftime0)/ (MeanFctrl – Mean Ftime0) [4] 
 
Where: 
Mean Ftime0 = the averaged measured fluorescence intensities of AlamarBlue 
reagent at the time just before the exposure of the cells to the test substance.  
Mean Ftest = the averaged measured fluorescence intensities of AlamarBlue 
reagent after 24 or 72 h exposure of the cells to the test substance at a particular 
concentration. 
Mean Fcrtl = the averaged measured fluorescence intensities of AlamarBlue 
reagent after 24 or 72 h exposure of the cells to the vehicle without the test 
substance. 
The IC50 (50% Inhibition Concentration) is defined as the test compound 
concentration where the increase from time0 in the number of mass of treated 
cells was only 50% as much as the corresponding increase in the vehicle-control 
at the end of the experiment. The IC50 values of UK-1 analogs were determined 
by non-linear regression using the program Kaleidagraph and fitting the data to 
the following equation:  
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y = Min + (Max-Min)/(1+10^((x-logIC50)*Hillslope))    [5] 
 
Where: 
Min= the minimum response plateau (0%Growth) 
Max= the maximum response plateau (100% Growth) 
y= % Growth at each test compound concentration 
 
6.6. Western blot analysis 
 
 Western blot analyses were performed by Chad McKee (The University of 
Texas at Austin). All proteins of interest were evaluated in A549 cell lines for total 
cellular protein levels via western blot analysis. Cells were treated for 24 h with 
vehicle, 10 µM CuCl2, 5 µM UK-1, 5 µM UK-1 + 10 µM CuCl2 or 5 µM UK-1-Cu
2+-
complex prior to sample collection. Western blots were performed using the 
primary antibodies caspase-8 (R&S Systems, Minneapolis, MN, part no. AF1650) 
and β-actin (Santa Cruz Biotechnology, Santa Cruz, Ca, part no. SC-1616) 
against the relevant protein in the appropriate dilution (usually 0.5 µg/ml). 
Horseradish peroxidase-conjugated secondary antibodies (SantaCruz 
Biotechnology, part no. SC-2031) were used to detect primary antibodies. 
Signals were detected by the use of an ECL kit (Amersham Pharmacia 
Biosciences, Piscataway, NJ). Images were collected by a Kodak DC-290 digital 




6.7. Synthetic Procedures 
6.7.1. Compound 8. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic acid 





















This compound was synthesized as described previously, COSY and 
NOSY relations were used to determine peak assignments (109). M.p. 134–135 
oC; Rf 0.578 (30% EtOAc in hexanes); 1H NMR d 4.05 (s, 3H, CH3), 6.99 (t, 1H, 
J=, 7.8 Hz, C5’-H), 7.13 (dd, 1H, J= 8.5, 0.5 Hz, C3’-H), 7.45-7.41, (m, 2H, C4’-H, 
C6-H), 7.80, (dd, 1H, J= 8.5, 1.0 Hz, C7-H), 7.99-7.96 (m, 2H, C5-H, C6’-H); 
13C 
NMR (CDCl3/MeOD 1:1) d 52.66 (CH3), 110.42 (C2’), 115.69 (C7), 117.92 (C3’), 
120.28 (C4’), 121.50 (C4), 125.51 (C6), 127.79 (C5), 127.80 (C6’), 134.78 (C5’), 
140.04 (C3a), 150.42 (C7a), 159.56 (C2), 164.90 (C1’), 166.39 (CO2); CIMS m/z 
270 (MH+); HRMS m/z calcd. for C15H12NO4: 270.0766, found 270.0766. 






















Oxalyl chloride (1.75 mL) was added to a solution of 2-benzyloxybenzoic acid 
(2 mmol, 456 mg) in 12 mL of dry dichloromethane, and the solution was stirred for 
10 min.  Dimethylformamide (0.3 mL) was then added drop-wise, and the mixture 
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was allowed to stir for 2 h, after which the solvents were removed in vacuo.  To the 
residue was added a solution of 3-amino-2-hydroxybenzoic acid (2 mmol, 306 mg) in 
30 mL THF, and 5 mL pyridine. The reaction mixture was stirred at room 
temperature overnight then heated under reflux for 1 h.  The solvent was evaporated 
and the resulting brown mass was dissolved in xylenes (50 mL).  p-Toluenesulfonic 
acid monohydrate (3.8 g, 20mmol) was added, and the mixture was heated under 
reflux overnight and then quenched with NaOH (20 mL, 1N).  The layers were 
separated, and the aqueous phase was acidified with conc. HCl to pH 2 and 
extracted with ethyl acetate. The organic phases were combined, dried, and 
evaporated.  The residue was dissolved in a mixture of MeOH/benzene (1:4, 20 mL) 
and TMSCHN2 (2M solution in ether, 2 mL, 4mmol) was added.  The reaction 
mixture was then concentrated in vacuo and subjected to flash chromatography 
(SiO2, EtOAc/Hex gradient) to afford 3 as light pink crystals (95 mg, 18%): mp 112–
113 oC; 1H NMR (CDCl3/MeOD 1:1) δ 3.75 (s, 3H, CH3), 6.73, (t, 1H, J=, 7.56 Hz, 
C5’-H), 6.78, (dd, 1H, J= 8.70, 0.81 Hz, C3’-H), 7.17-7.13, (m, 2H, C4’-H, C5-H), 7.60, 
(dd, 1H, J= 7.91, 1.13 Hz, C4-H), 7.67 (dd, 1H, J= 7.7, 1.13 Hz, C6-H), 7.79 (dd, 1H, 
J=7.91, 1.7 Hz, C6’-H); 
13C NMR (CDCl3/MeOD 1:1) δ 51.804 (CH3), 109.494 (C1’), 
114.386 (C7), 116.64 (C3’), 119.327 (C5’), 123.458 (C4), 124.311 (C5), 126.776 (C6), 
127.047 (C6’), 133.525 (C4’), 140.966 (C3a), 147.581 (C7a), 157.976 (C3’), 163.24(C2),  
164.195 (CO2); MS (CI) m/z 270 (MH




6.7.3. Compound 10. 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic 







Compound 4, 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic acid, 
(142 mg, 0.41 mmol) was dissolved in absolute ethanol (1.25 ml) in a flask fitted 
with a drying tube. Thionyl chloride (45 µl, 0.62 mmol) was then added drop-wise 
while stirring, and the reaction was left stirring overnight at room temperature. 
Afterwards, the reaction mixture was poured over ice, extracted with DCM, 
washed with sodium bicarbonate, 1% HCl, water, dried over anhydrous sodium 
sulfate, and filtered. The product was then concentrated by roto-evaporation, and 
purified by column chromatography (20% EtOAc in hexanes) to give a white solid 
(103 mg, 69 % yield). m.p. 112-114 oC;  Rf 0.30 (20% EtOAc in hexanes); 1H 
NMR δ 1.44 (t, 3H, J= 7.2 Hz), 4.49 (dd, 2H, J= 14, 7.2Hz), 5.27 (s, 2H), 7.07-
7.12 (m, 2H), 7.27-7.49 (m, 5H), 7.63 (d, 2H, J=7.8Hz), 7.71 (d, 1H, J=8.1 Hz), 
8.00 (d, 1H, J= 7.5 Hz), 8.28 (dd, 1H, J= 8, 2 Hz); 13C NMR δ 14.32, 61.09, 
70.50, 113.65, 114.41, 116.31, 120.97, 122.34, 123.97, 126.43, 126.72, 127.59, 
128.40, 131.94, 133.07, 136.62, 141.50, 151.24, 157.62, 163.64, 165.14 CIMS 
m/z 374(MH+); HRMS m/z calc for C23H20NO4: 374.1392, found 374.1389 
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6.7.4. Compound 11. 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic 







Methylaluminumchloride-methylamide was prepared as described by 
Levin et al (141). Briefly, methylaminehydrochloride (675 mg, 10 mmol) was 
suspended in 10 ml dry benzene, and placed in an ice bath. Trimethyl aluminum 
(2 M solution in hexanes, 5 ml) was carefully added portion-wise with evolution of 
methane. After the addition, the mixture was allowed to warm to room 
temperature and stirred for 2 hours. Compound 5, methyl2-[2-
(benzyloxy)phenyl)-1,3-benzoxazole-4-carboxylate (100 mg, 0.28mmol) was 
dissolved in 2.8 ml dry benzene. To this reaction mixture, 830 µl of the aluminum 
amide solution (0.67 M, 0.56 mmol) was added, and placed under reflux 
overnight.  The reaction mixture was then cooled to room temperature and 
quenched with 5% HCl. The organic layer was separated and the aqueous layer 
was extracted 3 times with EtOAc. The organic layers were combined, dried over 
magnesium sulfate, and concentrated in vacuo. The compound was re-
crystallized from EtOAc/hexanes to give light pink needle-like crystals (49 mg, 49 
% yield). mp. 158.5-160oC; Rf 0.74(10% MeOH in DCM); 1H NMR δ 2.82 (d, 3H, 
J= 4.8Hz), 5.24 (s, 2H), 7.11-7.17 (m, 2H), 7.32-7.44 (m, 4H), 7.50-7.55 (m, 3H), 
7.65 (dd, 1H, J= 8, 0.8Hz), 8.16-8.19 (m, 2H), 8.90(s, 1H); 13C NMR δ 26.20, 
70.64, 113.15, 113.56, 115.50, 121.03, 123.89, 124.69, 125.29, 127.03, 128.00, 
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128.56, 131.29, 133.40, 136.29, 139.47, 150.01, 157.77, 161.84, 164.92; CIMS 
m/z 359 (MH+); HRMS m/z calc for C22H19N2O3: 359.1396, found 359.1398 
 
6.7.5. Compound 12. General Procedure for CDI Coupling. 2-(2-






The benzoxazole acid imidazolide was prepared by dissolving 4, (2-(2-
Benzyloxy-phenyl)-benzooxazole-4-carboxylic acid, in dry dichloromethane 
(DCM), approximately 6 ml/g, and adding portion-wise 1.3 equivalents of CDI 
with stirring for 1 hour at room temperature, until the evolution of CO2 ceased.
 
Butylamine (215 mg, 3 mmol) was added to the reaction mixture, which was 
heated under reflux for 2 days. The reaction mixture was diluted with 
dichloromethane, and washed with 0.1 N HCl (x2), H2O (x2), 0.1 N NaOH (x2), 
and H2O (x2). The organic layer was dried over anhydrous Na2SO4, and the 
solvent was evaporated. Compound 12 was obtained after column 
chromatography as white needle-like crystals (157 mg, 45 % yield). mp. 122-
123°C; Rf 0.22 (20% EtOAc in hexanes); 1H NMR δ 0.89 (t, 3H, J= 7.2 Hz), 1.34-
1.42 (m, 2H), 1.49-1.57 (m, 2H), 3.42, (q, 2H, 6.4 Hz), 5.29 (s, 2H), 7.11-7.15 (m, 
2H), 7.29-7.52 (m, 7H), 7.66 (dd, 1H, J=8, 0.8 Hz), 8.16-8.20 (m, 2H), 9.16 (m, 
1H); 13C NMR δ 13.68, 20.16, 31.53, 39.31, 70.50, 113.11, 113.76, 115.72, 
121.03, 124.08, 124.64, 125.35, 126.67, 127.86, 128.48, 131.36, 133.33, 136.38, 
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139.35, 150.21, 157.67, 162.11, 164.16; CIMS m/z 401 (MH+); HRMS m/z calc 
for C25H24N2O3: 401.1865, found 401.1870 
 
 
6.7.6. Compound 13. 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic 








Following the general procedure described above, compound 4 (232 mg, 
0.67 mmol) was coupled with 262 mg of aminohexanol (2.24 mmol). Compound 
13 was obtained after column chromatography as white crystals (135 mg, 45 % 
yield). mp. 139-141°C; Rf 0.54 (10%MeOH in DCM)  1H NMR δ 1.35-.1.52 (m, 
8H), 2.47 (s, 1H), 3.38, (dd, 2H, J=13.2, 6.6 Hz), 3.57, (t, 2H, J= 6.6 Hz), 5.22 (s, 
2H), 7.09 (t, 2H, J= 7.2 Hz ), 7.26-7.50 (m, 7H), 7.60 (d, 1H, J=7.5Hz), 8.14 (t, 
2H, J=7.4Hz), 9.16 (m, 1H); 13C NMR δ 25.19, 26.58, 29.37, 32.47, 39.34, 62.37, 
70.45, 113.17, 113.70, 115.56, 120.99, 123.82, 124.62, 125.29, 126.64, 127.80, 
128.44, 131.29, 133.35, 136.33, 139.28, 150.14, 157.60, 162.12, 164.27; CIMS 






6.7.7. Compound 14. 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic 









Following the general procedure described above, compound 4 (112 mg, 
0.32 mmol) was coupled with 113mg of 2-(2-aminoethoxy)ethanol (1.08 mmol) 
Compound 14 was obtained after the aqueous workup as a white solid (120 mg, 
86 % yield). mp. 91-94°C Rf 0.68 (10% MeOH in DCM); 1H NMR  δ 2.2 (s(br), 
1H), 3.54-3.67 (m, 8H), 5.28 (s, 2H), 7.12-7.15 (m, 2H), 7.29-7.53 (m, 7H), 7.65-
7.68 (dd, 1H, J=8, 0.8Hz), 8.16-8.20 (m, 2H), 9.42 (m, 1H); 13C NMR δ 39.22, 
61.69, 69.86, 70.77, 72.08, 113.47, 114.01, 115.80, 121.21, 123.80, 124.76, 
125.53, 126.92, 127.96, 128.55, 131.56, 133.54, 136.45, 139.42, 150.38, 157.72, 




6.7.8. Compound 15. 2-(2-Benzyloxy-phenyl)-benzooxazole-4-carboxylic 











Following the general procedure described above, compound 4 (112 mg, 
0.32 mmol) was coupled with 210 mg of tetraethyleneglycol (1.08 mmol). 
Compound 15 was obtained after column chromatography as a transparent oil 
(86 mg, 51% yield). Rf 0.76 (10% MeOH in DCM); 1H NMR δ 2.6 (s(br), 1H), 
3.52-3.54 (m, 2H), 3.58-3.70 (m, 8H), 3.72-3.74(m, 2H), 3.87 (t, 2H, J= 4.8 Hz), 
4.58, (t, 2H, J= 4.8 Hz), 5.27 (s, 2H), 7.06-7.11 (m, 2H), 7.28-7.48 (m, 5H), 7.61 
(d, 2H, J= 7.2Hz), 7.71 (dd, 1H, J= 8, 0.8 Hz), 8.01 (dd, 1H, J= 7.6, 0.8 Hz), 8.27 
(dd, 1H, J= 8.2, 1.8 Hz); 13C NMR δ 61.54, 64.18, 69.08, 70.16, 70.44, 70.48, 
70.58, 72.37, 113.60, 114.61, 116.23, 120.95, 121.80, 123.96, 126.57, 126.68, 
127.59, 128.40, 131.97, 133.12, 136.57, 141.57, 151.27, 157.59, 163.78, 164.86; 
CIMS m/z 522 (MH+); HRMS m/z calc for C29H31NO8: 521.2050,  found: 
521.2036 
 
6.7.9. Compound 16. General procedure for hydrogenolysis. 2-(2-








The benzyl ether compound 10 (103 mg, 0.28 mmol) was dissolved in 
absolute EtOH (4 ml/mmol), and an equal weight of 10% palladium on activated 
carbon was added. The reaction mixture was placed under a balloon of hydrogen 
for approximately 2 hours. After verifying by TLC that the reaction had gone to 
completion, the solution was filtered through celite and washed with EtOAc and 
CH2Cl2. The solution was then evaporated under reduced pressure conditions, 
and the compound was purified by column chromatography (10% EtOAc in 
hexanes), recovering 16 as white crystals (75 mg, 96% yield).mp. 122-123.5 oC; 
Rf 0.56 (20% EtOAc in hexanes); 1H NMR δ 1.49 (t, 3H, J= 6.9 Hz), 4.46 (dd, 2H, 
J= 14.4, 7.2Hz), 6.95 (t, 1H, J= 7.4Hz), 7.08 (d, 1H, J= 8.7Hz), 7.34-7.43 (m, 2H), 
7.70 (d, 1H, J= 8.4 Hz), 7.92 (d, 1H, J= 7.5 Hz), 8.00 (dd, 1H, J= 7.8Hz), 11.80 
(s, 1H); 13C NMR δ 14.23, 61.34, 109.82, 114.66, 117.51, 119.43, 121.39, 
124.59, 127.02, 127.24, 134.05, 139.20, 149.57, 159.30, 164.06, 165.03; CIMS 
m/z 284 (MH+); HRMS m/z calc for C16H14NO4: 284.0923, found: 284.0926; EA 
calc for C16H13NO4: C, 67.84; H, 4.63; N, 4.94; found: C, 67.63; H, 4.52; N, 4.91 
 
 
6.7.10. Compound 17. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic 







Following the general procedure for hydrogenolysis, compound 11 (44 mg, 
0.12 mmol) was de-protected to give compound 17, which was purified by 
column chromatography (10% MeOH in DCM), and re-crystallized from  MeOH in 
DCM to recover white crystals (27.87 mg, 85% yield) mp. 225.5-226.5oC; Rf 
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0.74(10% MeOH in hexanes); 1H NMR δ 3.14 (d, 3H, J= 7.2 Hz), 7.06 (t, 1H, 
J=7.2Hz), 7.13 (dd, 1H, J= 8.7, 0.9 Hz), 7.46-7.53 (m, 2H), 7.73 (dd, 1H, J= 7.8, 
0.9Hz), 8.06 (dd, 1H, J=8.1, 1.5), 8.20 (dd, 1H, J= 0.9, 7.5); 13C NMR δ 26.69, 
109.89, 113.55, 117.45, 120.25,123.96, 125.48, 126.48, 127.75, 134.57, 137.18, 
148.95, 158.27, 163.39, 164.54 CIMS m/z 269 (MH+); HRMS m/z calc for 
C15H13N2O3: 269.0926, found 269.0926; EA calc for C15H12N2O3: C, 67.16; H, 
4.51; N, 10.44; found: C, 67.06, H, 4.54, N, 9.85 
 
6.7.11. Compound 18. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic 






Following the general procedure for hydrogenolysis, compound 12 (150 
mg, 0.37 mmol) was de-protected to give compound 18, which was recrystallized 
from EtOAc/hexanes to give white-flake like crystals (105.94 mg, 91% yield) mp. 
181-183oC; Rf 0.22 (20% EtOAc in hexanes); 1H NMR δ 0.99 (t, 3H, J= 7.2 Hz), 
1.45-1.52 (m, 2H), 1.66-1.72 (m, 2H),  3.56 (dd, 2H, J= 12.8, 6 Hz), 7.00 (t. 1H, 
J= 8.4 Hz), 7.08 (d, 1H, J= 8 Hz), 7.42-7.46 (m, 2H), 7.68 (d, 1H, J= 8.4 Hz), 7.80 
(s(br), 1H), 7.99 (dd, 1H, J= 8.2, 1.4 Hz), 8.15 (d, 1H, J= 8.1 Hz), 10.37 (s, 1H); 
13C NMR δ 13.72, 20.23, 31.53, 39.60, 109.81, 113.41, 117.43, 120.14, 124.08, 
125.42, 126.40, 127.65, 134.50, 137.15, 148.88, 158.33, 163.31, 163,70; CIMS 
m/z 311 (MH+); HRMS m/z calc for C18H19N2O3: 311.1396, found: 311.1397; EA 




6.7.12. Compound 19. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic 
acid (6-hydroxy-hexyl)-amide  
Error! Objects cannot be created from editing field codes. 
Following the general procedure for hydrogenolysis, compound 13 (120 
mg, 0.27 mmol) was de-protected to give compound 19, which was purified by 
column chromatography (10% MeOH in DCM), to afford an off-white solid (87 
mg, 90% yield). mp. 145.5-147oC; Rf 0.54(10% MeOH in DCM);  1H NMR δ 1.47-
1.49 (m, 4H), 1.59-1.62 (m, 2H),1.70-1.74 (m, 2H), 1.82 (s(br), 1H), 3.58 (dd, 2H, 
J=12.8, 6.8 Hz), 3.64 (t, 2H, J= 6.4Hz), 7.03 (t, 1H, J= 7.4 Hz), 7.10(d, 1H, J= 8.4 
Hz), 7.44-7.48 (m, 2H), 7.70 (d, 1H, J= 8 Hz), 7.83(m, 1H), 8.03 (dd, 1H, J= 8, 
1.2Hz), 8.16 (d, 1H, J= 7.6 Hz), 10.44 (s, 1H); 13C NMR δ 25.30, 26.72, 29.55, 
32.54, 39.71, 62.62, 109.89, 113.53, 117.46, 120.27, 124.04, 125.51, 126.48, 
127.74, 134.60, 137.20, 148.95, 158.30, 163.40, 163.84; CIMS m/z 355 (MH+); 
HRMS m/z calc for C20H23N2O4: 355.1658,  found: 355.1660; EA calc for 
C20H22N2O4: C, 67.78; H, 6.26; N, 7.90; found: C, 67.64; H, 6.33; N, 7.48  
 
6.7.13. Compound 20. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic 









Following the general procedure for hydrogenolysis, compound 14 (111 
mg, 0.27 mmol) was de-protected to give compound 20, which was purified by 
column chromatography (10% MeOH in DCM), recovering white crystals (56 mg, 
63 % yield). mp. 157-159oC; Rf 0.68 (10% MeOH in DCM);  1H NMR δ 2.65 
(s(br), 1H), 3.67 (t, 2H, J= 4.4 Hz), 3.74(t, 2H, J= 4.6), 3.80-3.84 (m, 4H), 7.05 (t, 
1H, J= 7.8 Hz), 7.12 (dd, 1H, J= 8.4, 0.8 Hz), 7.45-7.50 (m, 2H), 7.72 (dd, 1H, J= 
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8, 0.8 Hz), 8.04 (dd, 1H, J= 8.2, 1.4 Hz), 8.19 (dd, 1H, J= 7.4, 1 Hz), 8.38 (m, 
1H), 10.80 (s, 1H); 13C NMR δ 39.41, 61.93, 70.08, 73.24, 109.93, 113.70, 
117.59, 120.62, 123.87, 125.56, 126.54, 127.71, 134.69, 137.29, 149.01, 157.72, 
163.35, 163.64; CIMS m/z 343 (MH+); HRMS m/z calc for C18H19N2O5: 343.1294, 
found: 343.1285; EA calc for C18H18N2O5+1/3H2O: C, 62.06; H, 5.40; N, 8.04; 
found: C, 62.24; H, 5.19; N, 7.69 
 
6.7.14. Compound 21. 2-(2-Hydroxy-phenyl)-benzooxazole-4-carboxylic 











Following the general procedure for hydrogenolysis, compound 15 (65 mg, 
0.12 mmol) was de-protected to give compound 21, which was purified by 
column chromatography (10% MeOH in DCM), recovering a yellow oil (46 mg, 
85% yield). Rf 0.76 (10% MeOH in DCM); 1H NMR δ 2.60 (s(br), 1H), 3.52-3.54 
(m, 2H), 3.59-3.71 (m, 8H), 3.74-3.77 (m, 2H), 3.91 (t, 2H, J= 4.8 Hz), 4.58, (t, 
2H, J=4.8 Hz), 6.98 (t. 1H, J= 7.6 Hz), 7.09 (d, 1H, J= 8 Hz), 7.39-7.46 (m, 2H), 
7.76 (dd, 1H, J= 8, 0.8 Hz), 7.98 (dd, 1H, J= 8, 1.6 Hz), 8.05 (dd, 1H, J= 8, 0.8 
Hz), 11.82 (s, 1H); 13C NMR δ 61.64, 64.50, 69.10, 70.24, 70.53, 70.61, 72.44, 
109.88, 114.90, 117.59, 119.49, 121.16, 124.68, 127.13, 127.46, 134.12, 139.42, 
149.67, 159.34, 164.19, 165.04; CIMS m/z 432 (MH+); HRMS m/z calc for 
C22H26NO8: 432.1675, found 432.1658; EA calc for C22H25NO8+1/3H2O: C, 60.40; 















UK-1 (19.81 mg, 0.051mmoles) was dissolved in MeOH. A concentrated 
solution of copper acetate in MeOH (2.94 ml of a 8.74mM solution, 0.026 
mmoles) was added portion-wise. The solution was left under reflux for 2 days, 
after which solvent was slowly evaporated. The metal chelate was recovered 
after filtration and re-crystallization in MeOH; m.p. > 300 ºC; UVλmax
MeOH nm (ε) 
236 (33814), 267 (28423), 275 (26787), 317 (24749), 333 (24232), 348 (22749), 
418 (12974); ; Rf 0.27 (10% MeOH in DCM); IR νmax(KClpellet) 1750 cm
-1; CIMS 
m/z 432 (MH+); HRMS m/z calc for C22H13N2O5Cu
+: 448.0114, found 448.0115; 
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PART II:  G-QUADRUPLEX SELECTIVITY OF PERYLENE DIIMIDE 
COMPOUNDS 
CHAPTER 7.   INTRODUCTION  
 
7.1. DNA Structures 
7.1.1. B-DNA and other Helical Structures 
 
As discussed in chapter 1, the majority of genomic DNA exists as a 
double-stranded, antiparallel structure that is held together by a specific network 
of hydrogen bonds of its heterocyclic bases (Figure 7.1). The purine bases 
adenine and guanine are able to base-pair with the pyrimidine bases thymine 
and cytosine through two and three hydrogen bonds respectively giving rise to 
the classical “Watson-Crick” model of DNA. This arrangement leads to a 
structure that consists of a helix with a hydrophobic interior where the nucleic 
acid bases are stacked on top of each other and a hydrophilic exterior with the 
sugar phosphate backbone of the bases (1).  
The most common conformation of DNA is the B form, which is right-
handed helix with the bases oriented perpendicularly to the axis. It has 
approximately 10.5 base pairs for every turn of the helix, 20 Å in diameter and 
distinct major and minor grooves; the former is wide and deep while the latter is a 
narrow and deep (2, 3).  Other helical forms of DNA such as A and Z DNA have 
also been observed in in vitro studies, and have been proposed to occur in vivo 
under certain circumstances such as in promoter regions or during transcription 
(4).   
The A-form of DNA is broader (26 Å in diameter) and less twisted (11 
base pairs/turn) compared to the B-form. Other differences include the position of 
the bases, which lay off the helix axis, as well as the size of the grooves, with a 
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narrow and deep major groove and a wide a shallow minor groove (5, 6). Z-DNA 
is left-handed and has zigzag pattern in the sugar-phosphate backbone. It has 
approximately 12 bases per turn, and 18 Å in diameter (5, 7). While it does not 
have pronounced major groove, it does have a deep and narrow minor groove. 
Its formation is favored by high salt concentrations and alternating GC 

































































Figure 7.1. Helical DNA structure and base-pairing. (A) Schematic representation of the double 
Helix; the major and a minor groove are highlighted. (B) DNA base pairing; adenine forms two 
hydrogen bonds with thymine, and guanine forms three hydrogen bonds with cytosine 
 
 
7.1.2. Alternative DNA Structures 
 
In contrast to proteins that favor a particular structure based on its 
sequence, DNA molecules can be considered as an array of structural states. 
Over the past decades it has become evident that some of the structures that 
DNA can also adopt vary from the classical helical forms. Such structures include 
cruciforms, Holliday junctions, triplexes and quadruplexes. Initially studied as 
oddities, many of these structures are currently being studied for their possible 




7.1.2.1. Hairpin loops, Cruciforms and Holliday Junctions 
 
Hairpin Loops (Figure 7.2A) can form when an oligonucleotide that 
contains a segment of inverted complementarity folds and base pairs with itself. 
Longer palindromic duplex DNA sequences have the potential to form similar 
structures with two stems and two hairpin loops (Figure 7.2B). These branched 
structures are called cruciforms and occur when intra-strand base pairs replace 
the inter-strand base pairs of the duplex within the inverted complementary 
sequences (13, 14). Negative DNA supercoiling under conditions of torsion 
stress can favor the formation of these structures. There is evidence they can 









Figure 7.2. Hairpin Loops and DNA cruciforms. (A) Hairpin loop formed by an oligonucleotide 
with an inverted complementary sequence. (B) DNA cruciform from an inverted sequence repeat 
in double stranded DNA. 
 
 A structure related to the cruciform is the Holliday junction. These 
structures were originally proposed in the 60’s by Robin Holliday, and consist of a 
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four-armed transitory structures formed by two DNA duplexes during homologous 
recombination (15, 16).  
 
In this model, nicks are introduced at the same position in two DNA 
molecules which are located in different alleles. The single strands can then 
anneal to the complementary sequences in the other allele, as shown in Figure 
7.3. The crossover of the strands forms the four-stranded Holliday Junction.  The 




Figure 7.3. Holliday Junctions. (A) After DNA replication nicks are introduced on two homologous 
chromosomes. Strand exchange can occur giving rise to a Holliday junction which can result in 
crossover sequences. (B) Schematic model of an antiparallel open planar Holliday Junction. 
 
7.1.2.2. Triplex DNA 
 
Gel electrophoresis supercoiled DNAs carrying a homopurine-
homopyrimidine inverted repeats revealed that an unusual structure formed. This 
structure was named “H-DNA” because it was stabilized in the presence of 
hydrogen ions. The main element of the H-DNA is an intramolecular triple helix 
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formed by the entire pyrimidine strand and half of the purine strand; the other half 
of the purine strand remains single stranded (17, 18). Later studies showed that 
H-DNA is abundant in eukaryotic genomes.  
The triple helix is stabilized by base pairs that involve alternative donor 
and acceptor partners to the standard Watson-Crick base pairs called Hoogsten 
base pairs.  In this manner, two nucleobases on each strand can be held 
together by hydrogen bonds in the major groove. A parallel triple helical DNA can 
result from the interaction of two homo-pyrimidine and one homo-purine strand 
Figure 7.4A. Protonated C can form hydrogen bonds to the N7 and O6 of G, and 
T can hydrogen bond with the N7 and the C6 amino group of A . Anti-parallel 






































































































Figure 7.4. Triplex DNA. (A) Hoogsten base pairs that arise from parallel DNA triplexes. (B) 
Hoogsten base pairing form anti-parallel DNA triplexes. 
 100 
  
Triplex binders generally include extended planar aromatic rings that can 
allow stacking interactions with the base triplets. They also tend to have at least 
one cationic charge on the chromophore that can stabilize the larger negative 
charge density of the triplex. Some examples of common triplex-DNA selective 
binders include benzo[e]pyridoindole, BePI, and fused heterocycles such as 
















Figure 7.5. Examples of Triplex-DNA binding ligands. (A) BePI, benzo[e]pyridoinole. (B) 
Napthylquinoline. (C) Coralyne 
 
 
7.1.2.3. Four stranded structures: G-Quadruplex and i-motifs 
 
Certain DNA sequences can form four stranded helices by the folding of a 
single strand or through the association of two, or four strands of DNA (19). In 
particular, sequences with consecutive runs of Gs are prone to higher ordered 
structures. As early as 1962 it was observed by fiber diffraction studies that 
guanylic acid could form a four-stranded helix (20).  Other studies noted that G-
rich sequences presented unusual gel electrophoresis mobility (21, 22). Sen and 
Gilbert also showed that the unusual mobility bands were protected from the 
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characteristic methylation at the N7 position of guanines by dimethyl sulfate, 
which suggested their involvement in Hoogsten base pairing (22).  
In fact guanine nucleobases are capable of forming Hoogsten hydrogen-
bonds through the N7 and N2 amino groups, and the N1 amino and O6 carbonyl 
forming structures called G-tetrads, as seen in Figure 7.6A; the result is an 
almost coplanar arrangement, with each guanine both accepting and donating 
two hydrogen bonds, and directing its O6 carbonyl group into the core of the 
tetrad (23). The cavity in the center of the tetrad allows for metal binding, which 
also stabilizes the arrangement. The specific hydrogen bond network in the G-
tetrads causes the imino protons resonances in the 1H NMR spectrum to shift 
and are characteristic of these structures (24, 25) . When two or more tetrads are 
stacked on top of each other they can form structures known as G-Quadruplexes 

























































































































































Figure 7.6. G-tetrads and G-Quadruplexes. (A) Guanine bases can hydrogen bond through 
Hoogsten-base pairs in a planar configuration to give rise to a G-tetrad. (B) Schematic of an 
intramolecular G-quadruplex structure  
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The quadruplexes can be formed with various strand stoichiometries. A G-
rich single stranded sequence can fold on itself and give rise to an intramolecular 
quadruplex (Figure 7.7A). A sequence with two separate runs of Gs can also fold 
into a hairpin and associate with another hairpin to generate an intermolecular 
dimeric quadruplex (Figure 7.7B). Four separate strands can also combine and 
create a tetramolecular quadruplex (Figure 7.7C). In theory, quadruplexes could 
also be formed from the association of three strands, but this arrangement has 
yet to be observed. There is a wide array of nomenclature used throughout the 
literature to refer to these structures. For this work, conventional nomenclature 
will be employed; intramolecular quadruplexes will be referred to as G4’-DNA, 
while the dimeric quadruplexes will be described as G’2-DNA and tetrameric 







Figure 7.7. Strand Stoichiometries in G-Quadruplexes. (A) Unimolecular quadruplexes, or G4’-
DNA, formed by the folding of a single strand. (B) Dimeric quadruplexes (G’2-DNA) formed from 
two strands. (C) Association of four strands generates tetrameric quadruplexes, (G4-DNA) 
 
 
The four participating strands can have their phosphodiester backbones in 
a parallel, antiparallel, or mixed orientation regardless of the number of strands 
participating in the quadruplex (28).  Figure 7.8A shows a schematic of all the 
strands arranged in a parallel configuration, while figures Figure 7.8B, Figure 
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7.8C, and Figure 7.8D present the possible arrangements when 1 or 2 strands 




Figure 7.8. Possible strand orientations in G-Quadruplexes. (A). All strands parallel. (B). Three 
strands parallel and one strand antiparallel. (C) Two adjacent parallel and two adjacent 
antiparallel strands. (D). Alternating antiparallel stands 
 
 
C-rich sequences are also able to form four-stranded structures, termed i-
motifs. These structures were discovered in 1993 by Gehring and coworkers, 
revealing that two parallel duplexes of protonated cytosine–cytosine base pairs 
could intercalate with each other in an antiparallel orientation as seen in Figure 
7.9 (29). One of the main differences between G-quadruplexes and i-motifs is 
that the first are stable at neutral pH, whereas the i-motifs require protonation of 
half the cytosine residues, and therefore are only stable under slightly acidic 



























Figure 7.9. The i-motif. (A) The C·C+ base pair. (B) An intercalated intramolecular i-motif 
 
 
7.2. G-Quadruplex DNA topology and polymorphism 
G-rich sequences can assemble into an extensive number of quadruplex 
structures.  The loops that connect the guanine tracts of G’2-DNA and G4’-DNA 
can be connected to the tetrads through various orientations (26, 28). Figure 
7.10A presents some of the known conformations for G4’ loop connectivity; 
strands can be connected in an adjacent-diagonal-adjacent (basket), adjacent-
adjacent-adjacent (chair), diagonal-diagonal-diagonal (parallel), or a diagonal-
adjacent-adjacent (dog-eared) fashion. Bimolecular quadruplexes have been 
proposed or shown to have loops that connect the tetrads diagonally or edge-
wise, as shown in Figure 7.10B. Crossover G’2-DNA have loops that connect the 
opposite ends of the outer tetrads diagonally. Each strand in the edge 
quadruplex connects adjacent sides on opposing sides of the tetrad and can be 
in a parallel or in an alternating antiparallel (shown) configuration; the loops 
formed by the strands face opposite sides of the quadruplex. Syn-edge 
quadruplexes are similar to the edge, except the two strands face the same side 







Figure 7.10. Topological forms of G4’ and G’2-DNA generated by alternatives in loop 
connectivity. (A) G4’ Intramolecular quadruplexes where the strands adopt a basket, chair, 
parallel, or dog-eared configuration. (D) G’2 dimeric quadruplexes can adopt edge, crossover, 
syn-edge, or dog-eared type intermolecular quadruplexes.  
 
 
Many sequences are capable of forming more than one quadruplex 
structure (32-35). For instance, different intramolecular structures were 
uncovered for the oligonucleotide AG3(T2AG3)3 via NMR and X-Ray 
crystallography.  The NMR solution (in sodium ions) presented a basket-like 
intramolecular quadruplex, while the crystal structure (in potassium ions) 
displayed a parallel-type G4’ conformation (34, 36-38). Later studies showed that 
both structures can be present at the same time under near-physiological 
conditions and can interconvert on a minute time scale (32, 39). Still another 
 106 
intramolecular quadruplex structure for this sequence was discovered recently, 
finding a dog-eared structure in potassium solution (40, 41). It is clear that there 
is a wide array of polymorphism on the structures that G-rich sequences can 
adopt, and future studies are likely to unravel novel quadruplex structures. 
The stability of a particular structure depends on many factors, including 
the concentration, the number of strands, the number of tetrads, the sequence of 
the loops that connect the tetrads, and the solution conditions (19, 23, 42-49). 
The type and concentration of counterions is one of the most influential factors in 
the stabilization of a particular structure. The general stabilization of 
quadruplexes by counterions follows the order: Sr2+>K+>Rb+∼Ba2+>NH4
+>Ca2+> 
Na+>Mg2+∼Cs+>>Li+ (23, 25). Cations of ionic radii close to 1.3 Å, such as 
potassium and strontium can fit well in the cavities formed between the planes of 
two tetrads, coordinate with the eight O6 carbonyls of the guanines, and stabilize 
the quadruplex structures thermodynamically and kinetically (24, 25, 38, 50-53).  
Cations can affect the polymorphism of quadruplex. For example, the formation 
of G4-DNA is favored under high K+ ion concentrations, while lower K+ or lower 
K+/Na+ ratios lead preferentially to G4’ structures (25, 54-56). Cations can also 
affect the geometry of the loops in quadruplex structures and can favor the 
conversion from duplex DNA to quadruplex structures (53, 54, 57).  
  
7.3. G-rich sequences and G-quadruplexes 
7.3.1. Telomeric DNA 
 
Telomeres are located at the end of eukaryotic chromosomes and contain 
non-coding tandem repeats of G-rich sequences.  The human telomeric repeat is 
between 2 and 10 kb long, and consists of repeats of the sequence d(TTAGGG); 
other known telomeric sequences include those of Tetrahymena (protozoa) and 
Oxytricha nova (protozoa), d(TTTTGGGG), and S. cerevisiae (yeast), d(TG1-3) 
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(49, 58). In humans, most of the telomeric repeats are contained within the 
duplex regions, but there is also a nucleotide single stranded overhang of 
approximately 200 nucleotides long at the 3’ end of the telomeres (59, 60). 
Griffith and co-authors have observed the chromosome ends of HeLa nuclear 
extracts through electron micrographs (61). They noted that telomere overhangs 
are able to form loop-back structures (T-loops) that are incorporated into the 
double stranded telomeric region (D-loops); these structures are stabilized by the 
telomeric repeat-binding factors, TRF1 and TRF2, and could  aid in preventing 
chromosome end-to-end fusions and degradation (61).  
Telomeres shorten after every round of replication because of the end- 
replication problem (62, 63). DNA polymerases move in a 5' to 3' direction and 
can replicate DNA on the leading strand uninterruptedly.  In contrast, the lagging 
strand is oriented 3’ to 5’ can only be replicated in a discontinuous fashion, as 
described in Figure 7.11. Short RNA primers attach to the complementary strand 
close to the initiation site, allowing DNA polymerase to replicate the lagging 
strand in stretches called Okazaki fragments. DNA ligase then converts the RNA 
primers to their respective DNA sequences and seals the gaps in between the 
Okazaki fragments. DNA polymerase cannot add new nucleotides to the 5' end of 
the lagging strand because of the lack of a new RNA primer in 3’ end of the 
complementary DNA sequence. This ultimately causes a section of the telomeres 




















Figure 7.11. The end replication problem. DNA polymerase can replicate the leading strand 
uninterruptedly, while the lagging strand gets replicated in short discontinuous fragments. The 
lagging strand gets shortened after every round of replication because DNA polymerase cannot 
add nucleotides to the last fragment at the 5’ end 
 
In humans, approximately 50-200 base pairs in the telomeres are lost after 
every replication cycle (65, 66). Because of their shortening, telomeres play an 
important role in the regulation of cellular longevity and apoptosis. Programmed 
cell death can be signaled when telomeric sequences are reduced to a particular 
length (58, 67, 68). Somatic cells have a finite number of cell divisions until they 
become senescent (69). However, certain types of cells such as stem, 
endometrial, skin or germ cells have high proliferation rates, and require longer 
life spans (70-72). These cells are able to overcome the replication problem by 
expressing a ribonucleoprotein with reverse transcriptase activity called 
telomerase (70, 72). This enzyme is able to bind to a region of DNA on the 3' end 
of the complementary strand and insert additional telomeric repeats (73, 74). An 
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RNA primer can then to bind to the end of the complementary strand and be 
extended through normal lagging strand synthesis.  
Williamson and coworkers were able to see that the G-rich telomeric 
sequences could form quadruplexes in vitro (52). Since then, the formation of 
quadruplex structures from telomeric sequences in vitro has been well 
characterized by NMR, X-ray crystallography and FRET methods (24, 36, 38, 39, 
50, 75, 76). While the biological role of quadruplexes at the telomeres has not 
been elucidated, several speculative roles for these structures have been 
proposed and are depicted in Figure 7.12 (77, 78). Intramolecular G-
quadruplexes could form in the single-stranded overhang region to cap the 
telomeres and protect them from inappropriate recombination or nucloelytic 
attack as alternative or part of the T-loop structures (Figure 7.12 A and B) (78). In 
support of this idea, Tsai et al.. have shown that the human telomeric 3' single-
stranded overhangs sequence can protect the telomeres from being recognized 
as double strand breaks when G-quadruplex structures are present (79). G4’ 
quadruplexes could also facilitate packing of the telomeres by condensing the 
single strand overhang (Figure 7.12C) (77). Dimeric quadruplexes could also 
assist in telomere alignment and capping through interchromosomal 
associations, and tetrameric structures could appear during meiosis (Figure 7.12 











































Figure 7.12. Putative roles of G-Quadruplexes in the telomeres. (A) Intramolecular G-quadruplex 
formed from the single-stranded overhang in the telomeres could help telomere capping. (B) 
Quadruplex could form part of the T-loop structure. (C) G-Quadruplex structures may facilitate 
packing of telomeric DNA. (D) Dimeric quadruplexes could form during interchromosomal 




The formation of quadruplex structures in the telomeres has been 
correlated with decreased telomerase activity. (81). Studies have also shown that 
telomerase is active in over 85% of all cancers promoting their immortalization 
(82, 83). Thus, telomerase inhibition is an active target of anticancer drug design. 
Ligands that can stabilize telomeric quadruplex structures can serve as potential 
telomerase inhibitors and are currently being studied by numerous groups. 
Further discussion of G-quadruplex as a target for drug design will be covered 






7.3.2. Other regions in the Genome 
   
 Telomeric DNA is not the only G-rich sequence capable of forming 
quadruplex structures. In fact, there has been considerable interest in locating 
putative quadruplex sequences in non-telomeric genomic DNA. Part of the 
interest was heightened by the discovery that c-myc, which is one of the most 
commonly malfunctioning genes in human cancer, could form a biologically 
relevant quadruplex in a nuclease hypersensitive region upstream of the 
promoter known to control its activity (84, 85). Furthermore, it was established 
that c-myc transcription could be regulated by G-quadruplex stabilization through 
ligand binding (84, 86).  Since then, it has been discovered that G-quadruplex 
forming sequences are present in the promoter regions of other proto-oncogenes 
such as RET, c-kit, bcl-2, VEGF, K-ras, N-ras, and RFP2 (87-97) . These studies 
have set forward the idea that quadruplex motifs could be directly involved in 
gene regulation, either by suppressing or modifying their transcription when 
quadruplex sequences are formed (Figure 7.13). Furthermore, studies have 
demonstrated that the levels of certain ions such as potassium and sodium can 
affect gene expression and apoptosis, and are altered in certain tumor cells. The 
modified ratios of these cations in cancer cells could result in conformational 
changes in quadruplex structures and potentially in altered telomere function or 























Figure 7.13. Transcriptional regulation by quadruplex forming sequences in promoter regions. A. 
When quadruplex forming sequences are in a double stranded conformation, regular transcription 
occurs. B. Quadruplex formation can suppress or alter the transcription of a gene 
 
 
 Recently several computational and web server tools have been created 
to predict quadruplex forming structures within genomic sequences (102-106). 
The putative quadruplex sequences, or PQS, are defined as four equal length 
sets of guanines separated by arbitrary nucleotide sequences forming at least 
three tetrads (in some programs the user can include searches with only two 
tetrads and modify the length of the loops); sequences that follow the folding 
pattern d(G3+N1-7G3+N1-7G3+N1-7G3+), where N is any base, are tagged as having 
the potential to form quadruplex structures.  Using this algorithm over 370,000 
PQS have been identified in the human genome (105, 106).  
 Several noteworthy observations were made in these studies regarding 
the location and frequency of the PQS. Huppert and  Balasubramanian noticed 
that promoter regions of genes are significantly enriched in quadruplex motifs 
relative to the rest of the genome, finding that over 40% of human gene 
promoters have at least one PQS (103). Elevated tendency to form quadruplex 
motifs in promoter regions was uncovered in proto-oncogenes, as well as in 
genes with transcription factor activity, development, neurogenesis and kinase 
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activity, while those less likely to have promoter PQS included olfaction, G-
protein signaling, immune response, nucleic acid binding and protein 
biosynthesis (103). Another important discovery is PQS are over 200-fold more 
likely to be found in regions of the genome that have both nuclease 
hypersensitivity and are found within promoter regions,  compared to the rest of 
the genome.  Regions that have sensitivity to nucleases (such as DNAse I) in 
regulatory sequences like promoters and enhancers occurs when relevant 
elements are active; the sensitivity is thought to be due to a perturbation in the 
nucleosome that renders the adjacent sequences available for nuclease attack, 
such as by interaction with specific DNA binding proteins or because of  altered 
DNA structures (107). All these observations substantiate a possible role of G-
quadruplexes in the regulation of gene expression.  
7.3.3. Evidence of G-Quadruplex formation in vivo 
 
 Many G-rich sequences have the ability to form quadruplex structures 
and have been structurally characterized in vitro by NMR or X-ray crystallography 
as discussed in section 7.2. On the other hand, the existence of G-quadruplexes 
in intracellular environments is still controversial (108).  However, there is some 
recent compelling evidence that quadruplex structures can form in vivo (77).  
Some of the initial proof came from Schaffitzel and coworkers, who generated 
high-affinity antibodies specific for the guanine-quadruplex formed by the 
Stylonychia lemnae (ciliate) telomeric repeat; they were able to observe 
macronuclei staining by immunofluorescence using these antibodies (109). 
Staining was not detected in the replication band, which suggested that the 
quadruplex structures detected by the antibodies are resolved during DNA 
replication. Other groups are currently working on antibodies that target other 
quadruplex forming sequences (110, 111).  
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Further evidence for the existence of DNA in vivo comes from the 
expanding list of viral and cellular proteins that can recognize and interact with 
quadruplex DNA (77, 112). For instance, studies have demonstrated that 
helicases in the RecQ family, such as RecQ, Sgs1p, BLM, and WRN exhibit G-
quadruplex unwinding capability (113-116). Non-RecQ helicases such as SV40 
large T-antigen have been investigated by the Kerwin group and others, and can 
also unwind G-quadruplex structures, even with a greater affinity than double 
stranded DNA (117-119). Furthermore, known G-quadruplex interactive agents 
can in some cases inhibit the unwinding capability of these helicases (117, 120-
124). It has been suggested that G-quadruplex unwinding of these helicases 
could be necessary during DNA replication and recombination, validating a 
biological existence of quadruplex structures (116) . 
Other quadruplex interacting proteins can bind selectively and tightly to 
tetraplex DNA, and in some cases also promote their formation (77).  A recent 
study investigated the telomeric binding proteins αTBP and βTBP and 
demonstrated using RNAi that both proteins regulate G-quadruplex formation in 
vivo (80).  In addition, their data also indicated that βTBP is under the control of a 
cell-cycle phosphorylation event, possibly allowing for resolution of the 
quadruplexes during telomere synthesis. Additional quadruplex binding proteins 
include the repressor-activator protein 1 (Rap1), the G-Binding proteins TGP1 
and TGP3, the mammalian nucleolar protein Nucleolin, the Human 
Topoisomerase I enzyme (Topo I), the human replication protein (RPA), and the 
meiotic synaptonemal complex in yeast Hop1 (125-131). Nucleases that can 
cleave G-quadruplexes have also been found; for example, the KEM1 gene in S. 
cerevisiae, and GQN1 in humans; both cleave single stranded DNA when it is 5’ 
of a quadruplex structure, and release intact quartets after the cleavage (132, 
133). The wide range proteins that can recognize and interact with G-
quadruplexes discovered thus far corroborates the idea that quadruplex are 
biologically relevant species. 
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  Some of the most convincing proof of the existence of G-quadruplex DNA 
in cells comes from a study by Duquette and co-authors (134).  They inserted a 
plasmid with the TTAGGG human telomeric repeat in E. coli cells and monitored 
their intracellular transcription using electron microscopy. They were able to 
visualize novel structures termed “G-loops” in the non-template G-rich strand, 
and a RNA-DNA hybrid in the C-rich strand. The authors also corroborated that 
the G-loops contained quadruplex DNA by examining their interaction with 
proteins with high affinity towards quadruplex structures, such as GQN1 and 
Nucleolin, and through DMS footprinting. The formation of quadruplex DNA only 
occurred during the transitory denaturation of double stranded DNA that arises 
during the transcription of the G-rich region in their substrates. This suggests that 
quadruplex formation could occur in G-rich sequences during other events where 
there is a momentary denaturation of double stranded DNA, such as 
recombination or replication.   
 
7.4. G-Quadruplex as a good biological target 
 
As discussed earlier, telomerase is a ribonucleoprotein enzyme that 
elongates the G-rich strand of telomeres by reverse transcription. The majority of 
normal somatic cells has very low levels of this enzyme and ceases to proliferate 
after their telomeres reach a critically short length. In contrast, over 85% of 
cancer cells express high levels of this enzyme (82, 83). Telomerase expression 
per se does not cause tumorogenesis, but expression of the enzyme in 
cancerous cells can unintentionally assist them in immortalization by allowing a 
selective advantage to growth arrest and senescence (135-137). Inhibition of 
telomerase therefore presents an attractive target for drug design. One strategy 
to design inhibitors of this enzyme is to target its DNA substrate, in particular the 
quadruplex structures that telomeric sequences can form. In fact, Zahler and co- 
authors showed that stabilization of telomeric DNA into quadruplex structures 
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inhibited telomere elongation by telomerase (81). One way to stabilize 
quadruplex structures is through the interaction with ligands; not surprisingly, 
many small molecules that can bind to quadruplexes are being designed and 
researched by many laboratories. 
As reviewed earlier, quadruplexes are not only found at the telomeres but 
are also located throughout the genome, in particular in the promoter regions of 
many oncogenes (section 7.3.2). It has been postulated that quadruplex 
stabilization could be involved in the transcriptional regulation of these genes (84, 
103, 138). Consequently, targeting G-quadruplex structures in promoters of 
oncogenes has also become an emerging field in anticancer drug design (84, 
91).  Moreover, because of the apparent ubiquitous nature of quadruplexes in the 
genome, much research is needed to understand their biological significance and 
the factors that influence their formation. G-quadruplex interactive molecules may 
not only be used as anticancer treatment agents but can also be used as 
biophysical probes to investigate the biological role of quadruplexes in cells.  
 
7.5. G-Quadruplex interactive ligands  
 
Over the past years several worthy review papers have been published about 
G-quadruplex interacting ligands. (26, 78, 139-142). Because of the planar 
structure of the G-tetrads (section 7.1.2.3), compounds that can bind to 
quadruplex structures are generally polycyclic aromatic ligands substituted at 
multiple positions. Some of the most widely studied compounds will be described 

















































Figure 7.14. Examples of G-Quadruplex interactive compounds. (A) Telomestatin. (B) [tetra-(N-
methyl-4-pyridyl)-porphine] (TMPyP4). (C) 4,8,12-Trioxa-4,8,12,12c-
tetrahydrodibenzo[cd,mn]pyrenylium carbocation  tetrafluoroborate (TOTA+). (D) 2,6-
diamidoanthraquinone. (E) 3,3’-diethyloxyadicarbocyanine (DODC). (F) N,N’-bis[2-1-piperidino)-





Telomestatin (Figure 7.14A) is a natural product isolated from 
Streptomyces anulatus 3533-SV4 that is a very potent telomerase inhibitor (143). 
This compound also displays over 70 fold selectivity for quadruplex structures in 
comparison to duplex or single-stranded DNA (144-146). Cell assays have 
shown that treatment with Telomestatin is concomitant with quadruplex formation 
at the telomeric overhangs; the size of the overhangs is reduced in long term 
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treatments, leading to delayed loss of cell viability (147).  Telomestatin appears 
to cause telomere dysfunction in various tumor cell lines and to selectively target 
cancer over normal cells (148, 149). 
 
7.5.2. Porphyrins  
 
Porphyrins have been extensively studied as anticancer drugs mainly 
because they appear to accumulate preferentially in tumor tissues compared to 
normal ones (150). Perhaps the most widely studied G-quadruplex binding 
porphyrin is the compound [tetra-(N-methyl-4-pyridyl)-porphine], or TMPyP4 
(Figure 7.14B). Various groups have shown that this molecule is able to bind and 
stabilize G4, G4’ and G’2 quadruplex structures (146, 151, 152). TmPyP4 is also 
able to inhibit the activity of the enzyme telomerase, suppress c-MYC 
transcriptional activation, reduce the activity of the mouse KRAS promoter, and 
inhibit the G-quadruplex unwinding activity of several RecQ helicases (84, 91, 
120, 122-124).   
There is some controversy concerning the binding mode of porphyrins to 
quadruplex structures. Some research suggests that porphyrin molecules stack 
externally to the outer tetrads of the quadruplexes, while other studies suggest 
they can also intercalate in between the tetrads (153, 154). It has also been 
recently proposed that some porphyrins can bind to the loops of quadruplexes 
through external groove binding (155).  Structure–activity relationship studies of 
hundreds of porphyrins showed that charge number, hydrogen-bonds, and side-
chain length are crucial to their interaction with G-quadruplexes (156-158). 
Selectivity for quadruplexes over double or single-stranded DNA is also 
dependent on the porphyrin structure; TmPyP4 is not particularly selective as it 
can also bind to duplex and single-stranded DNA (159-164) On the other hand, 
the anionic porphyrin N-methyl mesoporhyrin, or NMM, is highly specific for 




The trioxatriangulenium ion (TOTA+, Figure 7.14C) is a stable cation that 
can bind and photooxidize duplex DNA, leading to cleavage chiefly at G residues 
(166, 167). X-ray crystallography diffraction of TOTA+ in the presence of a duplex 
oligonucleotide showed that it behaved as an intercalator and that it strongly 
polarized the binding site (167).  
Prior work investigated the interactions of this cation with duplex and 
quadruplex oligonucleotides through gel electrophoresis, ESI mass spectrometry 
and NMR spectroscopy (168). At lower concentrations this compound appears to 
interact with quadruplex structures by end-stacking at the outer tetrads, but 
presents additional binding modes at higher ratios.  Oligonucleotides containing 
either the human telomeric repeats or the Tetrahymena telomeric repeats are 
readily photooxidized by TOTA+ on the central guanine residues in each 
telomeric repeat when they are in a duplex form. However, there was significantly 
less photocleavage of these residues when the sequences formed quadruplex 
structures. 
 
7.5.4. Disubstituted Anthraquinone Derivatives  
 
Anthraquinone derivatives were originally studied as double stranded DNA 
intercalative agents. Fox et al. noted that various 1,4- and 2,6- substituted 
diamidoanthraquinones could selectively bind to  triplex DNA structures 
compared to double stranded DNA (169). This led the authors to speculate about 
their possible interaction with G-quadruplex DNA. Computer modeling predicted 
that these compounds could be potential G-quadruplex interactive agents. 
Indeed, NMR and UV-Vis spectroscopy studies showed that 2,6-
diamidoanthraquinone (Figure 7.14D) could bind and stabilize quadruplex 
structures.  Since then, this compound and several other anthraquinone 
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derivatives have proven to be effective telomerase inhibitors (170, 171).  The 
anthraquinone system has also been replaced with an acridine core, generating 
higher quadruplex specific ligands with lower dissociation rates (172, 173). 
 
7.5.5. Carbocyanine dyes  
 
Using DOCK computer modeling to predict compounds that could have 
preferential interactions with the grooves of G’2-DNA compared to the minor 
groove of duplex DNA, Chen and co-authors identified the carbocyanine dye 
N,N’-diethyloxatricarbocyanine (DOTC) as a potential G’2-DNA selective ligand 
(174). However, this compound has poor aqueous solubility so the more soluble 
analog, N,N’-diethyloxadicarbocyanine (DODC, Figure 7.14E) was used in in 
vitro studies (175). This compound exhibited unique spectroscopic changes in 
the presence of dimeric G-quadruplex structures, but not in the presence of 
single-stranded, duplex or parallel G-quadruplex DNA.  However, there is also 
evidence that DODC can bind to triplex DNA structures with a higher affinity than 
quadruplex structures (176). Since then, Kerwin et al.  have identified other 
carbocyanine dyes such as DTC (N,N'-diethylthiacarbocyanine iodide) which can 
bind to G4’-DNA (177). This family of compounds presents an alternative 
approach to study quadruplex structures, because unlike the majority of 
quadruplex ligands they appear to interact with the grooves of the quadruplexes 
rather than with the end tetrads (173). 
 
7.5.6. Perylene Diimides 
 
Previous studies identified through DOCK computer modeling that the 
3,4,9,10-perylenetetracarboxylic acid diimides (PTCDIs), with their planar, 
heterocyclic aromatic core could be potential G-quadruplex interactive molecular 
scaffolds. The compound N,N’-bis[2-1-piperidino)-ethyl-(3,4,9,10-perylene 
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tetracarboxylic acid diimide) (Figure 7.14F) was designed and synthesized by 
Fedoroff et al. to investigate its interactions with quadruplex structures (178).  
NMR spectroscopy revealed that this ligand could be sandwiched in between the 
terminal planes of two quadruplexes in a 2:1 tail-to-tail complex with a 5'-
TTAGGG sequence. It could also end stack to form 1:1 complexes with longer 
telomeric sequences, such as TTAGGGTT, TTAGGGTTA, and TAGGGTTA. 
PIPER displayed polymerase and telomerase inhibition the in vitro 
telomerase stop assay. It was also observed that this compound could 
significantly aid in the formation of quadruplex structures; the initial rate of 
formation of G’2 DNA was increased approximately 100 fold in the presence of 
10 mM PIPER (179).   PIPER also facilitates the formation of G-quadruplex DNA 
from the G-rich duplex DNA sequence found in the nuclease hypersensitive site 
that controls the c-myc proto-oncogene (86). 
The interactions between PIPER and quadruplex structures have served 
as the impetus to research other analogs of this compound. Because the majority 
of quadruplex DNA binders can also interact with other nucleic acid structures, it 
is important to investigate the factors that determine selectivity. This body of work 
seeks to accomplish two major goals: 1) To investigate the structural elements in 
the perylene diimide core that are important for G-quadruplex binding and 2) To 
examine the factors that influence the selectivity of perylene diimides for G-
quadruplex over double or single stranded DNA.  
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CHAPTER 8.  PERYLENE DIIMIDES LIGAND AGGREGATION 
AND G-QUADRUPLEX DNA SELECTIVITY UNDER LOW SALT 
CONDITIONS 
8.1. Properties of Perylene Diimides  
 
As mentioned in section 7.5.6, computer modeling identified the 3,4,9,10-
perylenetetracarboxylic acid diimides (PTCDIs) as potential G-quadruplex 
interactive moieties. NMR studies of a representative member of this family, the 
compound N,N’-bis(2-(1-piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid 
diimide (PIPER) confirmed that the ligand could interact with the 3’ or 5’ end G-
tetrad faces of various quadruplexes (178). A schematic representation of PIPER 
end-stacking to a tetrad is shown in Figure 8.1. Federoff et al.. suggested that 
this binding mode would be preferred over conventional intercalation due to the 
high energy cost of disrupting the stable tetrad planes within the quadruplex 
structure (178). Since then it has been observed that a vast number of 








Figure 8.1. End-stacking ligand interactions. Schematic of PIPER forming en-stacking 




Structure-activity relationship studies carried out by Kerwin and co-
workers investigated the effects of pH on G-quadruplex DNA binding by PIPER 
and N,N’-bis-(3-(4-morpholino)-propyl)-3,4,9,10-perylenetetracarboxylic acid 
diimide (Tel01, Figure 8.2) (180). The authors noted a high dependency on pH 
with respect to G-quadruplex binding selectivity: Tel01 was more selective than 
PIPER at pH values close to 7, but at higher pHs both compounds behaved 
similarly. Additionally, Kern et al. compared the NMR spectra of PIPER and 
Tel01 bound to quadruplex DNA and found no structural basis for differential G-
quadruplex selectivity between the two, finding instead that the aggregation state 
of these molecules was a primary determinant of their G-quadruplex selectivity 
(181). The ligands formed aggregates under pH conditions where they displayed 
preferential G-quadruplex binding over duplex sequences, whereas in non-
aggregating conditions the binding affinities for both DNA species were similar 
(180, 181). The pKas of the side chains play an important role in the pH at which 
the compounds begin to aggregate; PIPER with its more basic piperidino groups 
aggregates at pH values higher than 7, while Tel01 with the morpholino 
substituents starts forming aggregates at pH 7 (Figure 8.2). In addition to G-
quadruplex selectivity, conditions that favored ligand aggregation also promoted 
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Figure 8.2. Structures of PIPER and Tel01 and their pH-dependant aggregation. PIPER has 
more basic side chains than Tel01 and aggregates and forms aggregates at higher pH values.   
 
Since the original studies with PIPER and Tel01, other research groups 
have recently synthesized perylene diimides with modifications in the perylene 
aromatic core, bay-area or side chains (Figure 8.3) and found similar results.   
For instance, Rossetti and co workers studied PTCDIs with different side chains 
and noticed that G-quadruplex formation appeared to be related to drugs’ self-
association, which in turn was influenced by the side chains’ basicity (182, 183). 
Tuntiwechapikul et al. reached similar conclusions by studying PTCDIs with 
positively, negatively or neutral side chains whose charge and self-association 
was as influenced by pH, determining the type of G-quadruplex that could be 
formed as well as binding selectivity (159). Tri-, tetra- and heptacyclic perylene 
analogs prepared by Sissi and co-authors also displayed quadruplex selectivity in 













Figure 8.3. Modifications in the PTCDI structure. Modifications to the perylene structure include 
changes in the number of aromatic rings of the core (red), modifications of the side chains (blue) 
or modifications to the bay-area (green).  
 
 
Ligand aggregation has generally been regarded as problematic in 
medicinal chemistry since the discovery by Shoichet and co-workers that 
aggregating molecules could lead to non-specific inhibition of a wide range of 
enzymes (185). However, this is not necessarily the case for G-quadruplex 
interactive molecules. There is evidence that PTCDIs under aggregating 
conditions can selectively inhibit the SV-40 Large T-antigen helicase unwinding 
of quadruplex  sequences and not double stranded-DNA (117). If these 
molecules were inhibiting the enzyme through non-specific aggregation 
interactions they would be equally effective in preventing the unwinding of both 
substrates. Therefore, it is likely that the observed discriminating enzymatic 
inhibition is due to the selective G-quadruplex binding of aggregating PTCDIs.  
Likewise, Sissi et al. also observed selective inhibition of the enzyme 
telomerase compared to other polymerases by perylene derivatives that 
paralleled their extent of self-aggregation (184). However, the increase in 
selectivity via aggregation was accompanied by an overall decrease in 
telomerase inhibition and interactions with G-quadruplex structures. This 
suggested that ligand aggregation could increase G-quadruplex selectivity by 
reducing the affinity towards other nucleic acid conformations and not necessarily 
by enhancing affinity towards G-quadruplexes.  
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Because of their planar, heterocyclic aromatic nature, PTCDIs can easily 
self-assemble through stacking interactions. It is not currently known how their 
aggregates interact with DNA; aggregate formation could occur upon DNA 
binding, or aggregates in solution could be capable of binding to DNA. There is 
clearly much needed research in this field to understand the mechanism of action 
and selectivity of these compounds. In any case, the findings so far point out the 
importance of monitoring self-assembly of G-quadruplex ligands as a means to 
control their affinity for quadruplex-forming sequences. It is important to 
understand the structural features and factors that regulate their aggregation to 
design selective and efficient G-quadruplex interactive agents. The following 
work investigates structural and physical properties that affect PTCDI 
aggregation and G-Quadruplex selectivity as an extension of the work performed 
by Jonathan Kern (186). 
 
8.2. Modified Perylene Diimide Analogs  
 Analogs were previously synthesized by Jonathan Kern that contain 
representative structural modifications of the PTCDI core (186, 187).  The 
charged perylenes Tel11 and Tel12 bear cationic and anionic sidearms 
respectively (Figure 8.4A and B); Tel18 is an analog of Tel01 with chlorine 
substituents in the bay-area (Figure 8.4C); Tel32 and Tel34 have an extended 




















































Figure 8.4. Structures of perylene diimides analogs. (A) The positively charged analog Tel11. (B) 
The negatively charged perylene Tel12. (C) The polychlorinated analog Tel18. (D and E) The 
benzannulated analogs Tel 32 and Tel34 respectively. 
 
Previous studies of the aggregation state and G-quadruplex DNA binding 
selectivity of these analogs were carried out under relatively high-salt conditions, 
in 170 mM KCl phosphate buffer (180, 181, 186, 187). As discussed in the 
previous section, the selectivity of PTCDIs towards G- quadruplex DNA depends 
on the aggregation state of these ligands, which, in addition to pH, may also be 
affected by ligand concentration, buffer ionic strength, and the presence of non-
aqueous co-solvents. It is therefore important to investigate the aggregation 
behavior and G-quadruplex ligands under different solvent conditions. A lower 
salt buffer was selected (3:1 25 mM ammonium acetate/methanol) that could 
also be easily used in high-throughput techniques such as ESI-MS analysis to 
monitor the perylene-quadruplex interactions.  As discussed in the introductory 
chapter, G-quadruplex stability and topology is also highly dependent on ionic 
strength and could also affect the ligand-DNA interactions. The following sections 
detail the experiments used to monitor the G-quadruplex selectivity and 
aggregation state of these compounds. 
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8.3. Results and Discussion 
8.3.1. Visible Absorbance Spectroscopy experiments 
 
Visible absorbance spectroscopy is useful to investigate the aggregation 
state of perylene diimides as there is characteristic spectral changes dependant 
on the type of aggregate formed (188-190). A well-resolved vibrational structure 
with maxims close to 490 and 525 nm and a shoulder at 460 nm is typical of a 
monomeric species, while a red-shifted, lower intensity absorption maximums 
close to 500 nm and 540 nm, with a shoulder around 480 nm are representative 
of dimeric or lower aggregate species.  Higher aggregated species display a blue 
shift in the maximum absorption peak toward lower wavelengths (close to 475 
nm, with a shoulder around 545 nm) with an overall hypochromism. 
UV-Vis spectroscopy was used to identify changes in the spectra of the 
previously mentioned perylene diimide and benzannulated perylene diimide 
compounds in the methanolic buffer in the presence of different DNA structures. 
An intermolecular G4 quadruplex was used for this studies, [d(T2G5T)]4, 
denominated here on as G5-DNA. This particular G-quadruplex  is preferred over 
intramolecular G-quadruplexes because it can be easily distinguished from 
single-stranded DNA in the ESI-MS spectra. To verify that this sequence was in 
fact forming the expected parallel-oriented quadruplex in the 3:1 25 mM 
ammonium acetate/methanol buffer, its structure was monitored by CD 
spectroscopy. The CD spectra, Figure 8.5, presented a maximum at 263 and a 
minimum at 243 nm which is typical for parallel G-quadruplex structures, 



























Figure 8.5. CD spectra of G5-DNA. 100 µM of [d(T2G5T)]4 in 3:1 water/methanol 25mM 
ammonium acetate buffer, pH 7 
 
The absorption spectra of PIPER and Tel01 are highly dependant on the 
pH conditions of the buffer; there is a blue-shift from 500 nm to a broader peak at 
470 nm with an overall hypochromism at higher pH values, which is indicative of 
aggregation (Figure 8.6). This shift occurs at pH 8 in the case of PIPER, and at 
pH 7 for Tel01, which is in agreement with the spectral changes observed in the 
higher salt phosphate buffer (180, 181)  
At pH 7, the maximum absorbance peak for Tel01 is at 470 nm. Similar 
absorbance spectra are recorded for solutions of Tel01 in the presence of 
equimolar duplex or single-stranded DNA. However, in the presence of equimolar 
G-quadruplex DNA, the absorbance spectrum of Tel01 is significantly different, 
consisting of two large peaks at 550 and 510 nm. In contrast, the UV-Vis 
spectrum of PIPER at this pH displays an absorbance peak at 500 nm, which 
shifts to 510 nm in the presence of equimolar single-stranded, double-stranded, 
or G5 DNA. Additionally, in the presence of each of these DNA structures, there 
is a new absorbance from the PIPER chromophore at 550 nm. The intensity of 
this long-wavelength band increases in the order single-stranded DNA > double-
stranded DNA >G-quadruplex DNA. As the pH increases to 8, the spectra of 
PIPER is similar to that of Tel01 at pH 7, and its affinity for double or single 
stranded-DNA is greatly diminished, evidenced by the lesser spectral shifts 
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observed upon addition of these structures. However, the spectrum has a 
significant shift to 510 nm in the presence of G5 DNA. 
The UV-Vis spectral changes at different pH values for Tel01 and PIPER 
indicate a divergence in the G-quadruplex DNA binding selectivity of these two 
ligands that is dependant on their aggregation state. At neutral pH Tel01, whose 
absorbance spectrum in the absence of DNA is blue-shifted due to ligand 
aggregation, forms a complex with G-quadruplex DNA that absorbs in the 550 
nm region. PIPER, whose spectrum in the absence of DNA at this pH does not 
indicate ligand aggregation, forms similar long-wavelength absorbing complexes 
with G-quadruplex, duplex, and even single-stranded DNA. When both ligands 
are aggregated (pH >8) their affinities for double stranded DNA are similar, 









Figure 8.6. Absorption spectra of PIPER and Tel01 with different DNA structures. Absorption 
spectra of 10µM PIPER (A) or TEL01 (B) in 3:1 water/methanol 25mM ammonium acetate buffer 
pH 7, alone or in the presence of 1 equivalent G5-DNA [d(T2G5T)]4, ds-DNA [d(GCAAATTTCG)]2, 
or ss-DNA [d(T8)] at the indicated pH values. 
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The charged perylene diimides Tel11 and Tel12, whose absorbance 
spectra in the absence of DNA is similar to that of PIPER, display only modest 
changes as a function of pH. Their spectra are indicative of a dimeric or lower 
aggregated species. Both compounds also form complexes with G-quadruplex 
DNA characterized by absorbance peaks at 550, but only Tel11 gives rise to a 
peak at 550 nm in the presence of double-stranded DNA, as seen in Figure 8.7.  
The spectra of Tel 12, which appears slightly more aggregated at lower pH 
values, shows a clear shift in the presence of G5 DNA from 500 to 545 at the 










Figure 8.7. Absorption spectra of charged perylenes with different DNA structures. Absorption 
spectra of 10µM Tel11 (A) or Tel12 (B) in 3:1 water/methanol 25mM ammonium acetate buffer 
pH 7, alone or in the presence of 1 equivalent G5-DNA [d(T2G5T)]4, ds-DNA [d(GCAAATTTCG)]2, 




Introduction of chemical groups onto the bay region of the perylene core 
generally results in a non-planar, twisted aromatic chromophore with increased 
solubility (193).  This is demonstrated in the spectra of Tel18, Figure 8.8A, which 
presents characteristic spectra of monomeric perylene species with a maxims at 
525 nm and 492 nm. This compound is largely unaffected by pH changes in the 
range studied and presents hypochromic and bathochromic shifts to 532 nm in 
the presence of G-quadruplex DNA. Similar changes are also observed in the 
presence of duplex DNA, and to a lesser extent, single-stranded DNA.  
The absorbance spectrum of Tel34 (Figure 8.8B) includes a long 
wavelength peak at 450 nm with a shoulder at 490 nm. In the presence of G-
quadruplex DNA, there is a shift of the 490 nm absorbance to 480 nm, 
accompanied by slight hyperchromism. Immediately after the addition of double- 
stranded or single-stranded DNA, there is a slight hypochromism in the Tel34 
absorbance spectrum, but no appreciable changes in the position of the 
absorbance peak. Over a period of an hour, solutions of Tel34 containing duplex 
or single-stranded DNA exhibit a pronounced decrease in UV-Vis absorbance 
that is accompanied by the formation of insoluble material. This behavior is not 
observed in the presence of G5 DNA, presumably because the complex formed 
between this benzannulated PDI and the G-quadruplex DNA is more soluble in 
the buffer than the ligand itself. The benzannulated and uncharged PDI Tel32 is 
also relatively insoluble, and at the concentration employed for these absorbance 
studies (10 µM), the ligand precipitated from solution over the course of a few 










Figure 8.8. Absorption spectra of bay-substituted and benzannulated perylenes with different 
DNA structures. Absorption spectra of 10µM Tel18 (A) or Tel34 (B) in 3:1 water/methanol 25mM 
ammonium acetate buffer pH 7, alone or in the presence of 1 equivalent G5-DNA [d(T2G5T)]4, ds-
DNA [d(GCAAATTTCG)]2, or ss-DNA [d(T8)] at the indicated pH values; spectra shown were 
recorded after 1 hr addition of DNA. 
 
8.3.2. Fluorescence and Resonance Light Scattering experiments  
 
Fluorescence and Resonance light scattering (RLS) signal have been 
previously used as a qualitative measure of the aggregation state of PTCDIs in 
solution (180, 181). Fluorescence is a useful technique to monitor these 
compound’s aggregation state, as non-aggregated perylene diimides tend to be 
highly fluorescent in solution (194, 195). RLS is also a sensitive and selective 
method for studying electronically coupled chromophore arrays, since 
aggregated species can display enhancement in light scattering of several orders 
of magnitude compared to their monomeric counterparts (196).  
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Solutions of Tel01 display very low fluorescence and correspondingly 
large RLS signal (Figure 8.9). In contrast, the RLS signal for PIPER is absent 
and the compound displays a relatively high fluorescence signal. These data 
present further evidence that under these buffer conditions Tel01 displays 
extensive aggregation while PIPER does not. Similar observations were made for 
solutions of Tel01 and PIPER in high-salt buffer conditions, indicating that the 
aggregation state of these two PTCDIs is largely unaffected by the methanolic 



































































Figure 8.9. Relative fluorescence and RLS signal of PTCDIs. Relative fluorescence (A) or RLS 
signal (B) of 1µM ligand in 3:1 water/methanol 25mM ammonium acetate buffer, pH 7. Excitation 
was at 495 nm for all ligands except Tel34, which was excited at 469 nm. 
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The fluorescence and RLS spectra of the other PTCDIs were also 
examined under the methanolic buffer conditions. As shown in Figure 8.9, 
PIPER, Tel11, and Tel18 are not aggregated in solution, judged by the strong 
fluorescence and lack of RLS signals of these solutions. Peaks close to 585 nm 
are contamination from the fluorescence of the compounds; compounds that had 
higher fluorescence values were the ones to present this contamination pattern in 
the RLS spectra. Tel12 displays only weak fluorescence and no significant RLS 
spectra. The weak fluorescence of Tel12 may be due to ligand dimerization, or 
lower aggregate formation, as has been noted for this compound in 150 mM KCl 
phosphate buffer (187). However, the fluorescence intensity of Tel12 in 
methanolic buffer is higher than that in the high-salt buffer (data no shown), 
indicating that aggregation is likely less extensive in the methanolic buffer. Like 
Tel01, solutions of the benzannulated perylene Tel34 in methanolic buffer do not 
have significant fluoresce; however, unlike Tel01, Tel34 solutions do not display 
a strong RLS signal, indicating that if Tel34 is aggregated in solution, the 
aggregates are RLS-silent. Attempts to compare the aggregation state of Tel34 
in methanolic ammonium acetate and 150 mM KCl phosphate buffer were 
unsuccessful due to the very low solubility of this analog in the high-salt buffer. 
Similarly, the low solubility of Tel32, even in methanolic ammonium acetate, 
made characterization of this PTCDI difficult. Immediately prepared solutions of 
Tel32 showed very low fluorescence and RLS signals. However, over a period of 
minutes the ligand began to precipitate from these solutions. 
 
8.3.3.  Fluorescence quenching experiments  
 
DNA-drug complexation leads to optical changes that can provide useful  
information about the nature and strength of their binding interaction (197). 
Monitoring such changes using fluorescence spectroscopy relies on the fact that 
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the spectra are altered upon binding. Fluorescence emission of the DNA-bound 
drugs can be enhanced, as the case with the well-known intercalator ethidium 
bromide, or efficiently quenched, as with the majority of the perylene diimides 
compounds (180, 181, 187). 
Fluorescence-quenching experiments of the analogs with quadruplex, 
duplex, and single-stranded DNA allow better quantification and insight into the 
affinity and selectivity differences of these ligands for G-quadruplex DNA. 
Solutions of 1 µM perylene compound in 3:1 25 mM ammonium acetate/ 
methanol buffer, pH 7 were titrated with concentrated stock solutions of each 
DNA structure in the same buffer. Fluorescence spectra were recorded at 
appropriate emission and excitation wavelengths for each class of chromophore: 
unmodified PTCDIs Tel01, Tel11, Tel12, Tel34, and PIPER (emission at 545 nm, 
excitation at 495 nm); chlorinated analog Tel18 (emission at 555 nm, excitation at 
495 nm); and benzannulated compound Tel32 (emission at 565 nm, excitation at 
469 nm). Examples of the fluorescence titration curves obtained with quadruplex 
G5-DNA [d(TTGGGGGT)]4 duplex [d(GCAAATTTCG)]2, and single-stranded 
[d(T8)] are shown in Figure 8.10.  
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Figure 8.10. Normalized fluorescence titration data for different perylene diimides at 1µM 
concentration in the presence of G5-DNA [d(T2G5T)]4 (diamonds), ds-DNA [d(GCAAATTTCG)]2 
(squares), or ss-DNA [d(T8)] (triangles) in 3:1 water/methanol 25mM ammonium acetate buffer, 
pH 7. Fluorescence emission (ex=495nm, em=555) was determined at each DNA concentration. 
(A) TEL11. (B) TEL12. (C) TEL18. (D) TEL34 
 
It can be observed from the titration curves that Tel11 has similar affinity 
to G5 DNA as it does to double stranded DNA, and that its fluorescence gets 
quenched at very small ratios of DNA to ligand; it needs less than 0.2 equivalents 
of G5 DNA to quench half of its total fluorescence (Figure 8.10A). On the other 
hand, Tel12 needs several equivalents of G5 DNA to achieve the quenching of 
half the total fluorescence. At low DNA ratios there is higher preference for G5 
DNA, but at higher equivalents of DNA, there seems to be a greater affinity for 
the double stranded DNA in this buffer (Figure 8.10B). However, titration of the 
same DNA sequences in high salt buffer shows no significant binding to double 
stranded DNA up to 5 equivalents excess of the structure (Figure 8.11). It must 
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be noted that the overall fluorescence is lower at the higher salt buffer, indicating 
a higher degree of aggregation that could be aiding in this analogs’ selectivity in 


































































































































Figure 8.11. Fluorescence quenching of Tel12 in low and high salt buffers. Fluorescence 
titrations of  1µM Tel12 in 3:1 water/methanol 25 mM ammonium acetate buffer, pH 7 in the 
presence of increasing ratios of G5-DNA [d(T2G5T)]4, (A) or ds-DNA [d(GCAAATTTCG)]2 (B). 
Titrations were repeated in 170 mM K Phosphate Buffer, pH 7 with G5-DNA (C) or ds-DNA (D); 
ex=495nm 
 
While all three DNA samples quench the fluorescence of Tel18 there is 
clearly a difference between the efficiency of fluorescence-quenching, with G5-
DNA causing the most extensive quenching at low concentrations, single-
stranded DNA producing the least quenching, and duplex DNA leading to 
intermediate quenching (Figure 8.10C). In the case of G-quadruplex DNA, there 
is nearly 80% fluorescence quenching after the addition of just one-half 
 139 
equivalent of DNA, indicating that multiple Tel18 ligands are binding to the DNA. 
Tel34 appears to be selective for G5 structures when compared to double 
stranded DNA, and it seems to bind at very low DNA concentrations (Figure 
8.10D). It takes less than 0.01 equivalents of G5 to quench half the total 
fluorescence intensity of Tel34. It must be noted however, that the fluorescence 
of Tel34 by itself decreases rapidly with time since the compound comes out of 
solution, which makes its characterization difficult. Fluorescence titrations were 
not performed on Tel01 or Tel32 because the compounds did not have 
considerable readings at pH 7 in the conditions the study was carried out. 
The results of the fluorescence-quenching studies of the perylene 
compounds are summarized in Table 8.1, which shows the percent PTCDI 
fluorescence-quenching after the addition of one equivalent of the different DNA 
structures. In accord with the UV-Vis absorbance studies (Figure 8.6) Tel01 
displays a high degree of selectivity for G-quadruplex DNA binding, as shown by 
the minimal fluorescence quenching in the presence of either duplex or single-
stranded DNA compared to G-quadruplex DNA. Other analogs such as PIPER 
and Tel11, appear to interact more strongly with G-quadruplex DNA when 
compared to Tel01, but show very little selectivity for G-quadruplex DNA versus 
duplex DNA. Both PIPER and Tel18 also show significant interactions with 
single-stranded DNA; the addition of one equivalent of single-stranded DNA to 
these PTCDIs quenches their fluorescence by more than 50%. Tel18 and Tel34 
appear to be of intermediate selectivity for G-quadruplex DNA versus duplex 
DNA and have moderate affinity for single-stranded DNA. Tel12 does not interact 
strongly with G-quadruplex DNA in the methanolic buffer, as evidenced by only 
29% fluorescence quenching in the presence of one equivalent of G5-DNA; 
however, this PTCDI is relatively selective for G-quadruplex DNA at 1:1 ratios 
and does not bind to single-stranded DNA. Tel12 binds double stranded with 
greater affinity than quadruplexes at higher duplex/ligand ratios in the methanolic 
buffer, but not in the high salt 170 mM potassium phosphate buffer. There was 
insignificant fluorescence quenching of Tel32, indicating that this compound does 
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not interact with any of these DNA structures, perhaps because it does not 
remain in solution after a few minutes. 
 
Table 8.1. Fluorescence quenching of PTCDIs by quadruplex, duplex, and single-stranded DNA. 
Percent fluorescence quenching in the presence of 1µM ligand and 1µM DNA in 3:1 
water/methanol 25 mM ammonium acetate buffer, pH 7. 
 %Fluorescence Quenching in the presence of 1eq 
DNA 
Ligand G5-DNAa ds-DNAb ss-DNAc 
TEL01d 64 ± 4 6 ± 2 2 ± 1 
PIPERd 100  ± 1 94 ± 2 57 ± 4 
TEL11d 99.8 ± 0.1 96 ± 1 67 ± 5 
TEL12d 29  ± 6 16 ± 8 13 ± 6 
TEL18e 92.9 ± 0.1 66 ± 3 12  ± 9 
TEL32d 4 ± 2 1 ± 2 7 ± 2 




dEx=495nm, em=545.  




8.4. Conclusions  
There is good agreement between spectroscopic binding studies 
performed in the low and high salt buffer conditions. Similar binding behavior was 
observed in both cases and the quadruplex structure used in the study is also 
folded correctly under the experimental conditions. The buffer and quadruplex 
sequence used in this study can be easily employed in high throughput screening 
techniques such as ESI-MS analysis to quickly identify selective G-quadruplex 
DNA binding agents.  
The results of this work indicate that ligand aggregation is correlated with 
G-quadruplex selectivity within the compounds studied. The selectivity of PIPER 
and Tel01 for G-quadruplex DNA is directly related to the pH conditions where 
the compounds are aggregated; under physiological conditions (pH7) Tel01 is 
aggregated and binds G-quadruplex selectively while PIPER is not and binds 
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similarly to all DNA structures. The bay substituted analog Tel18 does not have a 
planar chromophore, which makes it monomeric under the conditions studied 
and binds to double stranded and single-stranded DNA with high affinity.  Similar 
behavior is observed with the compound Tel11, which is dimeric in solution under 
experimental conditions and binds all DNA structures even at very low ratios of 
ligand.  The benzannulated analog Tel34 has an extended aromatic ring system 
was originally designed to increase the interactions with G-tetrads (186).  This 
compound does indeed appear promising in terms of selectivity, but the 
hydrophobic nature of both Tel32 and Tel34 and their poor solubility makes it 
difficult to accurately determine their interactions with DNA in aqueous solutions. 
Novel analogs with an extended aromatic system but with hydrophilic groups that 
increase their solubility could potentially overcome this problem and be selective 
G-quadruplex interactive agents. 
Perhaps the most intriguing analog is Tel12, which presents marked G-
quadruplex selective binding in high salt conditions but not in the methanolic 
buffer. Fluorescence spectra of Tel12 indicate that the compound is less 
aggregated in the methanolic buffer which could explain the observed divergence 
in selectivity. Salt and buffer conditions are more important in determination of 
the aggregation state of Tel12 than changes in pH (as is the case for Tel01 and 
PIPER). It is therefore important to further study the factors that affect this 
compound’s aggregation state and G-quadruplex selectivity. These parameters 
will be further investigated in the following chapter. 
In conclusion, compound aggregation does appear to influence G-
quadruplex selectivity of the PTCDIs studied here. It is known that perylene 
diimides can interact with G-quadruplexes by end-stacking (178). Since this type 
of interaction requires only one free face from the ligand, it is possible that 
binding to G-tetrads occurs with both aggregated and monomeric species. On 
the other hand, binding to double stranded DNA through intercalation likely 
requires the ligand to be monomeric or dimeric, which is why affinity for these 
structures are diminished when the ligands are aggregated.
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CHAPTER 9. PERYLENE DIIMIDES METAL AND THERMAL 
MEDIATED AGGREGATION AND G-QUADRUPLEX SELECTIVITY 
 
9.1. Temperature and metal ion dependant-aggregation of 
perylene diimide compounds in the presence of metal ions and 
temperature changes 
 
Because of their intense color hues, perylene diimides were originally 
studied as industrial dyes, but their high electron affinity and prominent 
fluorescence quantum yields has led to their use in electronic materials and 
fluorescence applications (198). Much interest has also been devoted to 
supramolecular perylene diimides assemblies because of their ease to form 
aggregate species through π-π stacking interactions and their potential use in 
optical devices, photosensitizers, and fluorescence probes (198, 199). 
Supramolecular structures such as those formed by perylene compounds are 
held together by non-covalent interactions, and have received great attention in 
materials science because their associations are reversible and can therefore be 
controlled by experimental conditions (200). 
There are many factors that affect the aggregation of perylene diimides 
and thus their supramolecular assemblies, such as charge, substituents, 
concentration and pH. Recently, metal-coordination-directed self-assembly of 
certain perylene diimides has been achieved in the presence of metal ions; 
amongst the metals studied that can promote aggregation for some of PTCDIs 
are Cu2+, Ni2+, Zn2+, Fe2+, Ru2+, Pt2+, Ca2+, Li+, Ba2+, Pb2+, Mn2+, Cd2+ (190, 201-
206). As mentioned in the previous chapter, the aggregation state of perylene 
compounds has been correlated to their preferential G-quadruplex binding (159, 
180, 181). However, metal-mediated aggregation of perylene compounds has 
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never been studied in relationship to G-Quadruplex selectivity, and could present 
a promising avenue for regulation of PTCDI-quadruplex interactions; metallo-
supramolecular assemblies could be obtained by addition of metal salts, affecting 
their interactions with varying DNA structures. The following work examines the 
metal ion coordination and aggregation state of a series of perylene diimide 
compounds in aqueous buffers, their binding to duplex and quadruplex DNA, and 
their biological properties. 
 
9.1.1. Absorbance Spectroscopy 
 
It is important to note that the majority of current studies that encompass 
metal-ion induced PTCDI aggregation are involved in material science 
applications and have been carried out in organic solvents, where perylene 
diimides are very soluble (201, 204, 206, 207). An example is the bis-2,2’:6’,2’’-
terpyridine functionalized perylene diimide synthesized by Dobrawa et al., which 
can coordinate metal cations through the nitrogen atoms of the terpyridine group 
in chloroform:acetonitrile mixtures forming higher order structures upon zinc 
complexation, as shown in Figure 9.1A (201, 204). One of the few perylene 
derivatives that has been studied in the presence of metal ions in aqueous 
environments is Perylene-EDTA, which was synthesized by Tuntiwechapikul and 
co-workers and is a PIPER derivative modified with EDTA side chains (Figure 
9.1B). This compound was able to chelate Fe2+ and Ni2+ cations and bind with 
greater selectivity toward quadruplex structures when metal coordinated, but its 
aggregation state did not appear to be affected by metal chelation (205, 208). For 
this study, the metal ion induced aggregation was investigated for the 
compounds PIPER and TEL01 (Figure 8.2) as well as the water soluble 
derivatives Tel11, Tel12 and Tel18 (Figure 8.4).  The UV-Vis spectra was 
recorded in 8 mM sodium phosphate, 185 mM NaCl, pH 7.0 (BPS buffer) in the 



































































Figure 9.1. Terpyridine and EDTA functionalized perylene derivatives. (A) Complexation of zinc 
bis-2,2’:6’,2’’-terpyridine perylene diimides with zinc (II) triflate in chloroform:acetonitrile (80:20) 
(201, 204). (B) Perylene-EDTA coordinated with Fe2+ (205, 208) 
 
 Under these buffer conditions Tel01 was already aggregated and addition 
of metal ions did not cause changes in the absorbance spectra. Addition of 1:1 or 
2:1 metal:perylene resulted in no significant spectral changes in the case of 
PIPER, Tel18 and Tel11 (Figure 9.2A-C). In contrast, Tel12 displayed slight 
hypochromicity at 500 nm upon addition of 1 equivalent Cu2+ and Ni2+ ions 
(Figure 9.2D). There was also a major shift upon addition of Zn2+ ions, where the 
peak at 500 nm blue-shifted to a broader peak at 470 nm with an overall 
hypochromism, indicating the formation of higher aggregated species. To further 
test the metal-mediated aggregation of Tel12, the compound was examined in 
the presence of Fe2+, Fe3+, and Co2+ ions. However, no spectral changes were 



























































































Figure 9.2. Absorbance spectra of perylene diimides in the presence of metal cations. Spectra 
were recorded with 10 µM  PIPER (A),Tel18 (B), Tel11 (C), or Tel12(D) in 8 mM Na Phosphate, 
185 mM NaCl, pH 7, alone (solid black line) on in the presence of 10 µM Mg(NO3)2 (dashed black 
line),  Ca(NO3)2 (dotted black line), Zn(NO3)2 (solid gray line),Cu(NO3)2 (dashed grey line), or 
Ni(NO3)2 (dotted grey line) 
 
 
Within this series, the only analog that appeared to form aggregated 
species in the presence of metal cations is the negatively charged Tel12. 
However, there are examples of neutral PTCDIs with pentaoxa-heptadecane 
chains which have been reported to display metal-ion-induced aggregation in 
organic solvents (206). Taking this into consideration, a new neutral analog was 
devised with potential metal ion coordination sites; the tetra-MEM-serinol PTCDI, 
Tel45 (Figure 9.3), was synthesized by Sean Kerwin by introducing 
methoxyethoxymethyl (MEM) groups to the PTCDI core (unpublished results).  In 
addition to metal-coordination, the MEM groups in Tel45 should increase 















Figure 9.3. Structure of Tel45. 
 
The new perylene compound was in fact soluble in water and aqueous 
buffers, exhibiting brightly red colored solutions. To test for metal mediated 
aggregation, the UV-Vis spectra of Tel45 was recorded in BPS buffer, 
corresponding to a dimeric species; the spectral changes were monitored upon 
addition of equimolar amounts of Mg2+, Ca2+, Zn2+, Co2+, Cu2+, Ni2+, Fe2+, or Fe3+ 
(Figure 9.4A). Unexpectedly, none of the metal salts produced any significant 
spectral shifts. Further additions of metal cations (> 5 eq.) resulted in slight 
hyperchromicity, indicating a less aggregated species.  To investigate if this 
analog could form aggregates in organic solvents, measurements were also 
carried out in DCM/MeOH, observing a spectra corresponding to monomeric 
Tel45. Spectral changes of the analog in DCM/MeOH were monitored in the 
presence of (CF3SO3)2Zn, CF3SO3Ag, and Cu(ClO4)2, but no significant spectral 
shifts were observed (Figure 9.4B). The data suggest that under the conditions 
used for this study Tel45 does not form higher aggregated species by addition of 













































Figure 9.4. Absorbance spectra of Tel45 with metal cations in aqueous and organic solvents. (A) 
Spectra of 10 µM Tel45 in BPS buffer in the presence of 10 µM Mg(NO3)2, Ca(NO3)2, Zn(NO3)2, 
Cu(NO3)2, Ni(NO3)2, Co(NO3)2, or Fe(NO3)2. (B) Spectra of 10 µM Tel45 in DCM/MeOH 1:1 in the 
presence of 10 µM (CF3SO3)2Zn, CF3SO3Ag, and Cu(ClO4)2. 
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 Although Tel45 did not appear to form supramolecular assemblies in the 
presence of metal ions it did present an unanticipated thermal-mediated 
aggregation.  As seen in Figure 9.5A, upon heating Tel 45 between 10-50 ºC  the 
peak at 500 nm is red-shifted to approximately 520 nm with an overall 
hypochromicity, concomitant with an increase in absorbance intensity in the 565-
700 region.  This bathochromic shift (red shift towards longer wavelengths) is 
different than the hypsochromic (blue-shifted towards shorter wavelengths) from 
500 to 470 nm, generally observed when most perylenes (such as PIPER, Tel01, 

















































Figure 9.5. Absorbance Spectra of Tel45 with increasing temperature. UV-Vis spectral changes 
of 10 µM Tel45 in 170 mM potassium phosphate buffer at 5, 10, 15, 20, 25, 30, 40 and 50 ºC (A) 
or 50, 70 and 90 ºC (B). Arrows indicate direction of changes with increasing temperature. 
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There are two main types of aggregates described in the literature: J- and 
H-aggregates (209). H-aggregates present blue-shifts with respect to the 
monomeric chromophore as well as a decrease in fluorescence upon 
aggregation, while J-aggregates display red-shifts in their absorption and 
emission maxima and no fluorescence quenching upon aggregation. H-
aggregates loose their fluorescence because they are stacked one on top of the 
other, while J- aggregates are slipped with respect to each other (Figure 9.6). 
The observed spectral changes are in agreement with those corresponding to H-
type aggregation for Tel01, PIPER and Tel12, while Tel45 shares some of the 
characteristics of J-type aggregation. This finding is surprising in the case of 
Tel45 because most perylene diimides that form J-aggregates have substituents 
in the bay which enforce core twisting and facilitate slipped arrangements (210, 
211). However, the observed Tel45 aggregates are broader than those reported 
for other PTCDI J-aggregates held together through hydrogen bonding networks 
(211).  It is possible that the Tel45 aggregates are formed by stacking of the 
perylene core, but the MEM groups on the side chains force the aggregated 
species to have a slipped configuration and thus cause the aggregates to exhibit 
similar properties to those of J-aggregates. To further investigate the unusual 
Tel45 aggregates, the fluorescence of this PTCDI will also be examined in the 
next section with increasing temperature; bathochromically shifted fluorescence 
is characteristic for J-type aggregates and could aid in the investigation of the 
temperature-dependant Tel45 aggregates.   
Although the formation of higher aggregate species upon heating is very 
atypical it has been reported by Wang and co-workers for hybrid structures 
consisting of alternating hydrophobic perylene diimides and hydrophilic single-
stranded DNA sequences connected by tetraethylene glycol groups (212). Their 
study showed that the strength of hydrophobic forces holding the chromophores 
together in their molecular assembly was more pronounced at higher 
temperatures. In the case of Tel45, there is a balance where the aggregated 
species appear when the temperature is raised from 10 to 50 ºC (Figure 9.5A). At 
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higher temperatures (heating from 50 ºC to 90 ºC, Figure 9.5B), the peaks 
corresponding to the aggregates decrease and those corresponding to the 
















Figure 9.6. H- and J-aggregates. (A) In H-aggregates molecules are stacked on top of each other 
in a “deck of cards” fashion, quenching fluorescence properties. (B)  J-aggregates the molecule 
have slipped more with respect to each other; this aggregates are usually facilitated when 
substituents in the bay area (such as shown in the lower right corner) cause chromophore 
twisting and loss of planarity  
 
9.1.2. Resonance Light Scattering and fluorescence spectroscopy  
 
 To further confirm that Tel12 and Tel45 were forming aggregates in a 
metal ion and thermal dependent fashion respectively, fluorescence and 
Resonance Light Scattering (RLS) experiments were conducted. As discussed in 
the previous section, decreases in fluorescence concomitant with increases in 
RLS signal are indicative of aggregation in the case of H-type aggregates. As 
seen in Figure 9.7, Tel 12 displayed close to 4-fold decrease in fluorescence 
signal  at 550 nm along with an over a 10-fold increase in RLS signal upon 
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Figure 9.7. Fluorescence and Resonance Light scattering of Tel12 in the presence of Zn
2+
 ions. 
Fluorescence (empty marks) and RLS  (filled marks) spectra of 10 µM Tel12 in BPS buffer alone 
(triangles) or in the presence of 10 µM Zn2+ ions (squares).  
.  
The fluorescence and RLS of Tel45 was monitored at 10 and 100 µM at 
temperatures ranging from 5-100 ºC. As seen in Figure 9.8A, upon increasing the 
temperature to 50 ºC there was an increase in the peak at 550 nm, but there was 
also the appearance of a red-shifted peak at 655 nm, which is more evident at 
higher concentrations (Figure 9.8B). Similar bathochromic shifts have been 
reported in J-type PTCDI aggregates but have narrower peaks and higher 
quantum yields than those formed by Tel45 (209-211). The data suggest that 
under these conditions there may be equilibrium between monomeric and 
aggregated species; it is likely that the increase in fluorescence at 550 nm 
corresponds to formation of monomeric species while the appearance of the 
peak at 655 nm is related to formation of the aggregates. This idea is supported 
by the larger ratio of the peak at 655 nm to the peak at 550 nm observed at 
higher concentrations of Tel45. 
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Furthermore, at both concentrations there is a very sharp increase in RLS 
signal when the temperature reaches 30 ºC for 10 µM Tel45 (Figure 9.8C) or 25 
ºC for 100 µM Tel45 (Figure 9.8C). The RLS peaks also occur in the region 
where the aggregate was observed in the UV-Vis spectra (compare to Figure 
9.5) and have a maximum at 600 and 640 nm for 10 and 100 µM solutions of 
Tel45 respectively. The formation of these RLS peaks occurs concurrently with 
the appearance of a fluorescence peak at 655 nm, which indicates that this 
bathocromically shifted fluorescence peak is related to the compound’s 
aggregation. When temperatures are increased from 50 - 100 ºC there is an 
overall increase in the fluorescence signal and a slight decrease in RLS signal, 
indicating at least partial de-stabilization of the aggregated species. The 
observed aggregate formation is reversible upon decreasing the temperature 







































































































Figure 9.8. Fluorescence and Resonance light scattering of Tel45 with increasing temperature. 
Fluorescence of 10 µM (A), or 100 µM (B) Tel 45 at 5, 10, 15, 20, 25, 30, 40 and 50 ºC (arrows 
indicate fluorescence changes observed as temperature increases). Resonance Light Scattering 
of 10 µM (C), or 100 µM (D) Tel 45 at temperatures ranging from 5 to 100 ºC; a large increase in 




These results agree with the observed UV-Vis spectral changes and indicate 
that Tel45 is capable of forming fluorescent J-like aggregates by increasing 
temperature and Tel12 can form H-aggregates upon Zn2+ binding. It also appears 
that the aggregates formed by Tel45 are stable between 30-50 ºC, after which 
further temperature increments start favoring the monomeric species. Therefore 
at physiological temperature (37 ºC) Tel45 should be significantly aggregated 
and display preferential binding to G-quadruplexes. The two types of aggregation 
can be used to broaden the understanding as to how PTCDI aggregation is 
related to G-quadruplex selectivity.  
 
 
9.2. G-Quadruplex DNA Selectivity 
9.2.1. Visible Absorbance Spectroscopy Experiment  
 
9.2.1.1. DNA binding in the presence of Zn2+-mediated aggregation 
 
As discussed in section 8.3.1, visible absorbance spectroscopy is a useful 
tool to investigate the interactions between perylene diimides and DNA 
structures. Spectral changes upon addition of DNA are indicative of formation of 
DNA-drug complexes (197). Experiments were carried out in BPS buffer in the 
presence and absence of 1 or 10 equivalents zinc ions, using Tel12 and Tel11 as 
a negative control because they are both are charged PTCDIs, negatively and 
positively charged respectively. The absorbance spectra of 10 µM solutions of 
the perylene analogs with and without zinc were monitored after addition of 1 
equivalent G4’-DNA, G4-DNA or DS-DNA.  As seen in Figure 9.9A, in the 
absence of zinc, addition of the DNA structures cause an increase in the 
absorbance at 510 and 550 nm for both compounds, denoting complex 
formation. The spectral changes of Tel12 indicate a higher preference for G4’-
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DNA followed by G4-DNA, and to a lesser extent, DS-DNA. Conversely, Tel11 
displays similar spectral shifts in the presence of both quadruplex and duplex 
DNA, indicating lower G-quadruplex binding selectivity than that observed for 
Tel12.  
Addition of 10 µM Zn2+ (Figure 9.9B) results in aggregation of Tel12 but 
not Tel11. However, addition of the DNA structures at this Zn2+ concentration do 
not show significant spectral differences than those observed when no zinc is 
present. It is possible that the nucleic acids sequester available zinc, resulting in 
a non-aggregated Tel12 species. To test this idea, higher concentrations of zinc 
were employed (100 µM, Figure 9.9C); the control compound Tel11 did not 
experience any changes in DNA binding in the presence of Zn2+ under these 
conditions. In contrast, addition of 100 µM Zn(NO3)2 caused diminished binding 
of Tel12 to double stranded-DNA as judged by the minor differences between the 
spectra of the aggregated PTCDI and that in the presence of ds-DNA. Contrary 
to the behavior observed after addition of duplex DNA, the spectra of Tel12 in the 
presence of G4’ and G4-DNA at 100 µM Zn2+ result in the formation of marked 
peaks at 550 nm, which indicate binding to these structures and thus a higher 
preference for quadruplex DNA under aggregating conditions. However, there is 
a slight decrease in the intensity of these peaks compared to those observed in 
the absence of Zn2+, suggesting that the preference for quadruplex over duplex 






















































































































Figure 9.9. UV-Vis Spectra of Tel11 and Tel12 in the presence of Zn2+ with quadruplex and 
duplex DNA.  Spectra of 10 µM Tel11 (left panels) and Tel12 (right panels) alone (black line) or in 
the presence of 10 µM G4-DNA, [d(TAGGGTTA)]4 (yellow line), G4’-DNA, [d(TTAGGG)4] (green 
line) or  DS-DNA, [d(CGCGCGATATCGCGCG)]2 (red line) at (A) 0 (B) 10 or (C)  100 µM 
Zn(NO3)2. 
 
An estimate of the effect of metal-mediated aggregation on G-quadruplex 
DNA binding selectivity can be obtained by comparing the changes in 
absorbance at 550 nm for both PTCDIs under different Zn2+ concentrations after 
addition of G4’-DNA, G4-DNA, and ds-DNA. When the ligands exhibit a larger 
change in the absorbance at 550 nm in the presence of G-quadruplex DNA when 
compared to the absorbance change upon addition of duplex DNA they are 
considered more selective than when spectral changes at 550 nm are similar in 
the presence of both DNA structures. Table 9.1 summarizes the observed 
quadruplex-binding selectivity under the different Zn2+ concentrations employed. 
As the zinc concentration increases from 0 µM to 10 µM and then to 100 µM 
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there is a large increase in the selectivity for both G4’ and G4-DNA compared to 
DS-DNA for Tel12; there is over a 6-fold increase in quadruplex selectivity at 100 
µM Zn2+. In contrast, the binding ratios for the control compound Tel11 are 
largely unaffected by addition of Zn2+. The data indicates that the Tel12 metal-
mediated aggregation is correlated with an increase in quadruplex binding 
selectivity, particularly for G4’ structures. 
 

























Tel11 0.132 0.132 0.117 1.12 1.13 
0  
Tel12 0.221 0.101 0.033 6.62 3.01 
Tel11 0.131 0.135 0.112 1.17 1.21 
10 
Tel12 0.196 0.078 0.014 14.31 5.70 
Tel11 0.128 0.136 0.111 1.15 1.22 
100 
Tel12 0.160 0.092 0.004 43.65 25.01 
a Difference between the A550nm of a 10 µM solution of the PTCDI in BPS buffer, 
pH 7, in the presence of the DNA sample (10 µM structure) and in the absence of 
the DNA; DNA structures used were  G4’-DNA, [d(TTAGGG)4], G4-DNA, 
[d(TAGGGTTA)]4, and DS-DNA, [d(CGCGCGATATCGCGCG)]2  
b Ratio of ∆A550nm in the presence of G4’-DNA to ∆A550nm in the presence of ds-
DNA 
c Ratio of ∆A550nm in the presence of G4-DNA to ∆A550nm in the presence of ds-
DNA 
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9.2.1.2. DNA binding in the presence of temperature-dependant 
aggregation. 
 
Spectral changes of Tel45 in 170 mM potassium phosphate buffer, pH 7 
were monitored in the presence of G4’-DNA, G4-DNA or DS DNA with increasing 
temperature; the PTCDI Tel11 was used as negative control because it does not 
exhibit temperature-dependant aggregation. As seen in figure Figure 9.10A, at 20 
°C, where Tel45 does not form aggregates, the spectra of this ligand indicates 
binding to G4’-DNA, followed by G4-DNA and to a lesser extent, DS-DNA. As the 
temperature increases to 40 and 50 °C, there is evidence of aggregate formation 
concomitant with an overall decrease in DNA binding, especially for the duplex 
sequence (Figure 9.10 B and C). In contrast, Tel11 binding to all the DNA 
structures remained relatively unaffected by these temperature changes. Figure 
9.10B shows that at 40 °C, which is a temperature below the melting point of all 
of the DNA structures, there are only modest spectral differences between the 
spectra of Tel45 in the presence and absence of double-stranded DNA. On the 
other hand, there are significant spectral shifts in the presence of G4’-DNA. 
Similar to the results obtained from Zn2+-mediated Tel12 aggregation, the data 
implies that the temperature dependant aggregation of Tel45 results in a 
reduction of double-stranded-DNA binding and therefore a preference for 
quadruplex structures when the PTCDIs are aggregated. An estimate of the 
quadruplex-binding selectivity was done by comparing the absorbance changes 
at 550 nm of both PTCDIs in the presence of G4’, G4 and DS-DNA at 
temperatures ranging from 20 to 90ºC; the results are summarized in Table 9.2.  
There is almost a 3 and 1.5-fold increase in G4’ and G4-DNA binding 
respectively when the temperature increases from 20 ºC to 40 ºC. In contrast, 
Tel11 quadruplex selectivity is slightly diminished after the same temperature 
raise. At 70 °C (Figure 9.10D) there is less Tel45 binding observed to any of the 
DNA structures which could be related to a combination of factors including a 
lower amount of Tel45 aggregates present in solution, melting of the DNA 
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structures, and an overall diminished affinity for nucleic acids with aggregation. 
This is reflected on the lack of quadruplex selectivity observed for Tel45 at 
temperatures above 70 ºC (Table 9.2). The quadruplex selectivity index of Tel11 
is also diminished at higher temperatures. These results suggest that Tel45 
temperature mediated aggregation increases G-quadruplex binding selectivity for 


























































































































































Figure 9.10. UV-Vis Spectra of Tel11 and Tel45 at different temperatures in the presence of 
quadruplex and duplex DNA.  Spectra of 10 µM Tel11 (left panels) or Tel45 (right panels) alone 
(black line) or in the presence of 10 µM G4-DNA, [d(TAGGGTTA)]4 (yellow line), G4’-DNA, 
[d(TTAGGG)4] (green line) or  DS-DNA, [d(CGCGCGATATCGCGCG)]2 (red line) at (A) 20 ºC (B) 
40 ºC (C) 50 ºC, or  (D) 70 ºC 
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Tel11 0.124 0.119 0.099 1.25 1.20 
20  
Tel45 0.253 0.098 0.031 8.14 3.15 
Tel11 0.114 0.116 0.100 1.14 1.16 
30 
Tel45 0.240 0.069 0.022 10.85 3.11 
Tel11 0.104 0.106 0.094 1.10 1.12 
40 
Tel45 0.197 0.043 0.009 21.61 4.67 
Tel11 0.105 0.111 0.103 1.03 1.08 
50 
Tel45 0.121 0.031 0.006 18.75 4.74 
Tel11 0.093 0.102 0.104 0.89 0.98 
70 
Tel45 0.008 0.021 0.012 0.63 1.65 
Tel11 0.018 0.051 0.068 0.26 0.75 
90 
Tel45 0.015 0.022 0.015 0.98 1.42 
a Difference between the A550nm of a 10 µM solution of the PTCDI in the presence 
of the DNA sample (10 µM structure) and in the absence of the DNA; DNA 
structures used were  G4’-DNA, [d(TTAGGG)4], G4-DNA, [d(TAGGGTTA)]4, and 
DS-DNA, [d(CGCGCGATATCGCGCG)]2 
b Ratio of ∆A550nm in the presence of G4’-DNA to ∆A550nm in the presence of ds-
DNA 
c Ratio of ∆A550nm in the presence of G4-DNA to ∆A550nm in the presence of ds-
DNA 
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9.2.2. Surface Plasmon Resonance Experiments  
 
To further understand how perylene diimides ligands interact with G-
quadruplex structures, Surface Plasmon Resonance (SPR) analysis were carried 
out in conjunction with Bodin Tuesuwan and Dr. Wendi David at Texas State 
University.  Tel11 was chosen as a representative candidate of the PTCDI family 
and the well characterized G-Quadruplex interactive agent, TmPyP4 (Figure 
7.14B) was used as a control to investigate their differences in binding affinity 
and kinetics. PTCDI aggregation was not investigated using this technique due to 
potential clogging of the instrument’s fluidics system. A biotinylated 
intramolecular human telomeric sequence, 5’ biotinylated- (TTAGGG)4TT was 
immobilized on a streptavidin coated chip, and the binding of the two ligands was 
monitored by injecting solutions of varying ligand concentrations in running 

















































Figure 9.11. SPR sensograms TMPyP4 and Tel11 binding to G4’ human telomeric DNA. The 
interaction of 5’ biotinylated- (TTAGGG)4TT  in HBS-EP buffer supplemented with 200 mM K
+ 
quadruplex was monitored with increasing ligand concentrations; 50 µl were injected at a flow 
rate of 10 µL/min.  (A) Injections of TMPyP4 at 50, 150, 300, and 450 nM concentration. (B) Tel11 
injections solutions were 5, 10, 50, 100, 150, 200, and 350 nM. 
 
The two molecules exhibited very different binding behaviors. TmPyP4 
displayed a fast kon and koff rates at all the concentrations studied (Figure 9.11A). 
This compound also reached steady-state equilibrium almost immediately after 
the start of the injections and dissociated rapidly from the quadruplex substrate 
directly after the injection end.  The observed RU (response units) in the steady-
state region were plotted against the concentration of TMPyP4 to calculate its 
binding constant (KA = 6.04 *10
6 M-1, KD = 16.6 µM).  The kinetic kon and koff 
values were also determined using the 1:1 Langmuir binding model using the 
BIAevaluation software (8.05 * 105 M-1 and 0.133 s-1). 
On the other hand, as seen in Figure 9.11B, Tel11 presented a much 
slower dissociation rate; in fact, consecutive regeneration buffer injections were 
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required to return to the original baseline levels (buffer flow was sufficient to 
regenerate the surface in the case of TMPyP4). Closer inspection revealed that 
there is an initial fast dissociation at higher Tel11 concentrations, but after 
approximately 80 seconds the dissociation phase is similar at all the 
concentrations studied.  Plotting the differential RU units in the steady state 
regions of the sensograms did not fit well to a 1:1 binding model. In addition, the 
differential behavior observed at higher compound concentrations complicated 
the calculations for kinetic constants. Fitting of koff separately from kon in 
BIAevaluation software beginning 80 seconds after the injection end gave a 
value of 1.4 ± 0.1 *10-3 s-1 for all the Tel11 concentrations studied, which is two 
orders of magnitude slower than the rate observed for TMPyP4.  Furthermore, in 
contrast to the porphyrin compound, Tel11 does not reach steady state 
equilibrium rapidly at the lower concentrations tested. Overall, the observed 
kinetic behavior suggests that Tel11 possesses two different binding modes; at 
low compound concentrations there is tighter, more specific binding with a slow 
dissociation while at higher concentrations there is a less specific binding mode. 
These results are in agreement with the observed fluorescence quenching and 
circular dichroism experiments that indicate that multiple ligands are able to 
associate with a quadruplex structure. It is likely that the higher specificity binding 
mode corresponds to the initial G-tetrad end-stacking interactions while the non-




9.3. Cell entry and cytotoxicity 
 
A549 (human lung cancer) and MCF-7 (human breast cancer) cells were 
treated with 20 µM Tel11, Tel12 or Tel45 for 24 h after which their morphology 
was analyzed by microscopic analysis. Cellular entry varied considerably 
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depending on the PTCDI used. Tel 11–treated cells (Figure 9.12A) exhibited 
overall red staining which was most intense in the nucleus, suggesting nuclear 
localization. The observed staining is not uniform within the nucleus, which could 
indicate binding to specific  Treatment with Tel12 resulted in large aggregates, 
both in the media and surrounding the cells (Figure 9.12B), while incubation with 
Tel45 also formed aggregated species of smaller size (Figure 9.12C). However, 
although aggregate formation has promising potential in G-quadruplex selectivity, 
neither Tel12 nor Tel45 stained the cells red which could be interpreted as no 




Figure 9.12. Cellular localization of A549 cells treated with Tel11, Tel12 and Tel45. A549 cells 
grown on chamber slides were treated with 20 µM Tel11 (A), Tel12 (B), or Tel18 (C) for 24 h 
before microscopic analysis. 
 
 To further verify if any of the aggregated species were entering the cells 
they were visualized using fluorescence microscopy. Cells were fixed and 
propidium iodide (PI) was used to stain the nucleus. PI displays fluorescence 
when bound to nucleic acids, the absorption maximum for PI is 535 nm and the 
fluorescence emission maximum is 617 nm). Cells were also examined under the 
FITC filter which is in the fluorescence range of perylene diimides (FITC 
excitation maxima is 494nm, and emission is 518nm). Figure 9.13 shows the 
results obtained in MCF-7 cells in the absence (panels A and B) and presence of 
20 µM Tel12 (panels C and D) or Tel45 (panels E and F). Treatment with Tel12 
appears to surround the cells, making it difficult to discern if there is cellular entry 







Figure 9.13. Fluorescence micrographs of MCF-7cells.  MCF-7 cells were fixed with mounting 
media containing PI and visualized under a PI filter (left panels) or a FITC filter (right panels). 
Cells were left untreated (A), or incubated for 24 h with 20 µM Tel12 (B) or Tel 45 (C) prior to 
visualization. 
 
In contrast, treatment with Tel45 show fluorescence in the cytoplasmic 
region of treated cells, which indicates that although this analog forms 
aggregates in the media, it is able to enter the cells. This is particularly clear from 
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micrographs of Tel45 in A549 cells that display bright fluorescence in the 




Figure 9.14. Fluorescence micrographs of A549 cells.  A549 cells were treated for 24 h with 20 
µM Tel45 and subsequently fixed with mounting media which contains PI and visualized under a 
PI filter (left panels) or a FITC filter (right panels).  
 
 
It is evident that charge plays an important role in the cellular entry of the 
PTCDI ligands. The positively charged Tel11 is able to enter the cells and can 
bind to the nucleus. In contrast, the negatively charged Tel12 appears to 
aggregate on the media and cellular surface. Although the neutral compound 
Tel45 also aggregates in the media it does appear to enter the cells from its 
fluorescence properties.  The aggregation of Tel45 was confirmed by 
fluorescence and RLS at the concentrations employed for this study; the ligand 
displays fluorescence at 655 nm and RLS signal in both A549 and MCF-7 cell 

















































Figure 9.15. Fluorescence and RLS of Tel45 in cell culture media. Fluorescence emission (ex = 
500 nm) spectra (A) and RLS signal (B) of 20 µM Tel45 in A549 (black lines) or MCF-7 (gray 
lines) cell culture media at 20 ºC (dashed lines) or 37.5 ºC (solid lines) 
 
Cellular cytotoxicity was also evaluated in MCF-7 and A549 cells using the 
AlamarBlue assay after treating the cells with varying concentrations of Tel11, 
Tel12, and Tel45 for 72 h. Because these ligands have a high intrinsic 
fluorescence, the fluorescence response at each ligand concentration tested was 
subtracted from the values calculated using the assay. The cytotoxicity values 
obtained are shown in Table 9.3.  Tel11 displayed activity in both cells lines with 
IC50 values of 4 and 18 µM for MCF-7 and A549 cells respectively. Tel45 
displayed similar levels in MCF-7 cells (IC50 = 2 µM) but exhibited less than 50% 
cell death at the highest concentration studied (100 µM). Tel12 was the least 
cytotoxic analog, with no apparent inhibition of cellular growth in the 
concentration range studied. It is possible that the extensive aggregation or 
negative charge of Tel12 prohibits its cellular entry and therefore no cellular 
death is observed. This makes sense in regards to the positively charged Tel11 
which experienced an overall lower cytotoxicity; it is possible that the positive 
charge in Tel11 facilitates its interactions with DNA. The neutral Tel45 is only 
partially successful in killing the cancer cells, but it still has a larger effect than 
compound Tel12. Furthermore, the observation that Tel45 can form aggregates 
at physiological conditions could indicate that this compound is binding 





Table 9.3Cytotoxicity of MCF-7 or A549 cells treated with PTCDI analogs during 72h. Cellular 
proliferation was assayed using the AlamarBlue assay. IC50 values represent 50% growth 
inhibition relative to cell treated with vehicle alone 




Tel11 4.3 ± 1.3 18 ± 4 
Tel12 >100 >100 
Tel45 1.7±0.6 >100 




This study has illustrated several of the mechanisms that affect perylene 
diimide aggregation and their biological properties. Tel12, with its negatively 
charged phosphate groups, can aggregate in the presence of metal cations, 
particularly in the presence of Zn2+ ions. Tel45 was designed with MEM groups to 
facilitate metal-mediated aggregation. In spite of this, no aggregation was 
observed with any of the metal cations used in this study even in organic 
solutions. However, this analog unexpectedly displayed aggregation at higher 
temperatures. This unusual behavior has been reported for perylene diimides 
synthesized by Wang et al. which contain alternating single-stranded DNA and 
planar PTCDI chromophores (212). 
The metal- and thermal-mediated aggregation of Tel12 and Tel45 
respectively allowed for evaluation of their G-quadruplex selectivity. Both 
compounds displayed enhancement in selectivity upon aggregation, particularly 
for G4’ structures. In contrast, the positively charged compound Tel11 does not 
aggregate in any of the pH ranges studied, nor is influenced by temperature 
changes or metal coordination; it displays similar affinities for duplex and both 
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inter and intra-molecular quadruplexes under the conditions studied. 
Nevertheless, ligand-DNA ratios determined by fluorescence quenching and SPR 
experiments indicate that Tel11 may aggregate upon binding to DNA structures. 
In addition, its positive charge may aid in its interactions with DNA and cell death 
observed in cultured cells. 
Cells treated Tel11 show that this compound is capable of entering cells 
and is preferentially located in specific portions of the nucleus. Tel12 and Tel45 
form aggregate structures in the media and on the cellular surface. In spite of the 
lack of visible red staining, fluorescence microscopy showed that both 
compounds fluoresce within the cells, suggesting that these ligands are at least 
partially capable of cell entry. Cytotoxicity studies showed that Tel11 was highly 
cytotoxic, while Tel12 and Tel45 only displayed moderate cytotoxicity. The 
observed behavior for Tel12 and Tel45 can be related to their lower cellular 
incorporation compared to Tel11. 
In general, the water soluble perylene diimides present different but 
interesting interactions with DNA. The positively charged Tel11 can translocate 
into the nucleus and induce cytotoxicity in cells perhaps aided by its charge. 
Tel12 displays aggregation upon metal coordination and a higher preference for 
G-quadruplex in in vitro studies, but its negative charge could present problems 
for cellular entry. The neutral compound Tel45 is particularly important because 
its aggregation occurs at physiologically relevant temperatures and appears to be 
capable of entering cells with specificity for the nucleus. 
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CHAPTER 10. SUMMARY AND FUTURE DIRECTIONS 
10.1. Summary   
 
G-Quadruplexes are four stranded nucleic acid structures which can form 
in G-rich sequences such as telomeric regions. There is continuously increasing 
evidence that these unique four-stranded structures not only occur in vitro but 
also have biological significance. Furthermore, computational studies have 
shown that there is at least one putative quadruplex sequence (PQS) in over 
40% of all human promoter sequences. G-Quadruplexes have thus emerged as 
an important target for drug design both to inhibit enzymes that interact at G-rich 
regions of the genome, such as telomerase, and to control the transcriptional 
regulation of genes with PQS. Moreover, G-quadruplex interactive molecules 
may not only be used as therapeutic agents but can also be used as biophysical 
probes to investigate the biological role of quadruplexes in cells. It is therefore 
vital to understand the mechanisms that regulate drug-DNA interactions in order 
to design compounds that specifically target quadruplexes.   
One group of compounds that is capable of binding G-quadruplexes are 
the perylene diimides tetracarboxylic acid diimides (PTCDIs). Original studies 
observed a correlation between the aggregation state of PTCDI ligands at 
varying pH values and their selectivity for G-quadruplex DNA versus duplex 
DNA. This work expanded on the initial studies by investigating a series of 
PTCDIs with different structural features under high and low salt buffers, changes 
in pH, metal binding and temperature changes. Studies performed at low and 
high salt buffers at pH values ranging from 6 to 8 indicated that compounds 
whose side chain basicity was dependant on pH, such as PIPER and Tel01, 
displayed pH-dependent aggregation concomitant with G-quadruplex selectivity. 
The charged perylenes Tel11 and Tel12, and the bay-substituted compound 
Tel18 were not significantly affected by pH changes. It was also observed that 
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analogs with extended benz-annulated ring systems in the perylene core 
displayed promising G-quadruplex selectivity but also exhibited decreased 
solubility, impeding accurate characterization of their DNA interactions.  
Tel12, with its negatively charged phosphate side chains was able to form 
abundant H-aggregates in the presence of Zn2+ ions, and was the only PTCDI 
studied that displayed metal-mediated aggregation in aqueous buffers. Under 
conditions where the ligand was aggregated, less pronounced binding to duplex 
DNA was observed by UV-Vis. On the other hand, the positively charged analog 
Tel11 was not able to form aggregates under any of the conditions used, and did 
not present marked structural selectivity. Nonetheless, Tel11 was able to enter 
the nuclei of cultured cells and displayed cellular toxicity. The aggregation state 
of a new PTCDI with hydrophilic methoxyethoxymethyl groups, Tel45, was also 
examined. It was observed that this compound could form unusual fluorescent 
aggregates similar to reported PTCDI J-aggregates in a novel- thermal 
dependant fashion. This compound was the most selective for quadruplex 
structures at temperatures where it displayed aggregation. In addition, it was 
observed that Tel45 was able to enter the cells and exhibit cellular cytotoxicity 
under aggregating conditions. Overall, this work supports the idea that ligand 
aggregation increases quadruplex selectivity by decreasing double-stranded 
DNA binding. These findings can be used to design more G-quadruplex selective 
ligands with increased solubility and cellular/nuclear entry. 
 
10.2. Future Directions  
 
New PTCDI analogs are currently being designed to have improved 
physical properties and potential interaction with the tetrads of G-quadruplexes. 
Benz-annulated analogs of Tel45 (such as in Figure 10.1A) could display 
increased π-π stacking interactions with G-tetrads and retain solubility by having 
hydrophilic side chains. Ansa-bridged PTCDIs (Figure 10.1B) could also display 
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Figure 10.1. Future PTCDI analogs. (A) Benz-annulated analog of Tel45. (B) Ansa-bridged 
analog of Tel01 
 
In addition to synthesizing new analogs, the effects of PTCDI ligands are 
currently being studied with G-quadruplex-processing enzymes. The results from 
this work can be adapted to study enzyme inhibition with quadruplex and duplex 
substrates under experimental conditions that affect ligand aggregation.  Aside 
from G-quadruplex interactions, this work also has implications in cell imaging 
and supramolecular chemistry. Supramolecular polymers formed by PTCDIs 
have potential applications in optical devices, photosensitizers, and as 
fluorescent probes. The ease of formation of aggregates in conjunction with their 
fluorescence properties make the perylene diimides studied here valuable 
polymer building blocks. In particular, the unusual thermophilic J- like aggregates 
formed by Tel45 display increased fluorescence upon ligand aggregation, 
properties that should be exploited and require further investigation.  It is also 
important to investigate whether having a positive charge within aggregated 
species could facilitate cellular entry and retain G-quadruplex specificity.
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CHAPTER 11. EXPERIMENTALS FOR PART II 
 
 
11.1. General Information  
 
Unless otherwise noted, all materials were obtained from commercial 
suppliers and used without further purification. PTCDI analogs PIPER, Tel01, 
Tel11, Tel12, Tel18, Tel32 and Tel34 were synthesized by Jonathan Kern (181, 
186, 187). The new analog Tel45 was synthesized by Dr. Sean Kerwin 
(unpublished results). Stock solutions of Tel01 and PIPER were prepared in 
0.1% trifluoroacetic acid; Tel11, Tel12, Tel18, and Tel45 in deionized water, 
Tel32 and Tel34 in dimethylsulfoxide and stored at room temperature. 
 
 
11.2. DNA Synthesis  
 
Oligonucleotides were synthesized on a 10 or 1 µM scale in columns from 
Glen Research (Sterling, VA) using a Perceptive Biosystems Expedite 8909 
automatic DNA synthesizer using a DMT-on or DMT-off procedure. Quadruplex 
forming sequences included G5-DNA, [d(T2G5T)4]; G4-DNA, [d(TAGGGTTA)]4; 
and G4’-DNA, [d(TTAGGG)4]. The self-complimentary duplex-forming sequences 
used  were oligos [d(CGCGCGATATCGCGCG)]2 and [d(GCAAATTTCG)]2 and 
the single-stranded sequence employed was d(T)8.  
The oligos were cleaved from the column and purified with Poly-Pak (II) 
Cartridges (Glen Research, Sterling, VA) when synthesized with DMT-on 
strategy, or by RP-HPLC when synthesized with a DMT group off. HPLC 
collected fractions were dialyzed against deionized water and completely 
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lyophilized. The oligos were then annealed by preparing a 2mM stock solution in 
buffer (3:1 25 mM ammonium acetate/methanol buffer (pH 7), 70 mM potassium 
phosphate, 100 mM potassium chloride, 1 mM EDTA buffer (pH 7), or BPS buffer 
consisting of 8 mM sodium phosphate, 185 mM NaCl (pH 7) as indicated in the 
text) by heating to 90 oC for five minutes, and slowly letting them cool down to 
room temperature. Quadruplex forming sequences were also submitted to two 
successive freeze-thaw cycles. Select structures were confirmed by CD 
spectroscopy and are included in Appendix D. 
 
 
11.3. Fluorescence and RLS Spectroscopy  
 
Spectra were recorded on a Hitachi model F-2000 spectrofluorometer or a 
Cary-Varian Fluorescence spectrophotometer. Quartz and glass cuvettes were 
treated with SigmaCote (Cat. No. Sl2, Sigma Aldrich, St. Louis, MO) for 1 h 
followed by extensive washing with water to minimize nonspecific binding of the 
ligands to the surface of the cuvette. Fluorescence and resonance light scattering 
(RLS) measurements were carried out on the ligands under both high- and low-
salt conditions. The high-salt conditions employed solutions of compound in 70 
mM potassium phosphate, 100 mM potassium chloride, 1 mM EDTA buffer at the 
indicated pH. Low-salt conditions employed solutions of compound in 3:1 25 mM 
ammonium acetate/methanol at the indicated pH. Solutions were allowed to 
equilibrate for the specified time before scans were performed at 25 °C using the 
noted excitation and emission wavelengths. 
Tel12 Zn+2-mediated aggregation were carried in BPS buffer consisting of 
8 mM sodium phosphate, 185 mM NaCl, pH 7.0, at 1 and 10 µM ligand and the 
indicated metal cation concentrations.  Thermal studies were performed using a 




11.4. Visible and absorbance Spectroscopy 
 
Spectra were recorded on Varian Cary Spectrophotometer. Experiments 
were carried out in polystyrene cuvettes or quartz cuvettes treated with 
SigmaCote to minimize nonspecific binding of the ligands to the surface of the 
cuvettes. For DNA binding experiments, the absorption spectra were obtained 
under high and low salt conditions. For the high salt conditions, the compound 
(20 µM) in 70 mM potassium phosphate, 100 mM potassium chloride, 1 mM 
EDTA buffer (pH 7) was analyzed alone or in the presence 20 µM structure of 
G4-DNA [d(TAGGGTTA)]4, G4'-DNA [d(TTAGGG)4] double-stranded DNA 
[d(CGCGCGATATCGCGCG)]2, or single-stranded DNA d(TTTTTTTT). For the 
low salt conditions, the compound (10 µM) in 3:1 25 mM ammonium 
acetate/methanol was analyzed alone or in the presence of 10 µM structure of 
G4-DNA [d(TTGGGGGT)]4, double-stranded DNA [d(GCAAATTTCG)]2 or single-
stranded DNA d(TTTTTTTT). Samples were monitored until equilibrium was 
achieved, as evidenced by constant absorbance readings.  
For metal-mediated aggregation studies the utilized aqueous buffers were 
50 mM potassium Cacodylate (pH =7.4), or BPS buffer consisting of 8 mM 
sodium phosphate, 185 mM NaCl (pH 7.0). Spectra were recorded in the 
presence and absence of the following salts: Mg(NO3)2, Ca(NO3)2, Zn(NO3)2, 
Ni(NO3)2, Cu(NO3)2, Co(NO3)2, Fe(NO3)2, and Fe(NO3)3. Tel45 studies were also 
carried out in dichloromethane/methanol in the presence of (CF3SO3)2Zn, 
CF3SO3Ag, and Cu(ClO4)2. 
 
 
11.5. Circular Dichroism  
 
Determination of CD spectrum was carried out on a JASCO-J815 CD 
spectropolarimeter. The instrument conditions were as follows: scan range, 320 
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200 nm; scan speed, 100 nm/min; quartz cell length, 1 mm; accumulation times, 
2; temperature, 25 ºC. Samples containing the only the buffer of interest were 
used for reference subtraction.   
 
 
11.6. Surface Plasmon Resonance Experiments 
 
The SPR experiments were performed using a Biacore X instrument on 
streptavidin-coated SA5 sensor chips (part no. BR-1000-32, from BIAcore, 
Piscataway, NJ) with HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA, 0.005% v/v polysorbate 20, pH 7.4).   Sensor chips were prepared and 
derivatized as described in section 6.3. Flow cell 1 was used as a reference cell, 
and flow cell 2 was immobilized with 243 RU units of 5’-Bio-TEG-(TTAGGG)4TT-
3’ oligonucleotide (Integrated DNA Technologies, Coralville, IA). Intramolecular 
G-quadruplex formation was facilitated by addition of KCl (200 mM) to the 
running and storage buffers.  
Samples of TMPyP4 and Tel11 were prepared in running buffer and 
injected manually (50 µL) at different concentrations using a flow rate of 10 
µL/min, with delayed wash of 420 s. The surface was regenerated by injection of 
running buffer in the case of TMPyP4, but required alternating injections of 
running buffer, 5% DMSO, and 1% P20 for injections of Tel11. All binding 
responses were determined by subtraction of the reference flow cell 1.  Fitting of 
steady-state equilibrium binding constants and kinetic association and 
dissociation curves was performed using BIAevaluation software supplied with 




11.7. Cytotoxicity Assays 
 
Cell viability was determined using the AlamarBlue assay as described in 
section 6.5. MCF-7 and A549 cells were treated with 2 µl of compound in DMSO 
at different concentrations and incubated during 72 h at 37 oC prior to data 
evaluation. There was no effect on the growth of cells compared to that of cells in 
culture media alone at this DMSO concentration. Tel11, Tel12, and Tel45, along 
with Mitomycin-C (part no. 100498, from MP Biomedicals, Solon, OH) as a 
positive control were evaluated at final concentrations ranging from 0.005 to 100 
µM. IC50 values were determined as described in section 6.5.  
 
11.8. Fluorescence detection of PTCDI cellular entry 
 
A549 and MCF-7 cells were grown at 37 ºC, trypsinized, and inoculated 
into four chambered slide plates (Lab Tek II part no. 125652, Nalgene Nunc 
International, Rochester, NY) at approximately 1.0 *105  cells per well. Cells 
were grown at 24 h at 37 ºC before treatment with PTCDI analogs at 20 µM or 
vehicle for an additional 24 h. Both sets of cells were collected after 24 following 
treatment.  Cells were then fixed in ice-cold 1:1 methanol/acetone for 10 minutes 
and air-dried. Following three washes with PBS, the slides were then mounted 
using VectorShield mount (VectorLabs, part no. H-1300, Burlingame, CA) 
containing PI to stain the nucleus. Evaluation of fluorescence cell morphology 
was performed using a Nikon TMS-100 phase contrast microscope and images 
were captured using a Nikon CoolSnap digital camera and images were 
processed using MetaMorph imaging software. 
 176 
 
REFERENCES FOR PART II 
 
1. Watson, J. D., and Crick, F. H. (1953) Molecular structure of nucleic acids; 
a structure for deoxyribose nucleic acid, Nature 171, 737-738. 
2. Wang, J. C. (1979) Helical repeat of DNA in solution, Proc Natl Acad Sci U 
S A 76, 200-203. 
3. Mandelkern, M., Elias, J. G., Eden, D., and Crothers, D. M. (1981) The 
dimensions of DNA in solution, J Mol Biol 152, 153-161. 
4. Ghosh, A., and Bansal, M. (2003) A glossary of DNA structures from A to 
Z, Acta Crystallogr D Biol Crystallogr 59, 620-626. 
5. Bates, A. D., and Maxwell, A. (2005) DNA topology, 2nd ed., Oxford 
University Press, Oxford ; New York. 
6. Wahl, M. C., and Sundaralingam, M. (1997) Crystal structures of A-DNA 
duplexes, Biopolymers 44, 45-63. 
7. Blackburn, G. M., and Royal Society of Chemistry (Great Britain) (2006) 
Nucleic acids in chemistry and biology, 3rd ed., RSC Pub., Cambridge. 
8. Wang, G., and Vasquez, K. M. (2007) Z-DNA, an active element in the 
genome, Front Biosci 12, 4424-4438. 
9. Herbert, A., and Rich, A. (1996) The biology of left-handed Z-DNA, J Biol 
Chem 271, 11595-11598. 
10. Phan, A. T., Kuryavyi, V., and Patel, D. J. (2006) DNA architecture: from G 
to Z, Curr Opin Struct Biol 16, 288-298. 
11. Wadkins, R. M. (2000) Targeting DNA secondary structures, Curr Med 
Chem 7, 1-15. 
12. Bukowiecka-Matusiak, M., and Wozniak, L. A. (2006) [DNA structure from 
A to Z--biological implications of structural diversity of DNA], Postepy 
Biochem 52, 229-238. 
13. Courey, A. J. (1999) Analysis of altered DNA structures: cruciform DNA, 
Methods Mol Biol 94, 29-40. 
14. Timsit, Y., and Moras, D. (1996) Cruciform structures and functions, Q 
Rev Biophys 29, 279-307. 
15. Liu, Y., and West, S. C. (2004) Happy Hollidays: 40th anniversary of the 
Holliday junction, Nat Rev Mol Cell Biol 5, 937-944. 
16. Holliday, R. A. (1964) A mechanism for gene conversion in fungi., Genet 
Res Camb 5, 282-304. 
17. Chan, P. P., and Glazer, P. M. (1997) Triplex DNA: fundamentals, 
advances, and potential applications for gene therapy, J Mol Med 75, 267-
282. 
18. Frank-Kamenetskii, M. D., and Mirkin, S. M. (1995) Triplex DNA 
structures, Annu Rev Biochem 64, 65-95. 
19. Gilbert, D. E., and Feigon, J. (1999) Multistranded DNA structures, Curr 
Opin Struct Biol 9, 305-314. 
 177 
20. Gellert, M., Lipsett, M. N., and Davies, D. R. (1962) Helix formation by 
guanylic acid, Proc Natl Acad Sci U S A 48, 2013-2018. 
21. Sen, D., and Gilbert, W. (1990) A sodium-potassium switch in the 
formation of four-stranded G4-DNA, Nature 344, 410-414. 
22. Sen, D., and Gilbert, W. (1988) Formation of parallel four-stranded 
complexes by guanine-rich motifs in DNA and its implications for meiosis, 
Nature 334, 364-366. 
23. Guschlbauer, W., Chantot, J. F., and Thiele, D. (1990) Four-stranded 
nucleic acid structures 25 years later: from guanosine gels to telomer 
DNA, J Biomol Struct Dyn 8, 491-511. 
24. Wang, Y., and Patel, D. J. (1992) Guanine residues in d(T2AG3) and 
d(T2G4) form parallel-stranded potassium cation stabilized G-
quadruplexes with anti glycosidic torsion angles in solution, Biochemistry 
31, 8112-8119. 
25. Hardin, C. C., Henderson, E., Watson, T., and Prosser, J. K. (1991) 
Monovalent cation induced structural transitions in telomeric DNAs: G-
DNA folding intermediates, Biochemistry 30, 4460-4472. 
26. Kerwin, S. M. (2000) G-Quadruplex DNA as a target for drug design, Curr 
Pharm Des 6, 441-478. 
27. Sa-Carvalho, D., and Traub-Cseko, Y. M. (1995) Sequences with high 
propensity to form G-quartet structures in kinetoplast DNA from 
Phytomonas serpens, Mol Biochem Parasitol 72, 103-109. 
28. Simonsson, T. (2001) G-quadruplex DNA structures--variations on a 
theme, Biol Chem 382, 621-628. 
29. Gehring, K., Leroy, J. L., and Gueron, M. (1993) A tetrameric DNA 
structure with protonated cytosine.cytosine base pairs, Nature 363, 561-
565. 
30. Gueron, M., and Leroy, J. L. (2000) The i-motif in nucleic acids, Curr Opin 
Struct Biol 10, 326-331. 
31. Phan, A. T., and Mergny, J. L. (2002) Human telomeric DNA: G-
quadruplex, i-motif and Watson-Crick double helix, Nucleic Acids Res 30, 
4618-4625. 
32. Lee, J. Y., Okumus, B., Kim, D. S., and Ha, T. (2005) Extreme 
conformational diversity in human telomeric DNA, Proc Natl Acad Sci U S 
A 102, 18938-18943. 
33. Krafft, C., Benevides, J. M., and Thomas, G. J., Jr. (2002) Secondary 
structure polymorphism in Oxytricha nova telomeric DNA, Nucleic Acids 
Res 30, 3981-3991. 
34. Li, J., Correia, J. J., Wang, L., Trent, J. O., and Chaires, J. B. (2005) Not 
so crystal clear: the structure of the human telomere G-quadruplex in 
solution differs from that present in a crystal, Nucleic Acids Res 33, 4649-
4659. 
 178 
35. Mills, M., Lacroix, L., Arimondo, P. B., Leroy, J. L., Francois, J. C., Klump, 
H., and Mergny, J. L. (2002) Unusual DNA conformations: implications for 
telomeres, Curr Med Chem Anticancer Agents 2, 627-644. 
36. Wang, Y., and Patel, D. J. (1993) Solution structure of the human 
telomeric repeat d[AG3(T2AG3)3] G-tetraplex, Structure 1, 263-282. 
37. Parkinson, G. N., Lee, M. P., and Neidle, S. (2002) Crystal structure of 
parallel quadruplexes from human telomeric DNA, Nature 417, 876-880. 
38. Zhang, X. Y., Cao, E. H., Zhang, Y., Chou, C., and Bai, C. (2003) K+ and 
Na+-induced self-assembly of telomeric oligonucleotide d(TTAGGG)n, J 
Biomol Struct Dyn 20, 693-702. 
39. Ying, L., Green, J. J., Li, H., Klenerman, D., and Balasubramanian, S. 
(2003) Studies on the structure and dynamics of the human telomeric G 
quadruplex by single-molecule fluorescence resonance energy transfer, 
Proc Natl Acad Sci U S A 100, 14629-14634. 
40. Phan, A. T., Luu, K. N., and Patel, D. J. (2006) Different loop 
arrangements of intramolecular human telomeric (3+1) G-quadruplexes in 
K+ solution, Nucleic Acids Res 34, 5715-5719. 
41. Luu, K. N., Phan, A. T., Kuryavyi, V., Lacroix, L., and Patel, D. J. (2006) 
Structure of the human telomere in K+ solution: an intramolecular (3 + 1) 
G-quadruplex scaffold, J Am Chem Soc 128, 9963-9970. 
42. Petraccone, L., Erra, E., Esposito, V., Randazzo, A., Mayol, L., Nasti, L., 
Barone, G., and Giancola, C. (2004) Stability and structure of telomeric 
DNA sequences forming quadruplexes containing four G-tetrads with 
different topological arrangements, Biochemistry 43, 4877-4884. 
43. Gros, J., Rosu, F., Amrane, S., De Cian, A., Gabelica, V., Lacroix, L., and 
Mergny, J. L. (2007) Guanines are a quartet's best friend: impact of base 
substitutions on the kinetics and stability of tetramolecular quadruplexes, 
Nucleic Acids Res 35, 3064-3075. 
44. Risitano, A., and Fox, K. R. (2003) Stability of intramolecular DNA 
quadruplexes: comparison with DNA duplexes, Biochemistry 42, 6507-
6513. 
45. Xue, Y., Kan, Z. Y., Wang, Q., Yao, Y., Liu, J., Hao, Y. H., and Tan, Z. 
(2007) Human Telomeric DNA Forms Parallel-Stranded Intramolecular G-
Quadruplex in K(+) Solution under Molecular Crowding Condition, J Am 
Chem Soc. 
46. Miyoshi, D., Karimata, H., and Sugimoto, N. (2006) Hydration regulates 
thermodynamics of G-quadruplex formation under molecular crowding 
conditions, J Am Chem Soc 128, 7957-7963. 
47. Kan, Z. Y., Yao, Y., Wang, P., Li, X. H., Hao, Y. H., and Tan, Z. (2006) 
Molecular crowding induces telomere G-quadruplex formation under salt-
deficient conditions and enhances its competition with duplex formation, 
Angew Chem Int Ed Engl 45, 1629-1632. 
 179 
48. Miyoshi, D., Nakao, A., and Sugimoto, N. (2002) Molecular crowding 
regulates the structural switch of the DNA G-quadruplex, Biochemistry 41, 
15017-15024. 
49. Yu, H. Q., Miyoshi, D., and Sugimoto, N. (2006) Characterization of 
structure and stability of long telomeric DNA G-quadruplexes, J Am Chem 
Soc 128, 15461-15468. 
50. Kang, C., Zhang, X., Ratliff, R., Moyzis, R., and Rich, A. (1992) Crystal 
structure of four-stranded Oxytricha telomeric DNA, Nature 356, 126-131. 
51. Chen, F. M. (1992) Sr2+ facilitates intermolecular G-quadruplex formation 
of telomeric sequences, Biochemistry 31, 3769-3776. 
52. Williamson, J. R., Raghuraman, M. K., and Cech, T. R. (1989) Monovalent 
cation-induced structure of telomeric DNA: the G-quartet model, Cell 59, 
871-880. 
53. Inoue, M., Miyoshi, D., and Sugimoto, N. (2005) Structural switch of 
telomere DNA by pH and monovalent cation, Nucleic Acids Symp Ser 
(Oxf), 243-244. 
54. Marathias, V. M., and Bolton, P. H. (1999) Determinants of DNA 
quadruplex structural type: sequence and potassium binding, Biochemistry 
38, 4355-4364. 
55. Lu, M., Guo, Q., and Kallenbach, N. R. (1992) Structure and stability of 
sodium and potassium complexes of dT4G4 and dT4G4T, Biochemistry 
31, 2455-2459. 
56. Miura, T., Benevides, J. M., and Thomas, G. J., Jr. (1995) A phase 
diagram for sodium and potassium ion control of polymorphism in 
telomeric DNA, J Mol Biol 248, 233-238. 
57. Schultze, P., Hud, N. V., Smith, F. W., and Feigon, J. (1999) The effect of 
sodium, potassium and ammonium ions on the conformation of the 
dimeric quadruplex formed by the Oxytricha nova telomere repeat 
oligonucleotide d(G(4)T(4)G(4)), Nucleic Acids Res 27, 3018-3028. 
58. Zakian, V. A. (1995) Telomeres: beginning to understand the end, Science 
270, 1601-1607. 
59. Makarov, V. L., Hirose, Y., and Langmore, J. P. (1997) Long G tails at 
both ends of human chromosomes suggest a C strand degradation 
mechanism for telomere shortening, Cell 88, 657-666. 
60. Wright, W. E., Tesmer, V. M., Huffman, K. E., Levene, S. D., and Shay, J. 
W. (1997) Normal human chromosomes have long G-rich telomeric 
overhangs at one end, Genes Dev 11, 2801-2809. 
61. Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., 
Moss, H., and de Lange, T. (1999) Mammalian telomeres end in a large 
duplex loop, Cell 97, 503-514. 
62. Olovnikov, A. M. (1973) A theory of marginotomy. The incomplete copying 
of template margin in enzymic synthesis of polynucleotides and biological 
significance of the phenomenon, J Theor Biol 41, 181-190. 
 180 
63. Bryan, T. M., and Cech, T. R. (1999) Telomerase and the maintenance of 
chromosome ends, Curr Opin Cell Biol 11, 318-324. 
64. Allsopp, R. C., Chang, E., Kashefi-Aazam, M., Rogaev, E. I., Piatyszek, M. 
A., Shay, J. W., and Harley, C. B. (1995) Telomere shortening is 
associated with cell division in vitro and in vivo, Exp Cell Res 220, 194-
200. 
65. Harley, C. B., Futcher, A. B., and Greider, C. W. (1990) Telomeres 
shorten during ageing of human fibroblasts, Nature 345, 458-460. 
66. Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., and Harley, C. 
B. (1992) Telomere end-replication problem and cell aging, J Mol Biol 225, 
951-960. 
67. Counter, C. M. (1996) The roles of telomeres and telomerase in cell life 
span, Mutat Res 366, 45-63. 
68. Linskens, M. H., Harley, C. B., West, M. D., Campisi, J., and Hayflick, L. 
(1995) Replicative senescence and cell death, Science 267, 17. 
69. Shay, J. W., and Wright, W. E. (2000) Hayflick, his limit, and cellular 
ageing, Nat Rev Mol Cell Biol 1, 72-76. 
70. Bryan, T. M., Englezou, A., Dunham, M. A., and Reddel, R. R. (1998) 
Telomere length dynamics in telomerase-positive immortal human cell 
populations, Exp Cell Res 239, 370-378. 
71. Hertzog, R. G. (2006) Ancestral telomere shortening: a countdown that will 
increase mean life span?, Med Hypotheses 67, 157-160. 
72. Kyo, S., and Inoue, M. (2002) Complex regulatory mechanisms of 
telomerase activity in normal and cancer cells: how can we apply them for 
cancer therapy?, Oncogene 21, 688-697. 
73. Greider, C. W., and Blackburn, E. H. (1985) Identification of a specific 
telomere terminal transferase activity in Tetrahymena extracts, Cell 43, 
405-413. 
74. Shippen-Lentz, D., and Blackburn, E. H. (1990) Functional evidence for an 
RNA template in telomerase, Science 247, 546-552. 
75. Shida, T. (1995) [Structure of four-stranded telomeric DNA], 
Tanpakushitsu Kakusan Koso 40, 1578-1582. 
76. Smith, F. W., and Feigon, J. (1992) Quadruplex structure of Oxytricha 
telomeric DNA oligonucleotides, Nature 356, 164-168. 
77. Oganesian, L., and Bryan, T. M. (2007) Physiological relevance of 
telomeric G-quadruplex formation: a potential drug target, Bioessays 29, 
155-165. 
78. Han, H., and Hurley, L. H. (2000) G-quadruplex DNA: a potential target for 
anti-cancer drug design, Trends Pharmacol Sci 21, 136-142. 
79. Tsai, Y. C., Qi, H., and Liu, L. F. (2007) Protection of DNA ends by 
telomeric 3' G-tail sequences, J Biol Chem 282, 18786-18792. 
80. Paeschke, K., Simonsson, T., Postberg, J., Rhodes, D., and Lipps, H. J. 
(2005) Telomere end-binding proteins control the formation of G-
quadruplex DNA structures in vivo, Nat Struct Mol Biol 12, 847-854. 
 181 
81. Zahler, A. M., Williamson, J. R., Cech, T. R., and Prescott, D. M. (1991) 
Inhibition of telomerase by G-quartet DNA structures, Nature 350, 718-
720. 
82. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., 
Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. 
(1994) Specific association of human telomerase activity with immortal 
cells and cancer, Science 266, 2011-2015. 
83. Shay, J. W., and Bacchetti, S. (1997) A survey of telomerase activity in 
human cancer, Eur J Cancer 33, 787-791. 
84. Siddiqui-Jain, A., Grand, C. L., Bearss, D. J., and Hurley, L. H. (2002) 
Direct evidence for a G-quadruplex in a promoter region and its targeting 
with a small molecule to repress c-MYC transcription, Proc Natl Acad Sci 
U S A 99, 11593-11598. 
85. Yang, D., and Hurley, L. H. (2006) Structure of the biologically relevant G-
quadruplex in the c-MYC promoter, Nucleosides Nucleotides Nucleic 
Acids 25, 951-968. 
86. Rangan, A., Fedoroff, O. Y., and Hurley, L. H. (2001) Induction of duplex 
to G-quadruplex transition in the c-myc promoter region by a small 
molecule, J Biol Chem 276, 4640-4646. 
87. Guo, K., Pourpak, A., Beetz-Rogers, K., Gokhale, V., Sun, D., and Hurley, 
L. H. (2007) Formation of Pseudosymmetrical G-Quadruplex and i-Motif 
Structures in the Proximal Promoter Region of the RET Oncogene, J Am 
Chem Soc 129, 10220-10228. 
88. Phan, A. T., Kuryavyi, V., Burge, S., Neidle, S., and Patel, D. J. (2007) 
Structure of an unprecedented G-quadruplex scaffold in the human c-kit 
promoter, J Am Chem Soc 129, 4386-4392. 
89. Kumari, S., Bugaut, A., Huppert, J. L., and Balasubramanian, S. (2007) An 
RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates 
translation, Nat Chem Biol 3, 218-221. 
90. Dai, J., Chen, D., Jones, R. A., Hurley, L. H., and Yang, D. (2006) NMR 
solution structure of the major G-quadruplex structure formed in the 
human BCL2 promoter region, Nucleic Acids Res 34, 5133-5144. 
91. Cogoi, S., and Xodo, L. E. (2006) G-quadruplex formation within the 
promoter of the KRAS proto-oncogene and its effect on transcription, 
Nucleic Acids Res 34, 2536-2549. 
92. Dexheimer, T. S., Sun, D., and Hurley, L. H. (2006) Deconvoluting the 
structural and drug-recognition complexity of the G-quadruplex-forming 
region upstream of the bcl-2 P1 promoter, J Am Chem Soc 128, 5404-
5415. 
93. Skoblov, M., Shakhbazov, K., Oshchepkov, D., Ivanov, D., Guskova, A., 
Rubtsov, P., Prasolov, V., Yankovsky, N., and Baranova, A. (2006) 
Human RFP2 gene promoter: unique structure and unusual strength, 
Biochem Biophys Res Commun 342, 859-866. 
 182 
94. Dai, J., Dexheimer, T. S., Chen, D., Carver, M., Ambrus, A., Jones, R. A., 
and Yang, D. (2006) An intramolecular G-quadruplex structure with mixed 
parallel/antiparallel G-strands formed in the human BCL-2 promoter region 
in solution, J Am Chem Soc 128, 1096-1098. 
95. Sun, D., Guo, K., Rusche, J. J., and Hurley, L. H. (2005) Facilitation of a 
structural transition in the polypurine/polypyrimidine tract within the 
proximal promoter region of the human VEGF gene by the presence of 
potassium and G-quadruplex-interactive agents, Nucleic Acids Res 33, 
6070-6080. 
96. Rankin, S., Reszka, A. P., Huppert, J., Zloh, M., Parkinson, G. N., Todd, 
A. K., Ladame, S., Balasubramanian, S., and Neidle, S. (2005) Putative 
DNA quadruplex formation within the human c-kit oncogene, J Am Chem 
Soc 127, 10584-10589. 
97. Cogoi, S., Quadrifoglio, F., and Xodo, L. E. (2004) G-rich oligonucleotide 
inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly 
reduces cell growth in human carcinoma pancreatic cells, Biochemistry 
43, 2512-2523. 
98. Jansson, B. (1996) Potassium, sodium, and cancer: a review, J Environ 
Pathol Toxicol Oncol 15, 65-73. 
99. Nagy, I., Lustyik, G., Lukacs, G., Nagy, V., and Balazs, G. (1983) 
Correlation of malignancy with the intracellular Na+:K+ ratio in human 
thyroid tumors, Cancer Res 43, 5395-5402. 
100. Bortner, C. D., and Cidlowski, J. A. (1998) A necessary role for cell 
shrinkage in apoptosis, Biochem Pharmacol 56, 1549-1559. 
101. Roomans, G. M., and Von Euler, A. (1996) X-ray microanalysis in cell 
biology and cell pathology, Cell Biol Int 20, 103-109. 
102. Scaria, V., Hariharan, M., Arora, A., and Maiti, S. (2006) Quadfinder: 
server for identification and analysis of quadruplex-forming motifs in 
nucleotide sequences, Nucleic Acids Res 34, W683-685. 
103. Huppert, J. L., and Balasubramanian, S. (2007) G-quadruplexes in 
promoters throughout the human genome, Nucleic Acids Res 35, 406-413. 
104. Kikin, O., D'Antonio, L., and Bagga, P. S. (2006) QGRS Mapper: a web-
based server for predicting G-quadruplexes in nucleotide sequences, 
Nucleic Acids Res 34, W676-682. 
105. Huppert, J. L., and Balasubramanian, S. (2005) Prevalence of 
quadruplexes in the human genome, Nucleic Acids Res 33, 2908-2916. 
106. Todd, A. K., Johnston, M., and Neidle, S. (2005) Highly prevalent putative 
quadruplex sequence motifs in human DNA, Nucleic Acids Res 33, 2901-
2907. 
107. Gross, D. S., and Garrard, W. T. (1988) Nuclease hypersensitive sites in 
chromatin, Annu Rev Biochem 57, 159-197. 
108. Riou, J. F., Gomez, D., Lemarteleur, T., and Trentesaux, C. (2003) [G-
quadruplex DNA: myth or reality?], Bull Cancer 90, 305-313. 
 183 
109. Schaffitzel, C., Berger, I., Postberg, J., Hanes, J., Lipps, H. J., and 
Pluckthun, A. (2001) In vitro generated antibodies specific for telomeric 
guanine-quadruplex DNA react with Stylonychia lemnae macronuclei, 
Proc Natl Acad Sci U S A 98, 8572-8577. 
110. Dong, Q. (2006) [Generation and characterization of the monoclonal 
antibody and scFv against yeast telomeric guanine-quadruplex DNA], Fen 
Zi Xi Bao Sheng Wu Xue Bao 39, 482-488. 
111. Brown, J. C., Brown, B. A., 2nd, Li, Y., and Hardin, C. C. (1998) 
Construction and characterization of a quadruplex DNA selective single-
chain autoantibody from a viable motheaten mouse hybridoma with 
homology to telomeric DNA binding proteins, Biochemistry 37, 16338-
16348. 
112. Fry, M. (2007) Tetraplex DNA and its interacting proteins, Front Biosci 12, 
4336-4351. 
113. Mohaghegh, P., Karow, J. K., Brosh Jr, R. M., Jr., Bohr, V. A., and 
Hickson, I. D. (2001) The Bloom's and Werner's syndrome proteins are 
DNA structure-specific helicases, Nucleic Acids Res 29, 2843-2849. 
114. Huber, M. D., Duquette, M. L., Shiels, J. C., and Maizels, N. (2006) A 
conserved G4 DNA binding domain in RecQ family helicases, J Mol Biol 
358, 1071-1080. 
115. Fry, M., and Loeb, L. A. (1999) Human werner syndrome DNA helicase 
unwinds tetrahelical structures of the fragile X syndrome repeat sequence 
d(CGG)n, J Biol Chem 274, 12797-12802. 
116. Sun, H., Karow, J. K., Hickson, I. D., and Maizels, N. (1998) The Bloom's 
syndrome helicase unwinds G4 DNA, J Biol Chem 273, 27587-27592. 
117. Tuesuwan, B., Kern, J. T., Thomas, P. W., Rodriguez, M., David, W. M., 
Li, J., and Kerwin, S. (2007) Simian Virus 40 Large T-antigen G-
Quadruplex DNA Helicase Inhibition by G-Quadruplex DNA-Interactive 
Agents., Biochem, submitted. 
118. Vaughn, J. P., Creacy, S. D., Routh, E. D., Joyner-Butt, C., Jenkins, G. S., 
Pauli, S., Nagamine, Y., and Akman, S. A. (2005) The DEXH protein 
product of the DHX36 gene is the major source of tetramolecular 
quadruplex G4-DNA resolving activity in HeLa cell lysates, J Biol Chem 
280, 38117-38120. 
119. Baran, N., Pucshansky, L., Marco, Y., Benjamin, S., and Manor, H. (1997) 
The SV40 large T-antigen helicase can unwind four stranded DNA 
structures linked by G-quartets, Nucleic Acids Res 25, 297-303. 
120. Li, J. L., Harrison, R. J., Reszka, A. P., Brosh, R. M., Jr., Bohr, V. A., 
Neidle, S., and Hickson, I. D. (2001) Inhibition of the Bloom's and 
Werner's syndrome helicases by G-quadruplex interacting ligands, 
Biochemistry 40, 15194-15202. 
121. Han, H., Bennett, R. J., and Hurley, L. H. (2000) Inhibition of unwinding of 
G-quadruplex structures by Sgs1 helicase in the presence of N,N'-bis[2-(1-
 184 
piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-
interactive ligand, Biochemistry 39, 9311-9316. 
122. Huber, M. D., Lee, D. C., and Maizels, N. (2002) G4 DNA unwinding by 
BLM and Sgs1p: substrate specificity and substrate-specific inhibition, 
Nucleic Acids Res 30, 3954-3961. 
123. Wu, X., and Maizels, N. (2001) Substrate-specific inhibition of RecQ 
helicase, Nucleic Acids Res 29, 1765-1771. 
124. Han, H., Langley, D. R., Rangan, A., and Hurley, L. H. (2001) Selective 
interactions of cationic porphyrins with G-quadruplex structures, J Am 
Chem Soc 123, 8902-8913. 
125. Giraldo, R., Suzuki, M., Chapman, L., and Rhodes, D. (1994) Promotion of 
parallel DNA quadruplexes by a yeast telomere binding protein: a circular 
dichroism study, Proc Natl Acad Sci U S A 91, 7658-7662. 
126. Giraldo, R., and Rhodes, D. (1994) The yeast telomere-binding protein 
RAP1 binds to and promotes the formation of DNA quadruplexes in 
telomeric DNA, EMBO J 13, 2411-2420. 
127. Lu, Q., Schierer, T., Kang, S. G., and Henderson, E. (1998) Purification, 
characterization and molecular cloning of TGP1, a novel G-DNA binding 
protein from Tetrahymena thermophila, Nucleic Acids Res 26, 1613-1620. 
128. Lu, Q., and Henderson, E. (2000) Two Tetrahymena G-DNA-binding 
proteins, TGP1 and TGP3, share novel motifs and may play a role in 
micronuclear division, Nucleic Acids Res 28, 2993-3001. 
129. Hanakahi, L. A., Sun, H., and Maizels, N. (1999) High affinity interactions 
of nucleolin with G-G-paired rDNA, J Biol Chem 274, 15908-15912. 
130. Arimondo, P. B., Riou, J. F., Mergny, J. L., Tazi, J., Sun, J. S., Garestier, 
T., and Helene, C. (2000) Interaction of human DNA topoisomerase I with 
G-quartet structures, Nucleic Acids Res 28, 4832-4838. 
131. Anuradha, S., and Muniyappa, K. (2004) Meiosis-specific yeast Hop1 
protein promotes synapsis of double-stranded DNA helices via the 
formation of guanine quartets, Nucleic Acids Res 32, 2378-2385. 
132. Liu, Z., and Gilbert, W. (1994) The yeast KEM1 gene encodes a nuclease 
specific for G4 tetraplex DNA: implication of in vivo functions for this novel 
DNA structure, Cell 77, 1083-1092. 
133. Sun, H., Yabuki, A., and Maizels, N. (2001) A human nuclease specific for 
G4 DNA, Proc Natl Acad Sci U S A 98, 12444-12449. 
134. Duquette, M. L., Handa, P., Vincent, J. A., Taylor, A. F., and Maizels, N. 
(2004) Intracellular transcription of G-rich DNAs induces formation of G-
loops, novel structures containing G4 DNA, Genes Dev 18, 1618-1629. 
135. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer, Cell 
100, 57-70. 
136. Blagosklonny, M. V. (2003) Cell immortality and hallmarks of cancer, Cell 
Cycle 2, 296-299. 
137. Kim Sh, S. H., Kaminker, P., and Campisi, J. (2002) Telomeres, aging and 
cancer: in search of a happy ending, Oncogene 21, 503-511. 
 185 
138. Simonsson, T., Pecinka, P., and Kubista, M. (1998) DNA tetraplex 
formation in the control region of c-myc, Nucleic Acids Res 26, 1167-1172. 
139. Alberti, P., Lacroix, L., Guittat, L., Helene, C., and Mergny, J. L. (2003) 
Nucleic acids as targets for antitelomerase agents, Mini Rev Med Chem 3, 
23-36. 
140. Hurley, L. H., Wheelhouse, R. T., Sun, D., Kerwin, S. M., Salazar, M., 
Fedoroff, O. Y., Han, F. X., Han, H., Izbicka, E., and Von Hoff, D. D. 
(2000) G-quadruplexes as targets for drug design, Pharmacol Ther 85, 
141-158. 
141. Mergny, J. L., and Helene, C. (1998) G-quadruplex DNA: a target for drug 
design, Nat Med 4, 1366-1367. 
142. Riou, J. F. (2004) G-quadruplex interacting agents targeting the telomeric 
G-overhang are more than simple telomerase inhibitors, Curr Med Chem 
Anticancer Agents 4, 439-443. 
143. Shin-ya, K., Wierzba, K., Matsuo, K., Ohtani, T., Yamada, Y., Furihata, K., 
Hayakawa, Y., and Seto, H. (2001) Telomestatin, a novel telomerase 
inhibitor from Streptomyces anulatus, J Am Chem Soc 123, 1262-1263. 
144. Rosu, F., Gabelica, V., Shin-ya, K., and De Pauw, E. (2003) Telomestatin-
induced stabilization of the human telomeric DNA quadruplex monitored 
by electrospray mass spectrometry, Chem Commun (Camb), 2702-2703. 
145. Kim, M. Y., Gleason-Guzman, M., Izbicka, E., Nishioka, D., and Hurley, L. 
H. (2003) The different biological effects of telomestatin and TMPyP4 can 
be attributed to their selectivity for interaction with intramolecular or 
intermolecular G-quadruplex structures, Cancer Res 63, 3247-3256. 
146. De Cian, A., Guittat, L., Shin-ya, K., Riou, J. F., and Mergny, J. L. (2005) 
Affinity and selectivity of G4 ligands measured by FRET, Nucleic Acids 
Symp Ser (Oxf), 235-236. 
147. Gomez, D., Paterski, R., Lemarteleur, T., Shin-Ya, K., Mergny, J. L., and 
Riou, J. F. (2004) Interaction of telomestatin with the telomeric single-
strand overhang, J Biol Chem 279, 41487-41494. 
148. Tauchi, T., Shin-ya, K., Sashida, G., Sumi, M., and Okabe, S. (2006) 
Telomerase inhibition with a novel G-quadruplex interactive agent, 
telomestatin: in vitro and in vivo studies in acute leukemia,, Oncogene 25, 
5719-5725. 
149. Tahara, H., Shin-ya, K., Seimiya, H., Yamada, H., and Tsuruo, T. (2006) 
G-Quadruplex stabilization by telomestatin induces TRF2 protein 
dissociation from telomeres and anaphase bridge formation accompanied 
by loss of the 3' telomeric overhang in cancer cells, Oncogene 25, 1955-
1966. 
150. Schuitmaker, J. J., Baas, P., van Leengoed, H. L., van der Meulen, F. W., 
Star, W. M., and van Zandwijk, N. (1996) Photodynamic therapy: a 
promising new modality for the treatment of cancer, J Photochem 
Photobiol B 34, 3-12. 
 186 
151. Anantha, N. V., Azam, M., and Sheardy, R. D. (1998) Porphyrin binding to 
quadrupled T4G4, Biochemistry 37, 2709-2714. 
152. Wheelhouse, R. T., Sun, D., Han, H., Han, F. X., and Hurley, L. H. (1998) 
Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-
methyl-4-pyridyl)porphine with Quadruplex DNA J Am Chem Soc 120, 
3261-3262. 
153. Han, F. X., Wheelhouse, R. T., and Hurley, L. H. (1999) Interactions of 
TMPyP4 and TMPyP2 with Quadruplex DNA. Structural Basis for the 
Differential Effects on Telomerase Inhibition, J Am Chem Soc 121, 3561-
3570. 
154. Haq, I., Trent, J. O., CHowdhry, B. Z., and Jenkins, T. C. (1999) 
Intercalative G-Tetraplex Stabilization of Telomeric DNA by a Cationic 
Porphyrin, J Am Chem Soc 121, 1768-1779. 
155. Yamashita, T., Uno, T., and Ishikawa, Y. (2005) Stabilization of guanine 
quadruplex DNA by the binding of porphyrins with cationic side arms, 
Bioorg Med Chem 13, 2423-2430. 
156. Han, H., Hurley, L. H., and Salazar, M. (1999) A DNA polymerase stop 
assay for G-quadruplex-interactive compounds, Nucleic Acids Res 27, 
537-542. 
157. Shi, D. F., Wheelhouse, R. T., Sun, D., and Hurley, L. H. (2001) 
Quadruplex-interactive agents as telomerase inhibitors: synthesis of 
porphyrins and structure-activity relationship for the inhibition of 
telomerase, J Med Chem 44, 4509-4523. 
158. Goncalves, D. P., Ladame, S., Balasubramanian, S., and Sanders, J. K. 
(2006) Synthesis and G-quadruplex binding studies of new 4-N-
methylpyridinium porphyrins, Org Biomol Chem 4, 3337-3342. 
159. Tuntiwechapikul, W., Taka, T., Bethencourt, M., Makonkawkeyoon, L., and 
Randall Lee, T. (2006) The influence of pH on the G-quadruplex binding 
selectivity of perylene derivatives, Bioorg Med Chem Lett 16, 4120-4126. 
160. Dixon, I. M., Lopez, F., Esteve, J. P., Tejera, A. M., Blasco, M. A., Pratviel, 
G., and Meunier, B. (2005) Porphyrin derivatives for telomere binding and 
telomerase inhibition, Chembiochem 6, 123-132. 
161. Arthanari, H., Basu, S., Kawano, T. L., and Bolton, P. H. (1998) 
Fluorescent dyes specific for quadruplex DNA, Nucleic Acids Res 26, 
3724-3728. 
162. Ren, J., and Chaires, J. B. (1999) Sequence and structural selectivity of 
nucleic acid binding ligands, Biochemistry 38, 16067-16075. 
163. Pasternack, R. F., Brigandi, R. A., Abrams, M. J., Williams, A. P., and 
Gibbs, E. J. (1990) Interactions of porphyrins and metalloporphyrins with 
single-stranded poly(dA) Inorg Chem 29, 4483-4486. 
164. Pasternack, R. F., Gurrieri, S., Lauceri, R., and Purrello, R. (1996) Single-
stranded nucleic acids as templates for porphyrin assembly formation, 
Inorg Chim Acta 246, 7-12. 
 187 
165. Li, Y., Geyer, C. R., and Sen, D. (1996) Recognition of anionic porphyrins 
by DNA aptamers, Biochemistry 35, 6911-6922. 
166. Pothukuchy, A., Ellapan, S., Gopidas, K. R., and Salazar, M. (2003) 
Photo-oxidation of duplex DNA with the stable trioxatriangulenium ion, 
Bioorg Med Chem Lett 13, 1491-1494. 
167. Reynisson, J., Schuster, G. B., Howerton, S. B., Williams, L. D., Barnett, 
R. N., Cleveland, C. L., Landman, U., Harrit, N., and Chaires, J. B. (2003) 
Intercalation of trioxatriangulenium ion in DNA: binding, electron transfer, 
x-ray crystallography, and electronic structure, J Am Chem Soc 125, 
2072-2083. 
168. Pothukuchy, A., Mazzitelli, C. L., Rodriguez, M. L., Tuesuwan, B., Salazar, 
M., Brodbelt, J. S., and Kerwin, S. M. (2005) Duplex and quadruplex DNA 
binding and photocleavage by trioxatriangulenium ion, Biochemistry 44, 
2163-2172. 
169. Fox, K. R., Polucci, P., Jenkins, T. C., and Neidle, S. (1995) A molecular 
anchor for stabilizing triple-helical DNA, Proc Natl Acad Sci U S A 92, 
7887-7891. 
170. Read, M. A., Wood, A. A., Harrison, J. R., Gowan, S. M., Kelland, L. R., 
Dosanjh, H. S., and Neidle, S. (1999) Molecular modeling studies on G-
quadruplex complexes of telomerase inhibitors: structure-activity 
relationships, J Med Chem 42, 4538-4546. 
171. Sun, D., Thompson, B., Cathers, B. E., Salazar, M., Kerwin, S. M., Trent, 
J. O., Jenkins, T. C., Neidle, S., and Hurley, L. H. (1997) Inhibition of 
human telomerase by a G-quadruplex-interactive compound, J Med Chem 
40, 2113-2116. 
172. Harrison, R. J., Gowan, S. M., Kelland, L. R., and Neidle, S. (1999) 
Human telomerase inhibition by substituted acridine derivatives, Bioorg 
Med Chem Lett 9, 2463-2468. 
173. White, E. W., Tanious, F., Ismail, M. A., Reszka, A. P., Neidle, S., Boykin, 
D. W., and Wilson, W. D. (2007) Structure-specific recognition of 
quadruplex DNA by organic cations: influence of shape, substituents and 
charge, Biophys Chem 126, 140-153. 
174. Chen, Q., Kuntz, I. D., and Shafer, R. H. (1996) Spectroscopic recognition 
of guanine dimeric hairpin quadruplexes by a carbocyanine dye, Proc Natl 
Acad Sci U S A 93, 2635-2639. 
175. Shafer, R. H. (1998) Stability and structure of model DNA triplexes and 
quadruplexes and their interactions with small ligands, Prog Nucleic Acid 
Res Mol Biol 59, 55-94. 
176. Ren, J., and Chaires, J. B. (2000) Preferential Binding of 3,3'-
Diethyloxadicarbocyanine to Triplex DNA, J Am Chem Soc 122, 424-425. 
177. Kerwin, S. M., Sun, D., Kern, J. T., Rangan, A., and Thomas, P. W. (2001) 
G-quadruplex DNA binding by a series of carbocyanine dyes, Bioorg Med 
Chem Lett 11, 2411-2414. 
 188 
178. Fedoroff, O. Y., Salazar, M., Han, H., Chemeris, V. V., Kerwin, S. M., and 
Hurley, L. H. (1998) NMR-Based model of a telomerase-inhibiting 
compound bound to G-quadruplex DNA, Biochemistry 37, 12367-12374. 
179. Han, H., Cliff, C. L., and Hurley, L. H. (1999) Accelerated assembly of G-
quadruplex structures by a small molecule, Biochemistry 38, 6981-6986. 
180. Kerwin, S. M., Chen, G., Kern, J. T., and Thomas, P. W. (2002) Perylene 
diimide G-quadruplex DNA binding selectivity is mediated by ligand 
aggregation, Bioorg Med Chem Lett 12, 447-450. 
181. Kern, J. T., Thomas, P. W., and Kerwin, S. M. (2002) The relationship 
between ligand aggregation and G-quadruplex DNA selectivity in a series 
of 3,4,9,10-perylenetetracarboxylic acid diimides, Biochemistry 41, 11379-
11389. 
182. Rossetti, L., Franceschin, M., Bianco, A., Ortaggi, G., and Savino, M. 
(2002) Perylene diimides with different side chains are selective in 
inducing different G-quadruplex DNA structures and in inhibiting 
telomerase, Bioorg Med Chem Lett 12, 2527-2533. 
183. Rossetti, L., Franceschin, M., Schirripa, S., Bianco, A., Ortaggi, G., and 
Savino, M. (2005) Selective interactions of perylene derivatives having 
different side chains with inter- and intramolecular G-quadruplex DNA 
structures. A correlation with telomerase inhibition, Bioorg Med Chem Lett 
15, 413-420. 
184. Sissi, C., Lucatello, L., Paul Krapcho, A., Maloney, D. J., Boxer, M. B., 
Camarasa, M. V., Pezzoni, G., Menta, E., and Palumbo, M. (2007) Tri-, 
tetra- and heptacyclic perylene analogues as new potential antineoplastic 
agents based on DNA telomerase inhibition, Bioorg Med Chem 15, 555-
562. 
185. McGovern, S. L., Caselli, E., Grigorieff, N., and Shoichet, B. K. (2002) A 
common mechanism underlying promiscuous inhibitors from virtual and 
high-throughput screening, J Med Chem 45, 1712-1722. 
186. Kern, J. T. (2002) Studies on 3,4,9,10-perylenetetracarboxylic acid diimide 
based ligands as G-quadruplex DNA interactive agents, The University of 
Texas Libraries, Austin, TX. 
187. Kern, J. T., and Kerwin, S. M. (2002) The aggregation and G-quadruplex 
DNA selectivity of charged 3,4,9,10-perylenetetracarboxylic acid diimides, 
Bioorg Med Chem Lett 12, 3395-3398. 
188. Ford, W. E. (1987) Photochemistry of 3,4,9,10-perylenetetracarboxylic 
dianhydride dyes: visible absorption and fluorescence of the 
di(glycyl)imide derivative monomer and dimer in basic aqueous solutions, 
J Photochem 37, 189-204. 
189. Karolin, J., Johansson, L. B.-A., Ring, U., and Langhals, H. (1996) 
Aggregation of perylene dyes in lipid vesicles: the effect of optically active 
substituents, Spectrochim Acta, Part A 52, 747-753. 
190. Marcon, R. O., dos Santos, J. G., Figueiredo, K. M., and Brochsztain, S. 
(2006) Characterization of a novel water-soluble 3,4,9,10-
 189 
perylenetetracarboxylic diimide in solution and in self-assembled 
zirconium phosphonate thin films, Langmuir 22, 1680-1687. 
191. Gray, D. M., Wen, J. D., Gray, C. W., Repges, R., Repges, C., Raabe, G., 
and Fleischhauer, J. (2007) Measured and calculated CD spectra of G-
quartets stacked with the same or opposite polarities, Chirality. 
192. Sun, X. G., Cao, E. H., He, Y. J., and Qin, J. F. (1999) Spectroscopic 
comparison of different DNA structures formed by oligonucleotides, J 
Biomol Struct Dyn 16, 863-872. 
193. Kohl, C., Weil, T., Qu, J., and Mullen, K. (2004) Towards highly 
fluorescent and water-soluble perylene dyes, Chemistry 10, 5297-5310. 
194. Johansson, L. B.-A., and Langhals, H. (1991) Spectroscopic studies of 
fluorescent perylene dyes Spectrochim Acta A Mol Biomol Spectrosc 47, 
857-861. 
195. Langhals, H., Jona, W., Einsiedl, F., and Wohnlich, S. (1998) Self-
Dispersion: Spontaneous Formation of Colloidal Dyes in Water, Adv. 
Mater. 10, 1022-1024. 
196. Pasternack, R. F., and Collings, P. J. (1995) Resonance light scattering: a 
new technique for studying chromophore aggregation, Science 269, 935-
939. 
197. Fox, K. R. (1997) Drug-DNA interaction protocols, Humana Press, 
Totowa, NJ. 
198. Wurthner, F. (2004) Perylene bisimide dyes as versatile building blocks for 
functional supramolecular architectures, Chem Commun (Camb), 1564-
1579. 
199. Chen, Z., Stepanenko, V., Dehm, V., Prins, P., Siebbeles, L. D., Seibt, J., 
Marquetand, P., Engel, V., and Wurthner, F. (2007) Photoluminescence 
and conductivity of self-assembled pi-pi stacks of perylene bisimide dyes, 
Chemistry 13, 436-449. 
200. Albrecht, M. (2007) Supramolecular chemistry-general principles and 
selected examples from anion recognition and metallosupramolecular 
chemistry, Naturwissenschaften. 
201. Dobrawa, R., and Wurthner, F. (2002) Photoluminescent supramolecular 
polymers: metal-ion directed polymerization of terpyridine-functionalized 
perylene bisimide dyes, Chem Commun (Camb), 1878-1879. 
202. Wu, Y., Li, B., Wang, W., Bai, F., and Liu, M. (2003) Coordination assisted 
molecular assemblies of perylene-3,4,9,10-tetracarboxylic acid with 
copper (II) ion at the air/water interface Mater Sci Eng C 23, 605-609. 
203. Li, Y., Wang, N., Gan, H., Liu, H., Li, H., He, X., Huang, C., Cui, S., Wang, 
S., and Zhu, D. (2005) Synthesis and characterization of 3,5-bis(2-
hydroxyphenyl)-1,2,4-triazole functionalized tetraaryloxy perylene bisimide 
and metal-directed self-assembly, J Org Chem 70, 9686-9692. 
204. Dobrawa, R., Kurth, D. G., and Würthner, F. (2004) Electrostatic Self-
Assembly Of Fluorescent Perylene Bisimide Coordination Polymers, 
Polym Prepr 45, 378-379. 
 190 
205. Tuntiwechapikul, W., and Salazar, M. (2001) Cleavage of telomeric G-
quadruplex DNA with perylene-EDTA*Fe(II), Biochemistry 40, 13652-
13658. 
206. Zheng, X., Zhang, D., and Zhu, D. (2006) A new tetrathiafulvalene–
perylene diimide dyad with a pentaoxa-heptadecane chain as the spacer: 
metal-ions-induced aggregation, Tetrahedron Lett 47, 9083–9087. 
207. Wurthner, F., Sautter, A., Schmid, D., and Weber, P. J. (2001) Fluorescent 
and electroactive cyclic assemblies from perylene tetracarboxylic acid 
bisimide ligands and metal phosphane triflates, Chemistry 7, 894-902. 
208. Tuntiwechapikul, W., Lee, J. T., and Salazar, M. (2001) Design and 
synthesis of the G-quadruplex-specific cleaving reagent perylene-
EDTA.iron(II), J Am Chem Soc 123, 5606-5607. 
209. Bohn, P. W. (1993) Aspects of Structure and Energy Transport in Artificial 
Molecular Assemblies, Annu Rev Phys Chem 44, 37-60. 
210. Wurthner, F., Thalacker, C., Diele, S., and Tschierske, C. (2001) 
Fluorescent J-type aggregates and thermotropic columnar mesophases of 
perylene bisimide dyes, Chemistry 7, 2245-2253. 
211. Kaiser, T. E., Wang, H., Stepanenko, V., and Wurthner, F. (2007) 
Supramolecular construction of fluorescent J-aggregates based on 
hydrogen-bonded perylene dyes, Angew Chem Int Ed Engl 46, 5541-
5544. 
212. Wang, W., Wan, W., Zhou, H. H., Niu, S., and Li, A. D. (2003) Alternating 
DNA and pi-conjugated sequences. Thermophilic foldable polymers, J Am 





APENDIX A. SELECTED SPECTRA FOR UK-1 ANALOGS 
 






























A.6. gHSQC compound 9 in CDCl3/MeOD 1:1 
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A.8. Compound 9 COSY in CDCl3 
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A.9. 1H and 13C NMR of compound 10 
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APENDIX B. NMR CHEMICAL SHIFTS OF COMPOUNDS 8 AND 
9 IN THE PRESENCE OF MG(NO3)2 
 
 
B.1. 1H NMR shifts of compound 8 in CDCl3/MeOD 1:1 in the 





H NMR shifts upon addition of Mg
2+



















C5-H 7.987 0.006 -0.002 -0.011 -0.018 
C6’-H 7.972 0.006 -0.002 -0.012 -0.018 
C7-H 7.803 0.012 0.008 0.002 -0.001 
C4’-H,  
C6-H 
7.439 0.000 -0.006 -0.012 -0.020 
C3’-H 7.062 -0.005 -0.015 -0.026 -0.032 
C5’-H 6.987 -0.003 -0.010 -0.017 -0.023 
MeOD 4.511 0.026 0.068 0.112 0.140 





B.2. 13C NMR shifts of compound 8 in CDCl3/MeOD 1:1 in the 




C NMR shifts upon addition of Mg
2+



















CO2 166.389 0.007   -0.067 
C1 164.899 0.024   -0.023 
C2 159.558 -0.004  -0.079 -0.060 
C7a 150.417 0.019 -0.009  -0.045 
C3a 140.041 0.008   -0.048 
C5’ 134.780 -0.004 -0.012 -0.020 -0.032 
C6’ 127.804 -0.012 -0.028 -0.052 -0.068 
C5 127.788     
C6 125.408 0.012 0.004 -0.008 -0.011 
C4 121.499     
C4’ 120.277  -0.008  -0.040 
C3’ 117.922 -0.020 -0.049 -0.064 -0.093 
C7 115.692 0.016 0.012 0.021 0.013 
C2’ 110.420 0.003 -0.025 -0.049 -0.061 
CH3 52.662 -0.028 -0.040 -0.072 -0.088 
MeOD 48.994 -0.057 -0.077 -0.101 -0.117 
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B.3. 1H NMR shifts of compound 9 in CDCl3/MeOD 1:1 in the 





H NMR shifts upon addition of Mg
2+






















C6’-H 8.054 -0.019 -0.024 -0.035 -0.046 -0.063 
C6-H 7.933 -0.017 -0.022 -0.031 -0.040 -0.058 
C4-H 7.865 -0.017 -0.021 -0.031 -0.039 -0.056 
C4’-H, 
C5-H 
7.421 -0.015 -0.018 -0.026 -0.033 -0.046 
C3’-H 7.038 -0.017 -0.021 -0.030 -0.038 -0.055 
C5’-H 6.992 -0.015 -0.019 -0.027 -0.034 -0.048 
MeOD 4.495 0.036 0.070 0.106 0.142 0.233 
CH3 4.172 -0.015 -0.018 -0.027 -0.034 -0.049 
 
 214 
B.4. 13C NMR shifts of compound 9 in CDCl3/MeOD 1:1 in the 





C NMR shifts upon addition of Mg
2+
 to compound 9. Chemical shifts 





















CO2 165.227 -0.028 -0.040 -0.052 -0.065 -0.101 
C2 164.272 -0.028 -0.048 -0.068 -0.089 -0.145 
C3a 159.008 -0.028 -0.048 -0.073 -0.094 -0.154 
C7a 148.612 -0.032 -0.052 -0.072 -0.097 -0.154 
C3a 141.996 -0.028 -0.048 -0.069 -0.090 -0.150 
C4’ 134.554 -0.024 -0.032 -0.048 -0.061 -0.089 
C6’ 128.075 -0.028 -0.040 -0.056 -0.073 -0.121 
C6 127.804 -0.024 -0.036 -0.052 -0.065 -0.101 
C5 125.340 -0.020 -0.028 -0.040 -0.049 -0.073 
C4 124.486 -0.028 -0.040 -0.056 -0.073 -0.109 
C5’ 120.354 -0.024 -0.032 -0.044 -0.056 -0.084 
C3’ 117.667 -0.032 -0.048 -0.068 -0.085 -0.133 
C7 115.413 -0.028 -0.044 -0.064 -0.085 -0.141 
C1’ 110.521 -0.028 -0.044 -0.063 -0.081 -0.129 
CH3 52.824 -0.032 -0.040 -0.052 -0.069 -0.097 
MeOD 48.994 -0.036 -0.048 -0.064 -0.085 -0.121 
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APENDIX C. METAL-MEDIATED DNA BINDING OBSERVED BY 
ESI-MS 
 
C.1. Fraction of HPB bound to DNA in the presence of metal ions  
 
The changes in the degree of ligand binding upon addition of the metal 
salt were determined by Carolyn Mazzitelli using ESI-MS; the fraction of bound 
DNA values were calculated by expressing the sum of the abundances of all ions 
attributed to DNA/ligand complexes as a fraction of the total abundances of all 
DNA containing ions (both free DNA and DNA/ligand complexes). The fraction of 
bound DNA values is summarized in Table C.1. 
 
Table C.1. Fraction of bound DNA values
a







 and in the absence of 





 HPB analog No Metal
 Ni2+ Cu2+ Zn2+ 
8 0 0.18 0.17 0 
16 0 0 0.14 0 
17 0 0.14 0.27 0 
18 0 0 0.40 0 
19 0.20 0.13 0.32 0.17 
20 0.09 0.08 0.15 0.17 
21 0.17 0.34 0.27 0.27 
a All values ±0.05. This error represents the largest standard deviation for 
experiments that were repeated on three separate days. 
bAll solutions were prepared in a solvent composed of 50 mM ammonium 
acetate with 50% methanol (vol/vol). 
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APENDIX D. CD SPECTRA OF DNA SEQUENCES USED IN 
PTCDI STUDIES 
 
D.1. DNA sequences in 70 mM potassium phosphate, 100 mM 


























































Figure D.1. CD spectra of G4’-DNA, [d(TTAGGG)4] (A), G4-DNA, [d(TAGGGTTA)]4 (B), DS-DNA, 
[d(CGCGCGATATCGCGCG)]2 in 170 mM K phosphate buffer, pH 7 
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D.2. DNA sequences in 8 mM sodium phosphate, 185 mM NaCl, 

































































Figure D.2. CD spectra of G4’-DNA, [d(TTAGGG)4] (A), G4-DNA, [d(TAGGGTTA)]4 (B), DS-DNA, 
[d(CGCGCGATATCGCGCG)]2 in BPS buffer 
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D.3. CD Spectra of DNA sequences in 8 mM sodium phosphate, 

































































Figure D.3. CD spectra of G4’-DNA, [d(TTAGGG)4] (A), G4-DNA, [d(TAGGGTTA)]4 (B), DS-DNA, 
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